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Abstract 
Energy production is a very important function for the cells to maintain homeostasis, survive 
and proliferate. Cellular energy can be produced either through oxidative phosphorylation 
(OXPHOS) in the presence of oxygen or glycolysis in its absence. Cancer cells, even in the 
presence of oxygen prefer to produce energy through glycolysis and this confers them a 
survival advantage. Energy metabolism has recently attracted the interest of several 
laboratories as targeting the pathways for energy production in cancer cells could be an 
efficient anticancer treatment. For that purpose the role of various transcription factors in 
determining the pathway of energy production has been investigated extensively and there is 
evidence to suggest that oncogenic transcription factors promote glycolysis whereas tumour 
suppressors demote it.  
 
In line with this notion, the master regulator of cellular response to hypoxia, the Hypoxia 
Inducible Factor 1 (HIF-1) has been shown to induce the expression of a variety of genes 
encoding enzymes involved in glucose metabolism as well as OXPHOS favouring energy 
production through glucose metabolism in hypoxic cells. The tumour suppressor p53 on the 
other hand inhibits glycolysis and stimulates OXPHOS. One of the pathways through which p53 
exerts these effects, is by inducing the inhibitor of glycolysis TIGAR and the cytochrome c 
oxidase assembly factor SCO2 gene expression under DNA damage conditions. However, the 
regulation of the expression of these genes in hypoxic conditions has been only partially 
elucidated.  
 
We hypothesised that under hypoxic conditions, TIGAR and SCO2 gene expression might be 
differentially regulated in cells bearing mutated p53 and in these cells the involvement of HIF-1 
could be crucial. Indeed under hypoxia mimicking conditions, the TIGAR and SCO2 protein and 
mRNA levels were found to be modulated differentially in p53 wild type and mutant cell lines. 
The bioinformatics analysis revealed the presence of hypoxia responsive elements (HREs) 
within the regulatory region of the promoters of TIGAR and SCO2 genes. Firefly reporter assays 
and chromatin immunoprecipitation (ChIP) assays have indicated that HIF-1 plays a crucial role 
in the regulation of TIGAR gene expression. The direct involvement of HIF-1 in the regulation of 
SCO2 gene expression requires further investigation.  
 
We and others have recently reported that PCAF is a common cofactor for p53 and HIF-1α, 
regulating the protein stability and transcription target selectivity of both transcription factors 
thereby orchestrating the balance between life and death in cancer cells. We hypothesised 
that PCAF plays a similar role in the regulation of cellular energy metabolism by differentially 
targeting HIF-1α and p53 to the promoter of TIGAR and SCO2 genes. In this study we present 
evidence to support the notion that PCAF plays an import role in the regulation of TIGAR and 
SCO2 gene expression under hypoxic mimicking conditions. This conclusion was supported by 
assessing the functional consequences of PCAFwt and PCAFΔHAT overexpression on the 
intracellular lactate production, cellular oxygen consumption, NAD+/NADH ratio and ROS 
generation in cells under hypoxia mimicking conditions. 
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1 Introduction  
1.1 Cancer 
Cancer is the result of the abnormal growth of cells caused by multiple changes in gene 
expression leading to dysregulated balance of cell proliferation and cell death and 
ultimately evolving into a population of cells that can invade tissues and metastasize to 
distant sites, causing significant morbidity and, if untreated, death of the host (Ruddon, 
2007).  
 
In 2000 Hanahan et al., proposed six biological features acquired during the multistep 
development of human tumours as hallmarks of cancer. The six phenotypes that a 
tumour requires in order to become a fully-fledged malignancy include self-sufficiency 
in growth signals, insensitivity to anti-growth signals, evading apoptosis, sustained 
angiogenesis, limitless replicative potential and tissue invasion and metastasis 
(Hanahan, 2000). However, in their recent update the authors have recognised two 
additional phenotypes as emerging hallmarks of cancer that include deregulated cellular 
energetics (reprogrammed energy metabolism) and evading immunological destruction 
(Hanahan and Weinberg, 2011).   
 
Most of the genetic changes found in human cancers can be classified into two 
categories. They include gain-of-function mutations in proto-oncogenes, which lead to 
the activation of oncogenes that promote cell growth and cell survival; and loss-of- 
function mutations in tumour suppressor genes which lead to defective tumour 
suppressors which cannot perform their tumour suppressive activities such as 
prevention of unrestrained cellular growth and promotion of DNA repair and activation 
of cell cycle checkpoints (Lee and Muller, 2010). The gain-of-function mutation 
normally confers to cancer cells the proliferative advantage, the proto-oncogene H-Ras, 
for example, when activated induces MAPK mediated cellular proliferation  as well as 
survival potential of the cancer cells (Karnoub and Weinberg, 2008). Other factors 
present in cancer cells such as the HIF-1α, regulate gene expression of genes encoding 
enzymes involved in glycolysis, promoting rapid utilization of glucose which is a 
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ubiquitously available energy source. As the glycolytic enzymes do not require oxygen 
to exert their function, high glycolysis enables cancer cells to survive in low oxygen 
conditions in which their normal counterparts cannot survive (DeBerardinis et al., 
2008).  
 
In contrast to oncogenes, mutations in tumour suppressors lead to either truncated 
proteins which lack tumour suppression activity or their expression is silenced due to 
epigenetic modifications (Ruddon, 2007). For example, the tumour suppressor p53 is 
mutated in more than 50% of the human cancers (Soussi et al., 2006). Mutated p53 
lacks tumour suppressive activities such as cell cycle arrest, cell repair and apoptosis.  
 
 
Figure 1.1.1: p53 differentially selects the target genes according to the stress conditions 
Depending on the type and severity of stress, p53 modulates different subsets of its 
transcriptional target genes which can either induce cell survival or death. P53R2: p53 inducible 
ribonucleotide reductase; GADD45: Growth arrest and DNA damage 45; ROS: Reactive 
oxygen species; Bax: Bcl2 associated X protein; PUMA: p53 upregulated modifier of apoptosis; 
PGM: Phosphoglycerate mutase; NQO1: NAD(P)H dehydrogenase (quinone) 1; PIG3: p53 
inducible gene 3; The figure is modified from (Bensaad and Vousden, 2007). 
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Apart from loss of function, mutations in tumour suppressor genes can lead to gain of 
function. For example, mutated p53 can promote tumorigenesis, poor prognosis and 
drug resistance (Seton-Rogers, 2009).  
 
Activated by various cellular stress conditions wild type tumour suppressors are able to 
sense oncogenic signalling and in response promote cell protective functions. For 
example, when cells are exposed to mild or reversible stress, the p53 tumour suppressor 
will transcriptionally activate a particular subset of its target genes to stimulate cell 
cycle arrest (p21
WAF-1/CIP-1
) (Tang et al., 1998), or antioxidant genes such as TIGAR and 
Sestrins to prevent ROS induced apoptosis (Bensaad et al., 2006; Budanov et al., 2004), 
or DNA damage repair genes (p53R2, GADD45) to repair damaged DNA (Figure 1.1.1)  
(Bensaad and Vousden, 2007). In the case of severe and irreversible genotoxic stress, 
p53 will turn on the gene expression of a different subset of its target genes to promote 
apoptosis (NOXA, PUMA, Bax) (Nakano and Vousden, 2001; Oda et al., 2000; 
Toshiyuki and Reed, 1995) and repress the expression of anti-oxidant genes (NQO1) 
(Bensaad and Vousden, 2007).  
1.2 Glucose metabolism 
The human diet is composed of complex nutrients such as proteins, lipids, and 
polysaccharides which must be broken down into smaller molecules before the cells can 
use them as a source of energy (Alberts et al., 2002). The digestive enzymes hydrolyse 
the most frequently used nutritive sugar, the disaccharide sucrose into the 
monosaccharide glucose. Glucose is actively transported into mammalian cells and 
subsequently converted to pyruvate which is either transformed to lactate in the 
cytoplasm or enters mitochondria where it is oxidized to carbon dioxide and water 
(Lehninger et al., 2005) and produces energy in the form of ATP (Figure 1.2.1) 
1.2.1 Glycolysis 
The cytoplasmic breakdown of glucose into pyruvate is called glycolysis. As all the 
enzymes of glycolysis are present in the cytoplasm and can function independent of 
oxygen availability, glycolysis can proceed in the cytoplasm both in the absence and 
presence of oxygen (Murray et al., 2003). In the first step of glycolysis, glucose is 
phosphorylated to glucose 6-phosphate (G6P) catalysed by hexokinase 2 (HK2) using 
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ATP as the phosphate donor. This is an irreversible reaction and hence one of the rate 
limiting reactions of glycolysis. G6P is then converted to fructose 6-phosphate (F6P) by 
glucose phosphate isomerase (GPI). Next F6P is phosphorylated to fructose 1,6-
bisphosphate (F1,6-BP) catalysed by phosphofructokinase 1 (PFK-1) using ATP as 
another substrate. PFK-1 is functionally inactive in physiological conditions and 
requires fructose 2,6-bisphoshate to be activated. This reaction is another rate liming 
reaction in the glycolytic pathway (Lehninger et al., 2005; Murray et al., 2003; Singh 
and Costello, 2009).  
 
F1,6-BP is cleaved by aldolase into two triose phosphates, glyceraldehyde 3-phosphate 
and dihydroxyacetone phosphate. Glyceraldehyde 3-phosphate and dihydroxyacetone 
phosphate are interconverted by the enzyme triose phosphate isomerase (TPI). The 
NAD dependent enzyme glyceraldehyde 3-phosphate dehydrogenase, converts 
glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate. Phosphoglycerate kinase 
catalyzes the transfer of one phosphate group from 1,3-bisphosphoglycerate to ADP to 
form ATP and 3-phosphoglycerate.  
 
Since two molecules of triose phosphate are formed per molecule of glucose two 
molecules of ATP are formed at this stage per molecule of glucose. 3-phosphoglycerate 
is isomerized to 2-phosphoglycerate by Phosphoglycerate mutase (PGM). Enolase 
catalyzes the conversion of 2-phosphoglycerate into phosphoenol pyruvate (PEP). 
Pyruvate kinase enzyme catalyzes the transfer of a phosphate group from PEP to ADP 
to produce pyruvate and 2 ATP molecules. Under anaerobic conditions, pyruvate is 
reduced in the cytoplasm to produce lactate, a reaction catalysed by lactate 
dehydrogenase enzyme. However, in aerobic conditions, pyruvate is taken up into 
mitochondria and converted to acetyl CoA which is subsequently oxidized to CO2 by 
the enzymes involved in the citric acid cycle. The 2 NADH produced in glycolysis, 2 
molecules of NADH produced in oxidative decarboxylation of pyruvate and 8 NADH 
and 2FADH2 molecules produced in the citric acid cycle are oxidised to form electrons 
which flow through the electron transport chain subunits through which a proton 
gradient is created across the inner mitochondrial membrane. 
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Figure 1.2.1: Cellular energy metabolisc pathways 
In glycolysis, glucose is converted to pyruvate by glycolytic enzymes. Pyruvate is either 
converted to lactate in the cytoplasm or enters mitochondria where it undergoes oxidative 
decarboxylation, TCA cycle and electron transport chain to produce 36 ATP molecules. HK – 
hexokinase, GPI – glucose phosphate isomerase, PFK-1 – phosphofructokinase, TPI – triose 
phosphate isomerase, GAPDH – glyceraldehyde phosphate dehydrogenase, PGK – 
Phosphoglycerate kinase, PGM – Phosphoglycerate mutase, PK – pyruvate kinase, LDH – 
lactate dehydrogenase, PDH – pyruvate dehydrogenase. Mitochondrion is drawn in green colour 
and the enzymes are mentioned in red colour. 
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ATP is synthesised by the ATP synthase enzyme using the chemiosmotic gradient to 
drive phosphorylation of ADP. The electrons are finally accepted by the molecular 
oxygen and water is produced. Thus a net of 38 ATP molecules (including 2 ATPs from 
glycolysis) are synthesised from each molecule of glucose consumed by the cells 
(Lehninger et al., 2005; Murray et al., 2003; Singh and Costello, 2009). Figure 1.2.1 
schematically represents the important steps of glycolysis and mitochondrial respiration.  
1.3 Cancer metabolism 
1.3.1 Background 
The cells require ATP for their growth and survival, which is primarily obtained from 
catabolizing glucose in a two-step process. The first step is glycolysis, in which the 
glucose is converted to pyruvate in the cytoplasm to produce a net of 2 ATPs from each 
glucose molecule utilized. The second step occurs in the mitochondria and includes 
oxidative decarboxylation in which pyruvate is converted to acetyl CoA, tricarboxylic 
acid cycle (also known as citric acid cycle and Krebs cycle) in which acetyl CoA is 
converted to CO2 and produces 2ATPs, 6NADH and 2FADH2 and oxidative 
phosphorylation in which NADH and FADH2 are oxidized to release the electrons 
which pass through a series of protein complexes called electron transport chain (ETC). 
The energy produced from the flow of electrons through ETC drives the synthesis of 
ATP by the phosphorylation of ADP hence known as oxidative phosphorylation  
(Lehninger et al., 2005).  
In low oxygen conditions such as intense exercise, the end product of glycolysis 
pyruvate, instead of entering mitochondria and proceeding to OXPHOS is converted to 
lactic acid in the cytoplasm by lactate dehydrogenase in a process termed anaerobic 
glycolysis. Although the glycolytic flux provides less ATP (2 ATP molecules per one 
molecule of glucose) cells succeed to obtain enough ATP for their survival by rapidly 
consuming glucose. However this metabolic shift towards glycolysis is a temporary 
cellular adaptation to hypoxia which switches back to OXPHOS when oxygen levels 
return to normal (Garber, 2004). This inhibitory role of oxygen in the utilization of 
glucose was first noted by Louis Pasteur in 1857 and hence named Pasteur Effect 
(Gatenby and Gillies, 2004). 
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1.3.2 Warburg effect 
In 1924 Otto Warburg observed that the cancer cells escape Pasteur Effect and convert 
glucose to lactic acid even in the presence of ample oxygen (Figure 1.3.1) (Warburg, 
1956; Warburg et al., 1924). This phenomenon is known as Warburg effect or aerobic 
glycolysis. Warburg hypothesised that this metabolic change from OXPHOS to 
glycolysis is due to the impaired mitochondrial respiration, and this was the cause of 
cancer (Warburg, 1956). The lack of experimental evidence however for impaired 
mitochondrial respiration in cancer cells led his hypothesis to controversies (Racker, 
1983; Weinhouse, 1976). However, more recent reports suggest that mutations in 
mitochondrial DNA that lead to defects in respiratory chain complexes and genes 
encoding TCA cycle enzymes such as succinate dehydrogenase (SDH) and fumarate 
hydratase (FH) might contribute to Warburg effect (Bayley and Devilee, 2010; Baysal 
et al., 2000). 
 
 
Figure 1.3.1: Energy production pathways in normal and cancer cells 
The normal and cancer cells follow different cellular energy production pathways. In hypoxic 
conditions, both normal and cancer cells produce energy through glycolysis. In normoxic 
conditions, while normal cells produce energy through OXPHOS in intact mitochondria, cancer 
cells with their defective mitochondria prefer to produce energy through glycolysis. Intact 
mitochondria are denoted by green circle whereas impaired mitochondria are denoted by dotted 
red circle. The normoxia and hypoxia are denoted in green and red background respectively.  
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1.3.3 Warburg Effect and cancer cells 
It has been shown that tumour cells benefit from high glycolytic shift in several ways. 
Pederson et al explain that glycolysis is a rich source of precursors which are essential 
for the biosynthesis of nucleic acids, phospholipids, fatty acids, porphyrins and 
cholesterol (Pedersen, 2007), thereby high glycolytic rates in cancer cells facilitate not 
only survival but also a high growth rate. Furthermore the low pH of lactic acid, the end 
product of aerobic glycolysis, creates acidic environment which assists tumour cells to 
protect themselves from the body’s immune system. Cancer cells can survive producing 
energy through glycolysis even when there is no oxygen since the enzymes involved in 
glycolysis are not only oxygen independent but their expression can be stimulated in 
hypoxic environment (Murray et al., 2003; Pedersen, 2007). It has been assumed that 
increased glycolytic rate facilitates cells to overcome the destructive effects of reactive 
oxygen species (ROS) produced by oxidative phosphorylation, thereby imposing cell 
survival (Simon et al., 2000). The immortalization potential conferred to cancer cells by 
aerobic glycolysis could be a step towards tumorigenesis (Kim and Dang, 2006; Lu and 
Finkel, 2008). 
 
1.3.4 Oncogenic activation of Warburg effect 
In addition to the mutations of genes encoding the enzymes involved in energy 
metabolism, the Warburg effect can be induced by oncogenes such as AKT, MYC and 
HIF-1α. The oncoprotein AKT activates GLUT4, thereby enhances glucose uptake and 
induces HK2 to promote glycolysis (Elstrom et al., 2004; Kim and Dang, 2006). Myc 
contributes to the Warburg effect in cancer cells by regulating the gene expression of 
many glycolytic enzymes such as HK2, enolase1, LDH-A, PFK-M, glyceraldehyde 
phosphate dehydrogenase (GAPDH) and TPI1 (Kim et al., 2004a) and promoting 
glycolysis. Activation of Myc in human B cell model has been shown to be associated 
with mitochondrial biogenesis (Li et al., 2005), and to increase intracellular ROS levels 
which might cause mutations in the mitochondrial DNA leading to dysfunctional 
mitochondria (Kim and Dang, 2006).   
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HIF-1 has been shown to contribute to the Warburg effect by up-regulating the glucose 
uptake by GLUT1 and GLUT3 (Iyer et al., 1998) and promote glycolysis by regulating 
most of the glycolytic enzymes including HK2 and PFK1, aldolase, triose phosphate 
isomerase (TPI), GAPDH, phospho glycerate kinase (PGK1) enolase and lactate 
dehydrogenase (LDH) (Figure 1.4.4) (Dang and Semenza, 1999; Gess et al., 2004; 
Marín-Hernández et al., 2006; Semenza et al., 1994). In addition to enhance glycolysis, 
HIF-1 also inhibits mitochondrial respiration by up-regulating PDK-1, which 
phosphorylates and inactivates the PDH complex thereby inhibiting the conversion of 
pyruvate to acetyl-CoA, an important step of mitochondrial respiration (Figure 1.4.4) 
(Kim et al., 2006; Papandreou et al., 2006).  
1.3.5 Warburg effect and tumorigenesis 
Although aerobic glycolysis is induced due in part to oncogenic activation of glycolytic 
enzymes and mutations in genes encoding enzymes involved in OXPHOS, a recent 
report suggests that increased glycolysis could contribute to immortalization and 
subsequent malignant transformation. The study (Kondoh et al., 2005) identified two 
genes encoding glycolytic enzymes namely glucose phosphate isomerase (GPI) and 
phospho glycerate mutase (PGM) to contribute to immortalization in mouse embryonic 
fibroblast (MEF) cells. Mutated p53 has also been shown to up-regulate PGM and 
contribute to the immortalization of MEFs.  
1.3.6 Exploiting Warburg effect in cancer therapy 
The principle of Warburg effect has successfully been used as cancer diagnostic tool 
known as Positron Emission Tomography (PET). High glucose utilizing cells such as 
brain, kidney and cancer cells can uptake Flurodeoxyglucose (
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F-FDG or FDG) which 
is a glucose-analogue. Since FDG cannot be metabolized further and cannot move out 
of the cells is easily detected by scanning inside cancer cells which normally utilize high 
glucose.  
 
Warburg proposed that increased glycolytic rate in cancer is connected to significant 
malfunction of the mitochondrial respiration due to various factors and for that reason 
tumour cells become more dependent on glycolysis. Elevated glycolysis is common in 
most of human cancers (Semenza, 2003), therefore understanding the molecular 
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pathways leading to up-regulated glycolysis in cancer cells may provide the means to 
design novel anticancer therapeutic approaches intervening at various steps of the 
process (Gatenby and Gillies, 2007). In addition, taking into account the fact that normal 
cells bearing competent mitochondrial respiration may produce energy through 
alternative energy sources such as fatty acids and amino acids, therapeutic approaches 
inhibiting glycolysis might prove to be selective in targeting cancer cells (Pelicano et al., 
2006). 
1.3.6.1 Known treatment strategies 
Several reports have indicated that inhibition of glycolysis effectively kills cancer cells 
with defective mitochondria (Xu et al., 2005). The most effective way to inhibit 
glycolysis is by targeting the activity of the rate limiting enzymes of glycolysis such as 
HK,  PFK, as well as GAPDH and lactate dehydrogenase (LDH) (Chen et al., 2007). 
PFK1 facilitates phosphorylation of fructose-6-phosphate and converts it to fructose-1, 
6-bisphosphate. This rate limiting enzyme is inhibited by ATP, PEP, and citrate 
(Lehninger et al., 2005). PFK1 is allosterically activated by fructose 2,6-bisphosphate 
which is regulated by PFKFB. Recently Bensaad et al reported that the p53 target gene 
TIGAR inhibits the formation of fructose-2,6-bisphosphate and inhibits glycolysis 
(Bensaad et al., 2006). TIGAR as one of the genes that has been studied further in this 
thesis is discussed in details in section 1.7. 
 
HK2 catalyses the first reaction of glycolysis, and is highly expressed in transformed 
cells. HIF-1α and mutated p53 stimulate HK2 expression (Pedersen et al., 2002) 
promoting glycolysis. Lack of HK2 enzymatic activity leads to the inhibition of both 
glycolysis and pentose phosphate pathway (PPP). In addition, HK2 inhibits apoptosis in 
cancer cells by binding to mitochondria and preventing the interaction of the pro-
apoptotic Bax with the mitochondrial surface thereby preventing the release of 
cytochrome c (Pastorino et al., 2002). Therefore targeted inhibition of HK2 by 2-
deoxyglucose, 3-bromo pyruvate, methyl jasmonate, 5-thioglucose and mannoheptulose 
(Chen et al., 2007; Goldin et al., 2008) results in decreased glycolysis, decreased PPP 
and increased apoptosis and these compounds are currently evaluated as anti-cancer 
therapeutics.  
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In addition glycolysis can be inhibited by GAPDH inhibitors α-chlorohydrin, ornidazole 
and iodoacetate (Bone and Cooper, 2000) and LDH inhibitor oxamate and butanedione 
(Wilkinson and Walter, 1972; Yang and Schwert, 1972). 
1.4 Hypoxia Inducible Factor - 1α 
1.4.1 Discovery 
In 1988, Goldberg et al., provided evidence that the transcriptional regulation of gene 
expression of erythropoietin (EPO) was under the control of a heme protein responsive 
to low oxygen concentration (Goldberg et al., 1988). Later studies on the hypoxia 
mediated induction of EPO led to the identification of a cis-acting hypoxia responsive 
element (HRE) in the 3’-flanking region of this gene (Beck et al., 1991; Pugh et al., 
1991; Semenza et al., 1991). In 1992 Semenza et al., identified a nuclear factor induced 
by hypoxia, that could bind with high efficiency to the HRE present within the 
regulatory region of the enhancer of EPO inducing its expression, which was named as 
hypoxia inducible factor 1 (HIF-1) (Semenza and Wang, 1992). Shortly after HREs 
were identified in several other hypoxia responsive genes such as VEGF (Levy et al., 
1995), GLUT-1 (Ebert et al., 1995), and genes encoding various glycolytic enzymes 
(Firth et al., 1994; Semenza et al., 1994). Other HIF family members were discovered 
later including HIF-2α (Ema et al., 1997; Flamme et al., 1997; Tian et al., 1997; Wenger 
and Gassmann, 1997), HIF-3α (Gu et al., 1998) and HIF-2  (also known as ARNT-2) 
(Hirose et al., 1996; Wines et al., 2001). 
1.4.2 Structural Characteristics of HIF family members 
HIF-1 is a heterodimer, composed of two different subunits, a hypoxia inducible HIF-1α 
and a constitutively expressed HIF-1  (also known as aryl hydrocarbon receptor nuclear 
translocator - ARNT) (Wang and Semenza, 1995). Both subunits of HIF-1 are basic-
helix-loop-helix (bHLH) proteins containing a Per-ARNT-Sim (PAS) motif (Wang et 
al., 1995). Along with the wild type HIF-1α which comprise a protein of 826 amino 
acids, eight alternative splice variants of HIF-1α (HIF-1α827 (Gothié et al., 2000), HIF-
1α736 (Gothié et al., 2000), HIF-1α557 (Chun et al., 2001), HIF-1α516 (Chun et al., 2002), 
HIF-1α785 (Chun et al., 2003), HIF-1α417 (Lee et al., 2004), HIF-1αTE (Depping et al., 
2004) and an isoform with alternative exon 1 (I.3 isoform) (Lukashev and Sitkovsky, 
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2008) have also been reported.  HIF-1  comprises of 774 amino acids (if exon 5 is 
excluded) or 789 amino acids (if exon 5 is included) (Wang et al., 1995). All HIF-1α 
splice variants dimerize with HIF-1  in human cells to form the transcriptionally active 
HIF-1 heterodimer (Dales et al., 2010).  
 
HIF-1α and HIF-2α are regulated in response to hypoxia in a similar way (Hu et al., 
2003) and exhibit 48% amino acid identity and high degree of homology in their bHLH 
(83%), PAS (70%), and ODDD (Hu et al., 2003) domains. In addition, their C–terminal 
domain, which is important for the binding of the transcriptional cofactor p300/CBP is 
highly conserved (Ebert and Bunn, 1998; Ema et al., 1999) implying that apart from the 
response to hypoxia the regulation of the transcriptional activity of both HIF-1α and 
HIF-2α is executed in a similar way. HIF-2α also dimerizes with HIF-1  and forms the 
transcriptionally active HIF-2 complex which binds to the HREs of hypoxia inducible 
genes regulating their expression (Ema et al., 1997). However, unlike HIF-1α which is 
ubiquitously expressed in most tissues, the distribution of HIF-2α is limited to various 
vascular structures (Jain et al., 1998) and brain, heart, lung, kidney and liver tissues 
(Wiesener et al., 2003).   
 
Six splice variants of HIF-3α have been reported namely HIF-3α 1 to 6 (Maynard et al., 
2003). Along with bHLH and PAS domains, HIF-3α also shares high homology with 
HIF-1α and HIF-2α in the N-terminal activation domain (N-TAD) and ODDD, but lacks 
C-terminal activation domain (C-TAD) (Gu et al., 1998) hence acts as a weak 
transcription factor compared to the other two members of the HIF-α family  (Hara et 
al., 2001). Moreover, the human HIF-3α4 splice variant lacks ODD, N-TAD and C-
TAD domains and functions as HIF-1α dominant negative repressing HIF-1 mediated 
transcription is downregulated in renal cell carcinoma cells demonstrating the role of 
HIF-3α4 in tumorigenesis (Maynard et al., 2005).  
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1.4.3 Functional domains of the HIF family members 
All HIF family members contain N-terminal bHLH domains followed by PAS A and B 
motifs (Wang et al., 1995). The dimerization between HIFα and HIF  subunits occurs 
through the HLH and PAS (A) domains whereas the DNA binding occurs through the 
basic and PAS (B) domains (Brahimi-Horn and Pouyssegur, 2009; Gradin et al., 1996; 
Jiang et al., 1996; Jiang et al., 1997b). Two nuclear localization signals (NLS) are found 
in HIF-1α; one in its N-terminal and the other in its C-terminal region (Figure 1.4.1) 
(Kallio et al., 1998; Luo and Shibuya, 2001). Upon stabilization, HIF-1α protein 
translocates into the nucleus and dimerizes with HIF-1  to form the HIF-1 transcription 
complex (Kallio et al., 1998). 
 
 
 
Figure 1.4.1: Domain structure of HIF family members 
Schematic diagram indicating the domain structure of the HIF family members. Dimerization 
between the HIF-α and HIF-  subunits occurs through binding of the HLH and PAS (A) 
domains located in the N-terminal region of each subunit and the DNA binding occurs through 
the basic and PAS (B) domains (Brahimi-Horn and Pouyssegur, 2009). The different domains 
are represented in different colours. NLS: Nuclear localization signal; bHLH: basic helix loop 
helix; PAS: Per-ARNT-Sim; ODDD: Oxygen dependent degradation domain; N-TAD: N-
terminal transactivation domain; C-TAD: C-terminal transactivation domain. ARNT: Aryl 
hydrocarbon nuclear translocator. 
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The oxygen dependent degradation domain (ODDD) plays an essential role in the 
stabilisation of HIF-α subunits (Huang et al., 1998). Under normoxic conditions prolyl 
hydroxylation occurring in their ODDD domain (Pro564 and Pro402) marks HIF-α 
proteins for proteasomal degradation by enhancing their interaction with the E3 
ubiquitin ligase von Hippel-Lindau protein (pVHL). However, as PHD hydrodroxylases 
are inactive in hypoxic conditions proline hydroxylation does not occur, leading to 
stabilisation of the HIF-α subunits (Cockman et al., 2000; Maxwell et al., 1999; Ohh et 
al., 2000; Tanimoto et al., 2000).  
 
HIF-1α and HIF-2α contain two transactivation domains, one N-terminal (N-TAD; 
amino acids 531 to 575 of HIF-1α) and one oxygen regulated C-terminal (C-TAD; 
amino acids 786 to 826) (Jiang et al., 1997b). Both N-TAD and C-TAD are involved in 
the recruitment of co-factors such as CBP/p300 (Arany et al., 1996; Ema et al., 1999), 
SRC-1 and TIF-1 (Carrero et al., 2000) and activate the transcription of HIF-1α and 
HIF-2α. In addition to hypoxia cobalt chloride and desferrioxamine can also induce 
HIF-α stabilisation and TAD functions (Jiang et al., 1997b; Pugh et al., 1997). The 
human inhibitory PAS (IPAS) protein orthologue HIF-3α4 lacks ODD and 
transactivation domains and acts as dominant negative regulator of both HIF-1α and 
HIF-2α (Maynard and Evans, 2007; Maynard et al., 2005). A schematic diagram 
indicating the functional domains of HIF proteins is shown in Figure 1.4.1. 
1.4.4 Regulation of HIF stability and transcriptional activity 
Although, both HIF-1α and HIF-1  subunits are constitutively expressed in normoxic 
and hypoxic conditions, HIF-1α protein stabilisation and enhanced DNA binding 
activity present only in hypoxic conditions. This indicated that HIF-1α subunit is 
responsive to low oxygen concentration (Kallio et al., 1997). Destruction of HIF-α 
subunits in normoxic conditions was found later to be mediated by the ubiquitin-
proteasome pathway (Huang et al., 1998; Salceda and Caro, 1997; Sutter et al., 2000). 
In particular the constitutive stabilization of HIF-α subunits and the transcriptional 
activation of HIF-1 complex in cells deficient of the tumour suppressor protein pVHL 
established a role for this protein in regulating the function of HIF-α subunits in 
normoxic conditions (Cockman et al., 2000; Kamura et al., 2000; Maxwell et al., 1999; 
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Ohh et al., 2000; Tanimoto et al., 2000). The α-domain of pVHL forms a complex 
(VCBCR) with elongin B, elongin C, Cul-2 and Ring-H2 box protein (Rbx1) (Kamura 
et al., 1999), which has E3 ubiquitin ligase activity. Prolyl hydroxylated HIF-α protein 
binds to pVHL  domain resulting in HIF-1α poly ubiquitination (Ivan et al., 2001; 
Jaakkola et al., 2001; Masson et al., 2001) and degradation by the 26S proteasomes 
(Figure 1.4.2) (Kallio et al., 1999; Sutter et al., 2000).  
 
The hydroxylation of proline residues at 564 (HIF-1α P564) (Ivan et al., 2001; Jaakkola 
et al., 2001) and 402 (HIF-1α P402) (Masson et al., 2001) within the ODD domain of 
HIF-α proteins is mediated by prolyl hydroxylase enzymes (PHDs 1-4) (Appelhoff et 
al., 2004; Bruick and McKnight, 2001; Epstein et al., 2001; Oehme et al., 2002). 
 
 
Figure 1.4.2: Oxygen dependent stabilization of HIF-1α 
Prolyl hydroxylases (PHDs) hydroxylate HIF-1α in the presence of oxygen. The hydroxylated 
HIF-1α then binds to VCBCR complex which promotes HIF-1α ubiquitination followed by 26S 
proteasome dependent degradation (upper panel). Hypoxia prevents HIF-1α prolyl 
hydroxylation by PHDs, leading to its protein stabilization, and subsequent nuclear 
translocation, dimerization with HIF-1  and binding to transcription co-factors of the p300/CBP 
multi-protein complex becoming transcriptionally active (lower panel). 
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PHDs are non-heme Fe (II) and 2-oxoglutorate dependent dioxygenases (2-OG 
oxygenases) that utilize molecular oxygen as a co-substrate (Epstein et al., 2001) 
therefore their function is inhibited by iron chelators such as desferrioxamine (DSFX), 
transition metal ion salts such as cobalt chloride (CoCl2) and small molecule inhibitors 
of 2-OG analogues.  
 
The receptor activated protein kinase C (RACK1) (Liu et al., 2007) has also been shown 
to regulate HIF-1α protein stability interfering with the interaction between HIF-α PAS-
A domain and HSP90 which protects HIF-α from degradation. In the case this 
interaction is inhibited, RACK1 binds to HIF-α and recruits components of E3 ubiquitin 
ligase such as Elongin-B and Elongin-C promoting HIF-α degradation (Liu et al., 2007). 
The E3 ubiquitin ligase hypoxia associated factor (HAF) has also been shown to 
mediate HIF-1α protein degradation (Koh et al., 2008). 
 
Reactive oxygen species (ROS) production in mitochondria play important part in the 
regulation of cellular oxygen concentration and thus in the regulation of HIF-α protein 
stability. Although the precise role of mitochondria-derived ROS in the stabilization of 
HIF-1α has not been clearly elucidated, it has been hypothesised that ROS mediated 
inhibition of PHD enzymes is the mechanism by which HIF-1α is stabilised under these 
conditions (Chandel et al., 2000; Schroedl et al., 2002), though recent reports suggest 
that the stabilization of HIF-1α in hypoxic conditions is independent of mitochondrial 
ROS production (Chua et al., 2010). PHD activity is also affected by the function of the 
succinate dehydrogenase (SDH) which converts succinate to fumarate in the TCA cycle. 
Downregulation of SDH leads to increased accumulation of succinate in the cells, 
leading to the dissociation of pVHL from HIF-1α and subsequent stabilization of the 
transcription factor (Selak et al., 2005).  
 
While oxygen concentration mainly mediates HIF-1α protein stability cell type specific 
stabilisation of HIF-1α in normoxic conditions by oxygen independent pathways have 
also been reported (Semenza, 2003). For example, genetic alterations including loss of 
function mutations in the tumour suppressor genes encoding p53, PTEN and pVHL 
(Maxwell et al., 1999; Ravi et al., 2000; Zundel et al., 2000), as well as gain of function 
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mutations of oncogenes that activate phosphatidyl-inositol 3-kinase (PI3K), SRC and 
mitogen-activated protein kinase (MAPK) pathways (Jiang et al., 1997a; Richard et al., 
1999; Zhong et al., 2000) have also been shown to regulate HIF-1α protein stability.  
 
Growth factors such as insulin (Zelzer et al., 1998), insulin like growth factor-2 (IGF-2) 
(Feldser et al., 1999), transforming growth factor-α (TGF-α) and interleukin-1β  
(Hellwig-Burgel et al., 1999) activate the phosphatidyl-inositol dependent kinase 1 
which in turn phosphorylates and activates protein kinase B (PKB, also known as AKT) 
thereby stimulating the expression of HIF-1α in normoxic conditions (Zhong et al., 
2000) in a series of reactions shown in Figure 1.4.3. Growth factors can also stimulate 
HIF-1α transcriptional activity by activating the Ras oncogene and eventually 
MAPK/ERK kinase (MEK1/2) and the extracellular signal-regulated kinase (ERK1/2) 
pathway as shown in Figure 1.4.3 (Richard et al., 1999; Sang et al., 2003).  
 
 
Figure 1.4.3: Signal transduction pathways of HIF-1α regulation 
Schematic representation of signal transduction pathways promoting HIF-1α synthesis and 
transcriptional activity. HIF-1α can be induced under normoxic conditions by growth factors 
stimulating the PI3K/AKT/FRAP pathway. In hypoxic conditions, the RAS/RAF/MEK/ERK 
pathway induces HIF-1α transcriptional activity.  
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In addition to hydroxylation of proline residues, acetylation of lysine 532 within the 
ODD domain of HIF-1α by ARD1 also promotes the interaction of HIF-1α with pVHL 
and promotes its degradation (Jeong et al., 2002). Although the K532 acetylation is not 
affected in hypoxic conditions, endogenous ARD1 mRNA and protein levels are 
downregulated in hypoxia leading HIF-1α stabilization in hypoxia (Jeong et al., 2002; 
Xenaki et al., 2008). Recently Xenaki et al., have shown that PCAF interacts with and 
acetylates HIF-1α which enhances the stability of HIF-1α protein (Xenaki et al., 2008).  
 
While prolyl hydroxylation of P564 and P402 and acetylation of K532 regulate HIF-1α 
protein stability, asparaginyl hydroxylation occurring at Asn803 in the C-TAD of the 
human HIF-1α by the factor inhibiting HIF (FIH) interferes with the binding of this 
transcription factor to p300/CBP co-activator complex and modulates its transcriptional 
activity (Hewitson et al., 2002; Lando et al., 2002a; Lando et al., 2002b; Mahon et al., 
2001). Similar to PHDs, FIH is also a Fe (II) and 2-OG dependent oxygenase and 
utilizes molecular oxygen as a co-substrate (Dann et al., 2002). In-vitro experiments 
using HIF-1α polypeptides have shown that PHDs are inactivated as the severity of the 
hypoxia increases whereas FIH activity is lost in anoxic conditions. Recent reports 
though demonstrate that endogenous human HIF-1α hydroxylation is suppressed by 
hypoxia in the order of Pro
402
 > Pro
564
 > Asn
803
 indicating that prolyl hydroxylation is 
more sensitive to hypoxia than asparaginyl hydroxylation (Tian et al., 2011). HIF-1α 
binding to the p300/CBP coactivator complex is also regulated by the HIF-1α 
transcription target CBP/p300 interacting transactivator with ED-rich tail 2 (CITED2; 
also known as Mrg1 and p35srj) in a negative feedback manner (Freedman et al., 2003). 
 
Apart from prolyl hydroxylation and acetylation, sumoylation of HIF-1α at K391 and 
K477 also regulates its protein stability and transcriptional activity (Bae et al., 2004) 
possibly through modulation of other post translational modifications (Bae et al., 2004; 
Carbia-Nagashima et al., 2007).  
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1.4.5 HIF-1α and cancer metabolism 
In hypoxic conditions, normal cells, in order to produce energy, switch from OXPHOS 
to glycolysis and when oxygen becomes again available, they revert back to OXPHOS. 
This is not the case for cancer cells which even in the presence of oxygen, adapt to 
glycolysis (Warburg, 1956). HIF-1 plays critical role in this metabolic adaptation since 
it activates the expression of genes encoding glucose transporters and glycolytic 
enzymes which convert glucose to pyruvate and subsequently to lactate (Seagroves et 
al., 2001).  
 
Figure 1.4.4: HIF-1α regulates cancer cell metabolism. 
HIF-1α activates the glucose transporters GLUT1 and GLUT3 which promote the uptake of 
glucose by cells. In addition, HIF-1α promotes the rapid utilization of glucose by inducing the 
genes encoding glycolytic enzymes (indicated in red colour). HIF-1α also activates pyruvate 
dehydrogenase kinase 1 (PDK1) which phosphorylates and deactivates the pyruvate 
dehydrogenase (PDH) which converts pyruvate to Acetyl CoA, an important component for 
TCA cycle. The extracellular medium and cytosol are denoted in blue and pale orange 
respectively. Mitochondrion is drawn in blue colour. 
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HIF-1 stimulates SLC2A1 and SLC2A3 gene expression, genes that encode for the 
glucose transporters GLUT1 and GLUT3 respectively which promote the uptake of 
glucose by the cells (Iyer et al., 1998). Furthermore, the rapid utilization of glucose by 
cells is assisted by the HIF-1 mediated induction of several glycolytic enzymes 
including hexokinase, PFK1, aldolase, triose phosphate isomerase, glyceraldehyde 
phosphate dehydrogenase, phospho glycerate kinase  enolase and lactate dehydrogenase  
(Dang and Semenza, 1999; Gess et al., 2004; Marín-Hernández et al., 2006; Minchenko 
et al., 2003; Semenza et al., 1994). Another HIF-1 transcription target gene named 
pyruvate dehydrogenase kinase 1 (PDK1) plays important role in cellular energy 
production. PDK1 phosphorylates and inhibits pyruvate dehydrogenase complex (PDH) 
(Kim et al., 2006; Papandreou et al., 2006), which catalyzes the conversion of pyruvate 
to Acetyl CoA. Inhibition of PDH activity limits the entry of glycolytic carbon into the 
TCA cycle and promotes the conversion of pyruvate to lactate. Also, by inducing the 
BH3 domain protein BNIP3, HIF-1 induces selective mitochondrial autophagy (Zhang 
et al., 2008). BNIP3 competes with Beclin 1 for binding to Bcl2 thereby freeing Beclin 
1 to trigger autophagy.  
 
HIF-1 regulates gene expression of several subunits of the mitochondrial cytochrome c 
oxidase (COX) complex thereby affecting oxidative phosphorylation and maintaining 
oxygen homeostasis in hypoxic cells (Fukuda et al., 2007). In particular, HIF-1α 
activates COX4-2 isoform gene expression and indirectly downregulates COX4-1 
protein levels by inducing the expression of the mitochondrial protease that degrades 
COX4-1 called LON (Fukuda et al., 2007). In addition to regulating COX subunits, 
HIF-1 also regulates mitochondrial biogenesis as it has been indicated by ectopically 
expressing pVHL tumour suppressor in pVHL deficient cells, which exhibit increased 
mitochondrial mass, mitochondrial DNA and oxygen consumption (Hervouet et al., 
2005).   
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1.4.6 Other functions of HIF-1 
Hypoxia and nutrient deprivation result in reduced viability of cancer cells. HIF-1 as a 
master regulator of the cellular response to hypoxia contributes towards restoring 
oxygen homeostasis and supports cell survival in hypoxic conditions by stimulating 
gene expression of genes involved in angiogenesis, glycolysis, erythropoiesis and cell 
proliferation (Iyer et al., 1998).  
1.4.6.1 Erythropoiesis 
Erythropoiesis involves utilization of large amounts of iron by the bone marrow, which 
is used in the synthesis of haemoglobin. HIF-1 by regulating EPO, EPO receptor 
(EPOR), hepcidin, transferrin and transferrin receptor (TfR) controls erythropoiesis 
(Semenza, 2009). In the liver, HIF-1 stimulates iron uptake by repressing the gene 
encoding hepcidin, which is an inhibitor of ferroportin, the major protein responsible for 
intestinal iron uptake (Semenza, 2009). HIF-1 also activates hepatic synthesis of 
transferrin, the major plasma protein responsible for transporting iron from the intestine 
to the bone marrow via the transferrin receptor.  
1.4.6.2 Angiogenesis 
HIF-1 maintains oxygen homeostasis by promoting the growth of new blood vessels 
from the pre-existing blood vessels. HIF-1 mediates this effect by upregulating VEGF 
which increases the vascular density (Levy et al., 1995). In addition, HIF-1 controls the 
expression of genes involved in the maintenance of the vascular tone, including nitric 
oxide synthase (NOS2), heme oxygenease 1, endothelin 1 (ET1), adrenomedulin 
(ADM), and the a1B-adrenergic receptor (Ke and Costa, 2006).  
1.4.6.3 Cell proliferation and survival 
HIF-1 induces growth factors such as IGF-2, interleukin-1 and TNF-α (Section 0) and 
promotes the binding to their cognate receptors which lead to cell proliferation and 
survival. In addition these growth factors and cytokines activate the MAPK and PI3K 
signalling pathways upregulating HIF-1 activity thus forming a positive feed-back loop.  
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1.4.6.4 Apoptosis 
In addition to promoting cell proliferation and cell survival in hypoxic conditions, HIF-
1α has also effects on apoptosis in a cell type specific manner (Ke and Costa, 2006). 
Specifically, decreased apoptosis has been observed in embryonic stem cells with 
deleted HIF-1α (Carmeliet et al., 1998). Furthermore, HIF-1α induces apoptosis by 
activating caspase-3 and Apaf-1-mediated cleavage and activation of caspase-9 thus 
promoting the release of cytochrome-c (Ke and Costa, 2006). Also HIF-1α down-
regulates anti-apoptotic Bcl-2 family members and up-regulates the pro apoptotic 
protein BNIP-3 (Ke and Costa, 2006). The cross talk between HIF-1α and the tumour 
suppressor p53 regulates apoptosis by determining the balance of the pro-apoptotic 
versus anti-apoptotic genes of the Bcl-2 family (Nakano and Vousden, 2001; Oda et al., 
2000; Selvakumaran et al., 1994). 
1.4.7 Targeting HIF-1α for cancer therapy.   
The role of HIF-1α in angiogenesis, in the metabolic shift to glycolysis and survival and 
proliferation of tumour cells as well as its association with negative prognosis has been 
well documented. Hence silencing of HIF-1 activity has been considered in cancer 
therapy with positive initial indications. In mouse tumour xenografts for example, 
deletion of HIF-1 expression inhibited tumour growth (Brown and Wilson, 2004). Small 
molecule inhibitors such as echinomycin, which inhibits the DNA binding activity of 
HIF-1 (Cairns et al., 2007), chetomin which prevents HIF-1α binding to p300 (Kung et 
al., 2000) 2-methoxyestradiol, vincristine, 2-methoxyestradiol (2ME2) and paclitaxel 
which inhibit the translation of HIF-1 mRNA have been reported to reduce tumour 
growth in mice (Mabjeesh et al., 2003; Yeo et al., 2003).    
1.5 p53 tumour suppressor 
1.5.1 Introduction to p53 
Although identified as an oncogene in 1979, p53 attained its tumour suppressor status 
within a decade of its discovery (Soussi, 2010). The significance of p53 as a tumour 
suppressor is demonstrated by the fact that more than 70% of human cancers either have 
mutations within the p53 gene or defects in p53 regulatory pathways (Lozano and 
Elledge, 2000). p53 protein is a stress responsive transcription factor that is stabilized 
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and activated in response to numerous cellular stress types which include oncogenic 
activation, DNA-damage, hypoxia and nutrient deprivation (Lowe, 1999). Upon 
activation, p53 promotes cellular homeostasis by initiating a cascade of biological 
events which lead to cell cycle arrest, DNA repair, senescence and apoptosis (Toledo 
and Wahl, 2006). These regulatory roles of p53 are attributed to its well-known tumour 
suppressive functions by permitting the cells with mild damage to undergo cell cycle 
arrest and DNA repair whereas eliminating the cells with irreversible damage by 
apoptosis. The ability of p53 to monitor and maintain the integrity of the genome is well 
recognized. It has therefore been named “molecular policeman”, “cellular gatekeeper” 
and “the guardian of the genome” (Lane, 1992; Müller et al., 2004). Recent studies have 
demonstrated that p53 is also involved in the regulation of glucose and glutathione 
metabolism, cellular redox homeostasis, autophagy, insulin resistance and longevity 
assurance (Bensaad et al., 2006; Bensaad and Vousden, 2007; Crighton et al., 2006; 
Donehower, 2006; Hu et al., 2010; Matoba et al., 2006; Minamino et al., 2009; Naito et 
al., 2010). These studies display that p53 plays broader roles not only in cancer but also 
in various other diseases such as myocardial infarction and diabetes. 
1.5.2 Structure of p53 
p53 is a nuclear phospho-protein encoded by a 20kb gene containing 11 exons and 10 
introns that is located on the short arm of chromosome 17 (17p13) (Isobe et al., 1986; 
Lamb and Crawford, 1986). The wild type p53 protein is made up of 393 amino acids 
and composed of several structural and functional domains (Figure 1.5.1). The amino 
terminal end of p53 contains an acidic transactivation domain (NTAD1) which 
facilitates the recruitment of factors of the basal transcriptional machinery such as TBP, 
TAFs and TFIID (Lu and Levine, 1995). This domain binds also to proteins with 
transcriptional repression function such as MDM2 (Lin et al., 1994). In the amino 
terminal end there is also a proline rich transactivation domain (NTAD2) which is 
involved in the p53 mediated apoptosis (Sakamuro et al., 1997). The central domain of 
p53 contains the DNA binding domain which is the domain where more than 90% of 
p53 mutations occur in human cancers (Bensaad et al., 2003) rendering this 
transcription factor incapable to bind to the consensus sequences within the promoters 
of its target genes and demonstrating the importance of its transcriptional activity in 
executing its tumour suppressor functions (Benchimol, 2001). 
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Figure 1.5.1: Domain structure of p53 protein 
NLS – Nuclear localisation signal sequence; NES – Nuclear export signal sequence; TAD1 – 
Transactivation domain 1; TAD2 – Transactivation domain 2; OD – Oligomerization domain; 
REG – Regulatory domain.  
The carboxy terminal end contains the oligomerization domain which facilitates the 
formation of p53 tetramer upon stabilization. Formation of p53 tetramer is essential for 
p53 dependent transactivation and p53 mediated growth suppression (Pietenpol et al., 
1994). The carboxy terminal end also contains three nuclear export and a nuclear 
localization signal sequences and a strongly basic negative regulatory domain which is 
involved in the down regulation of DNA binding of the central DNA binding domain 
(Gu et al., 2001; Li et al., 2003) by locking this domain in a latent conformation. When 
the interaction between C-terminal regulatory region and the DNA binding domain is 
disrupted by post translational modifications such as phosphorylation and/or acetylation 
the DNA binding domain becomes active leading to enhanced p53 transcriptional 
activity (Ling and Wei-Guo, 2006).  
1.5.3 Regulation of p53 
p53 is a stress responsive transcription factor which modulates the expression of  
diverse sets of its target genes in a manner dependent on the type and severity of the 
stress. For example, under mild stress conditions p53 induces the expression of genes 
involved in cell cycle arrest (p21WAF-1/CIP-1) and DNA repair (GADD45) 
(Xiangbing, 1999) whereas after prolonged or irreversible cellular damage elevated 
levels of p53 and possibly combination of different post-translational modifications are 
required to activate genes involved in the initiation of apoptosis (bax, PUMA, NOXA, 
Apaf-1) and stimulation of senescence (p14ARF) that leads to cell death (Bensaad and 
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Vousden, 2007). Thus the levels of p53 as well as combination of its post-translational 
modifications orchestrate the balance between cell survival and death. Therefore it is 
extremely important to keep p53 levels at the appropriate level in non-stressed cells to 
avoid any unnecessary detrimental events directed by p53 (Gottifredi and Prives, 2001).  
1.5.4 Post-translational modifications of p53 
Post-translational modifications play important part in sensing and transmitting 
signalling effects in stress conditions. As stress responsive transcription factor the 
tumour suppressor protein p53 can be modified by a variety of stress conditions which 
are crucial for the regulation of p53 stability and transcriptional activity (Xu, 2003). 
Several post-translational modifications of p53 have been studied extensively including 
phosphorylation, acetylation, sumoylation, ubiquitination, etc., which affect the stability 
and transcriptional activity of p53. 
1.5.4.1 Acetylation 
The histone acetyl-transferases p300 and CBP act as transcriptional cofactors for 
numerous transcription factors including p53. CBP/p300 acetylate p53 at K305, K370, 
K372, K373, K381, K382 and K386 in its C-terminal region and K164 in its DNA 
binding domain, while PCAF and TIP-60 acetylate K320 and K120 respectively (Figure 
1.5.2) (Gu and Roeder, 1997; Liu et al., 1999; Meek and Anderson, 2009; Sakaguchi et 
al., 1998; Tang et al., 2008; Wang et al., 2003). PCAF -mediated acetylation of the p53-
K320 under DNA damage conditions such as UV irradiation results in the induction of 
the expression of the cyclin/CDK inhibitor p21WAF-1/CIP-1 leading to cell cycle arrest 
(Knights et al., 2006) an effect that has also been observed after acetylation of p53-
K120 by TIP-60 (Tang et al., 2006). Similarly, in hypoxic conditions p53 is 
hypoacetylated in K320 and the limited amounts of acetylated p53K320 are 
preferentially recruited to the pro-survival gene p21
WAF-1/CIP-1
 and not to the pro-
apoptotic gene BID leading to cell survival (Xenaki et al., 2008). In addition PCAF 
dependent acetylation of p53 promotes p53 stability by decreasing its ubiquitination and 
degradation mediated by Mdm2 (Li et al., 2002b; Sakaguchi et al., 1997). Several 
reports have indicated that acetylation and phosphorylation occur simultaneously 
although a recently published report suggests that p53 transcriptional activation by 
acetylation is independent of p53 phosphorylation (Tang et al., 2008).  
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1.5.4.2 Phosphorylation 
Human p53 is phosphorylated at multiple sites at the N and C-terminal regions by a 
number of kinases (Figure 1.5.2) (Xu, 2003). Following DNA damage, p53 is 
phosphorylated directly or indirectly by the phosphatidylinositol-3-kinase (PI3K) 
related kinases such as ataxia telangiectasia mutated (ATM) and ATM and Rad3-related 
(ATR). Following DNA single-strand break in which ATR is activated, and DNA 
double-strand break, in which many of these serine/threonine protein kinases are 
activated that regulate the activity of another group of kinases called the effector 
checkpoint kinases known as Chk1 and Chk2. Phosphorylation of p53 by ATM and 
ATR regulates the transcriptional activation of genes involved in DNA repair and 
apoptosis (reviewed in (Xu, 2003)). In hypoxic conditions, Chk2 kinase is 
phosphorylated by ATM but not by ATR and this phosphorylated Chk2 in turn 
phosphorylates p53 and stabilizes it. Chk2 mediated phosphorylation of p53 leads to 
cell cycle arrest and DNA repair (Gibson et al., 2005). 
 
ATM and ATR phosphorylate p53 at Ser15 and Ser20 directly or indirectly by 
activating Chk1 and Chk2 (Lambert et al., 1998; Zhang and Xiong, 2001) which inhibit 
the interaction between p53 and MDM2 thereby stabilizing p53 protein (Unger et al., 
1999). In addition to the stabilization and transactivation of p53, phosphorylation at 
various sites regulate its DNA binding activity and promote the recruitment of cofactors 
such as CBP/p300 and PCAF (Sakaguchi et al., 1998);(Xu, 2003).   
1.5.4.3 Ubiquitination  
Various post-translational modifications including ubiquitination, phosphorylation and 
acetylation are involved in the regulation of p53 protein stability. However, since p53 
protein degradation is mainly carried out by the 26S proteasome, which recognises its 
target proteins when they are poly-ubiquitinated, this post-translational modification is 
of prime importance for p53 stability (Maki et al., 1996). Various ubiquitinase and 
deubiquitinase enzymes are involved in the degradation of p53 (Dai and Gu, 2010).  
 
MDM2 (HDM2 in humans), is an oncoprotein with E3 ligase activity and the major 
negative regulator of p53. MDM2 gene expression is transcriptionally regulated by p53 
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in an auto regulatory feedback loop mode (Barak et al., 1993; Brooks and Gu, 2006). 
Overexpressed in various cancer types, MDM2 is shown to bind to the N-terminal 
transactivation domain of p53 inhibiting its phosphorylation at amino acid residues lay 
in this region (Chen et al., 1993). Since phosphorylation of amino acids in this domain 
is crucial for the stability and transcriptional activity of p53, binding of MDM2 to this 
domain inhibits both stabilisation and transactivation function of p53 (Oliner et al., 
1993). MDM2 acts as an E3 ligase and ubiquitinates the lysine residues K101, K120, 
K132, K139, K370, K372, K373, K381, K382 and K386 (Coutts et al., 2009; Honda et 
al., 1997) (Figure 1.5.2). Mono-ubiquitination of p53 by low levels of MDM2 facilitates 
p53 cytoplasmic translocation (Dai and Gu, 2010; Li et al., 2003) whereas poly-
ubiquitination by high levels of MDM2 aids 26S mediated p53 proteasomal 
degradation. 
 
 
Figure 1.5.2: Major post translational modifications of p53 
Schematic diagram showing the major post translational modifications of p53.  The important 
sites of phosphorylation, acetylation and ubiquitination and the enzymes catalysing these 
modifications are shown. Figure modified from (Dai and Gu, 2010). 
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The feedback loop between p53 and MDM2 is affected by several enzymes including 
p14
ARF
, MDMX and deubiquitinating enzymes such as HAUSP. Among these, p14
ARF
 
protects p53 by facilitating its translocation to subnuclear compartments such as the 
nucleoli thereby hindering p53 MDM2 interaction, or inhibiting MDM2 E3 ligase 
activity (Honda and Yasuda, 1999; Weber et al., 1999). MDMX (also known as 
MDM4) shares significant structural homology with MDM2 but unlike MDM2, MDMX 
does not seem to have E3 ligase function. Despite the lack of E3 ubiquitin ligase 
activity, MDMX forms a complex with p53 and both destabilises it, albeit with lower 
efficiency than that of MDM2, and inhibits its transcriptional activity (Shvarts et al., 
1997; Shvarts et al., 1996). More recent studies have revealed more complex roles of 
MDMX demonstrating that ubiquitinated p53 is sequestered in the nucleus by MDMX 
and is stabilized (Stad et al., 2001).  
 
Polyubiquitination of p53 is also mediated by other enzymes apart from MDM2 
including RING domain containing p53 Induced protein with RING-H2 domain 
(PIRH2), Constitutively Photomorphogenic 1 (COP1) and HECT domain containing 
ARF Binding Protein 1 (ARF-BP1) (Honda et al., 1997; Moll and Petrenko, 2003; 
Oliner et al., 1992). Furthermore, the transcriptional cofactor p300 has been shown to 
exert E3 ligase activity and mediate p53 protein degradation (Grossman et al., 2003; Shi 
et al., 2009). Ubiquitination of p53 is counteracted by deubiquitinase enzymes (DUBs) 
which remove ubiquitin molecules from p53. Among the DUBs Herpesvirus-Associated 
Ubiquitin Specific Protease (HAUSP, also referred as USP7) deubiquitinates and 
stabilizes p53 mainly in the nucleus whilst USP10 functions mainly in the cytoplasm 
(Brooks et al., 2007; Dai and Gu, 2010; Li et al., 2002a; Yuan et al., 2010). Protein-
protein interactions involved in the stabilization of p53 include interaction with the Heat 
Shock Protein – 90 (Hsp-90) and Simian Virus 40 (SV40) large T antigen (Müller et al., 
2004).  
1.5.5 Ubiquitin independent degradation of p53 
Besides 26S proteasome, p53 protein degradation is also mediated by the 20S 
proteasome in an ubiquitin independent manner (Asher et al., 2002b). The 20S 
proteasomal degradation of p53 is regulated by NQO1 which binds to p53 in an NADH 
dependent manner (Asher et al., 2002a). NQO1 inhibitors such as dicoumarol compete 
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with NQO1 for NADH and the NQO1-p53 complex dissociates. Released p53 
undergoes ubiquitination and MDM2 independent degradation (Tsvetkov et al., 2009). 
High NADH levels protect p53 from degradation by increasing its association with 
NQO1, whereas when NADH levels are low and the NQO1-p53 complex disrupted, p53 
is subjected to degradation mediated by the 20S proteasome machinery (Tsvetkov et al., 
2009). Also NQO1 has been shown to be associated with 20S proteasome which 
prevents the degradation of unstructured proteins such as p53 and p73 (Asher et al., 
2005).  
1.5.6 p53 and metabolism 
1.5.6.1 p53 and metabolic stress 
Cell signalling response under conditions of metabolic stress such as nutrient 
deprivation is mediated by p53 (Vousden and Ryan, 2009). AKT phosphorylates 
MDM2 and induces its translocation into the nucleus where it binds to p53 and marks it 
for 26S proteasomal degradation. p53 is activated in response to nutrient deprivation by 
the activation of AMP-activated protein kinase (AMPK) and by the inhibition of AKT. 
ATP and ADP exert opposing effects on the stability of p53-DNA complexes as ATP 
promotes and ADP represses the p53 binding to DNA (Okorokov and Milner, 1999). 
The nucleocytoplasmic enzyme malate dehydrogenase 1 (MDH1), which is involved in 
the TCA cycle, has been shown to act as a transcriptional co-activator for p53. 
Specifically, under conditions of glucose depletion, MDH1 translocates to the nucleus 
where it binds to p53 binding sites within the promoters of p53 transcription target 
genes (Lee et al., 2009) indicating that metabolic signals during starvation or low 
energy conditions induce p53 to exert its tumour suppressive effects (Vousden and 
Ryan, 2009).  
1.5.6.2 p53 and energy production 
Highly expressed glucose transporters such as various GLUT isoforms in many cancer 
cells provide to these cells the metabolic advantage. By repressing GLUT1 and GLUT4 
gene expression, p53 reduces the pace of glucose uptake and slows down cancer cell 
proliferation (Schwartzenberg-Bar-Yoseph et al., 2004b). Another pathway by which 
p53 inhibits glycolysis is by stimulating the expression of genes exerting anti-glycolytic 
effects such as the Tp53 induced glycolysis and apoptosis regulator (TIGAR). TIGAR 
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shares structural and functional similarities with the phosphatase domain of the bi-
functional (kinase and phosphatase activities) enzyme phospho fructo kinase 2/ fructose 
2,6-bisphosphatase 2 (PFK2/FBPase2 or PFKFB). The PFK2 part of this enzyme with 
its kinase activity converts fructose 6-phosphate (F6-P) to fructose 2,6-bisphosphate 
(F2,6-BP) and promotes glycolysis, while the FBPase2 domain of this enzyme with its 
phosphatase activity reverses this reaction (Murray et al., 2003). The ratio of the kinase 
to phosphatase activity of the PFKFB3 enzyme in cancer cells has been shown to be 
700:1 favouring the conversion of F2-P to F2,6-BP (which is an allosteric activator of 
the glycolysis rate limiting enzyme PFK-1) and hence induction of glycolysis 
(Minchenko et al., 2002). By stimulating TIGAR gene expression, p53 inhibits the 
intra-cellular levels of F2,6-BP, possibly by reducing the ratio of kinase to phosphatase 
activity of the PFKFB isoforms and hence inhibits glycolysis (Bensaad et al., 2006).  
 
 
Figure 1.5.3: p53 regulates cellular energy metabolism 
p53 inhibits glycolysis by modulating gene expression of GLUT1, GLUT4, HKII, PGM and 
TIGAR and promotes mitochondrial respiration by inducing SCO2 and p53R2. The 
extracellular medium and cytosol are denoted in blue and pale orange respectively. 
Mitochondrion is drawn in blue colour 
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Apart from TIGAR, p53 regulates the expression of other genes encoding for enzymes 
involved in glycolysis such as  phospho glycerol mutase (PGM) which encodes for the 
phospho glycerate mutase (PGM) enzyme is downregulated by wild type p53 leading to 
inhibition of glycolysis and is upregulated by mutated p53 resulting in activation of 
glycolysis (Kondoh et al., 2005). Potential p53 DNA binding sites have been identified 
within the promoter of the gene encoding for the glycolytic enzyme hexokinase type II 
(HKII) (Mathupala et al., 1997). Figure 1.5.3 schematically demonstrates the 
involvement of p53 in cellular energy metabolism. 
 
Except from glycolysis OXPHOS is also regulated by p53 through the effects this 
transcription factor exerts on gene expression of the Synthesis of cytochrome c oxidase 
2 (SCO2). SCO2 is essential for the assembly of the subunit 2 of the cytochrome c 
oxidase (COX) complex, the major site of oxygen utilization in the eukaryotic cell 
(Matoba et al., 2006). In addition, mutation in Ribonuclotide reductase M2 B (RRM2B) 
gene which encodes for the p53 inducible ribonucleotide reductase (p53R2) has been 
shown to cause mitochondrial DNA depletion leading to the inhibition of OXPHOS 
indicating that p53 promotes OXPHOS by upregulating p53R2 (Bourdon et al., 2007).   
1.5.6.3 p53 and ROS production 
ROS mediated apoptosis is one of the mechanisms through which p53 exerts its tumour 
suppressive role. As explained in section 1.1 under mild or reversible stress conditions 
p53 allows the cells to undergo DNA repair and proceed to normal proliferation while 
under severe or irreversible stress conditions promotes apoptosis (Vousden and Ryan, 
2009). In line with this model, under severe or irreversible stress conditions, p53 has 
been shown to upregulate pro-oxidant genes such as p53 inducible gene 3 (PIG3) 
(Ostrakhovitch and Cherian, 2005) and proline oxidase (Donald et al., 2001) and 
downregulates anti-oxidant genes such as PGM (Kondoh et al., 2005), superoxide 
dismutase 2 (SOD2) and NQO1 which promotes the ROS mediated apoptosis (Vousden 
and Ryan, 2009). The elevated ROS in turn cause DNA damage which activate p53 thus 
forms a feedback loop (Bensaad and Vousden, 2007). At the same time, in low stress 
conditions, p53 has been shown to induce anti-oxidant genes such as TIGAR (Bensaad 
et al., 2006) and Sestrins (Budanov et al., 2002) to protect the cells from ROS induced 
apoptosis.  
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1.6 PCAF 
1.6.1 Acetylation and transcription  
In human cells, about 3 billion base pairs of DNA are tightly packed in 23 pairs of 
chromosomes in roughly 3 micron diameter nucleus. This tight packaging of DNA is 
achieved by condensation of DNA into higher order chromatin structure. Nucleosomes 
are the basic functional packaging units of chromatin which consists of 147 base pairs 
of DNA wound around two copies of each of four histone proteins H2A, H2B, H3 and 
H4. 
 
The regulation of gene transcription is a complex process which involves at least in part, 
the ATP dependent chromatin remodelling and post translational modifications of 
histone and non-histone proteins (Batta et al., 2007). Chromatin in its higher order 
compaction structure prevents whereas in its relaxed structure allows the access of the 
basal transcription machinery to the DNA which is essential for the initiation of gene 
expression. Various post translational modifications including methylation, acetylation, 
phosphorylation, ubiquitination, sumoylation, ADP-ribosylation, citrullination etc. 
determine the order of complexity of chromatin structure. Among many enzymes that 
change the structure of chromatin, the acetylating enzymes are the most extensively 
studied structurally and functionally.  
 
Acetylation of histone tails reduces its net positive charge thereby reducing its affinity 
to DNA leading to the formation of relaxed DNA which now becomes accessible to 
general transcription factors (Verdin, 2006). Acetylation of histones is generally 
associated with activation while deacetylation with repression of gene expression. The 
enzymes which add and remove acetyl groups to and from the ε-amino group of lysine 
residues of histone tails are known as histone acetyl transferases (HATs) and histone 
deacetylases (HDACs) respectively. Known proteins with intrinsic HAT activity 
include p300, cAMP responsive element binding protein (CREB) binding protein 
(CBP), p300/CBP associated factor (PCAF) and steroid receptor coactivator 1 (SRC-1) 
(Verdin, 2006). HDACs are divided in four classes (class I-IV) on the basis of their 
structure and substrate specificity. The class III HDACs consists of the NAD
+
 
dependent deacetylases called Sirtuins (Bock and Goode, 2004; Ramkumar et al., 2011). 
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Later studies have provided evidence that apart from histones, HATs and HDACs have 
a large number of non-histone substrates including p53 (Gu and Roeder, 1997) and HIF-
1α (Jeong et al., 2002; Lim et al., 2010; Xenaki et al., 2008) 
1.6.2 Discovery and functional domains of PCAF 
PCAF is a protein of 832 amino acids and the first identified mammalian cofactor with 
intrinsic histone acetyl transferase activity (Yang et al., 1996). PCAF belongs to GNAT 
(GCN-5 related N-acetyl transferases) superfamily of acetyl transferases (Dutnall et al., 
1998). The PCAF splice variant PCAF-B/hGCN5-L (837 amino acids) is expressed in 
high levels in day 8 of mouse embryogenesis, whereas PCAF can be detected after day 
12.5. PCAF-B null mice die in early stage of development, indicating that PCAF-B is 
essential for embryogenesis whereas PCAF plays a role in late development and 
differentiation. Moreover, increased PCAF-B levels observed in PCAF null mice 
suggest that PCAF-B compensates for the absence of PCAF (Yamauchi et al., 2000). 
While the C-terminal domain of PCAF is important for its intrinsic histone acetyl 
transferase activity, the N terminal domain has been shown to be essential for its 
interaction with p300/CBP complex (Yang et al., 1996) and stability (Herrera et al., 
1997). 
 
Figure 1.6.1: Domain structure of PCAF protein 
Diagram indicating the functional domains of PCAF. The N-terminal region of the protein 
exerts E3 ligase activity. HAT and bromo domains lie in the C-terminal region of the protein. 
p53 is a target of PCAF E3 ligase which also auto-ubiquitinates PCAF.   
 
PCAF functions as E3 ubiquitin ligase catalysing its own protein degradation and that of 
Hdm2 resulting in the stabilisation of p53 (Linares et al., 2007) and is auto-acetylated in 
its NLS domain indicating that acetylation plays an important role in the PCAF nuclear 
translocation (Santos Rosa et al., 2003). PCAF is auto-acetylated  and acetylated by 
p300 in its N- terminal region and C- terminal region by intra and inter-molecular 
events respectively, which might be involved in the enhancement of its HAT activity 
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(Santos Rosa et al., 2003). Figure 1.6.1 demonstrates schematically the functional 
domains of PCAF. 
1.6.3 Catalytic mechanism of PCAF 
PCAF has a conserved glutamate residue within its central core domain that is hydrogen 
bonded with a very well-ordered water molecule which is located between the carbonyl 
oxygen of the glutamate and the Nε nitrogen of the target lysine. Thus, the water 
molecule mediates the de-protonation of the histone lysine by the enzyme glutamate 
(Figure 1.6.2). The conserved glutamate residue (Glu122 of tGcn5) is surrounded by 
several hydrophobic residues that possibly shield it from solvent water and help raise its 
pKa to facilitate proton extraction. 
 
 
Figure 1.6.2: Catalytic mechanism of PCAF. 
Proposed catalytic mechanism of GCN5/PCAF. The residue numbering is for tGcn5. The figure 
is modified from (Bock and Goode, 2004).  
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Once the lysine proton is extracted, the acetyl group of the acetyl-CoA, which is 
hydrogen bonded to the backbone NH of Leu126 (in the tGCN5/acetyl-CoA structure), 
is transferred to the reactive Lys14 side chain of the histone. The backbone NH of 
Leu126 probably functions to polarize the carbonyl group of the thio-ester prior to 
nucleophilic attack of the amino group and stabilize the negative charge that develops 
on the oxygen in the tetrahedral transition state (Bock and Goode, 2004).   
1.6.4 PCAF complex and stability 
PCAF forms complex with more than 20 distinct proteins ranging from 400 to 10 kDa. 
PCAF is a component of the PCAF associated factor 400 (PAF400) which belongs to 
the ATM superfamily of kinases indicating the complex network of general and DNA 
binding transcription factors, acetylases and kinases of which PCAF is an integral 
component (Vassilev et al., 1998).  
 
PCAF is stable only in the presence of its co-enzyme acetyl-CoA which is required for 
its auto-acetylation in its N-terminal region (Herrera et al., 1997). PCAF was found to 
be in complex with p300/CBP and compete with E1A for binding to p300/CBP complex 
and antagonize E1A mediated cell proliferation (Yang et al., 1996). Later studies have 
shown that PCAF promotes cell survival by inducing E2F1 expression in cisplatin 
resistant cells (Hirano et al., 2010).  
1.6.5 Non-histone targets of PCAF 
While PCAF was identified initially as a histone acetylase, it is now clear that the 
substrate specificity of PCAF is not limited to histones. p53 is the first identified non-
histone target of histone acetylases. The C- terminal DNA binding regulatory domain of 
p53 is acetylated at multiple lysine residues by p300/CBP (K305, 370, 372, 373, 381, 
382) (Gu and Roeder, 1997; Wang et al., 2003). PCAF acetylates p53 at distinct sites 
from those acetylated by p300/CBP and particularly at K320 in response to stress (Liu 
et al., 1999). Acetylation of p53 is thought to increase its DNA binding affinity thereby 
enhancing its transcriptional activity (Liu et al., 1999). Acetylation of p53 possibly does 
not occur at multiple sites simultaneously but depends on the severity of cellular stress 
providing the means for amplification and target specificity of p53 transcriptional 
activity. In accord with this hypothesis recent reports have indicated that diverse types 
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of stress induce acetylation of p53 at different sites promoting either cell cycle arrest 
through induction of p21
WAF-1/CIP-1
 gene expression or apoptosis by stimulating pro-
apoptotic members of the Bcl-2 family (Knights et al., 2006; Xenaki et al., 2008) 
 
Mdm2 interacts with PCAF and inhibits PCAF-mediated acetylation of p53 in vivo and 
in vitro, thus inhibiting p53 transcriptional activity (Jin et al., 2002). At the same time, 
the E3 ligase activity of both PCAF and Hdm2 exibit synergistic actions (Linares et al., 
2007). PCAF mediated acetylation of p53 is also inhibited by the adenovirus encoding 
the E1B 55 kDa oncoprotein which interferes with the physical interaction between 
PCAF and p53 (Liu et al., 2000). Apart from p53 PCAF interacts with and acetylates 
HIF-1α at K674 (Lim et al., 2010) increasing its protein stability and transcription target 
selectivity in hypoxia (Lim et al., 2010; Xenaki et al., 2008) possibly facilitating the 
recruitment of p300 in the C-TAD domain of HIF-1α (Lim et al., 2010). Other 
transcription factors associated with PCAF include nuclear receptors such as RXR-RAR 
heterodimers, Estrogen receptor (ERα), androgen receptor (AR) and glucocorticoid 
receptor (GR) (Blanco et al., 1998).  
1.6.6 PCAF and cancer 
PCAF has been shown to interact with E2F transcription factors (Vassilev et al., 1998). 
Acetylation of E2F1 by PCAF increases its stability and transcriptional activity 
(Martínez-Balbas et al., 2000; Pillai et al., 2010) resulting in the promotion of cell cycle 
progression. Recently PCAF has been shown to interact with SIRT1 and control the 
E2F1 mediated apoptotic pathway (Pediconi et al., 2009). On the other hand PCAF 
dependent p53 acetylation induces p21
WAF-1/CIP-1
 mediated cell cycle arrest (Knights et 
al., 2006; Xenaki et al., 2008). In response to growth factors PCAF acetylates the PTEN 
tumour suppressor at two lysine residues (K125 and K128) within the catalytic cleft, 
which compromise the ability of PTEN to regulate G1 arrest and inhibit cell 
proliferation induced by the PI3K/Akt pathway (Okumura et al., 2006). Therefore, 
PCAF has been shown to exert contrasting effects in the control of cell cycle 
progression in other words it promotes cell proliferation by acetylating E2F and PTEN 
and cell cycle arrest by acetylating p53.  
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1.6.7 The cross talk between p53 and HIF-1α 
As p53 is stabilized in severe and prolonged hypoxia, hypoxia is considered to be one of 
the physiological inducers of p53 activity (Graeber et al., 1994; Halterman et al., 1999). 
The hypoxia mimicking agents DSFX and cobalt chloride induce p53 protein 
stabilisation in a HIF-1α dependent manner, however, stabilization of p53 under these 
conditions is not due to HIF-1α transcriptional activity, but rather a result of interaction 
between p53 and HIF-1α proteins (An et al., 1998). In-vitro studies have shown that the 
association between HIF-1α and p53 is indirectly mediated by MDM2 which interacts 
with both p53 and HIF-1α mediating ubiquitin dependent degradation of both 
transcription factors (Chen et al., 2003; Ravi et al., 2000).  
 
In contrast to MDM2 the tumour suppressor pVHL negatively regulates HIF-1α protein 
stability in normoxic conditions whereas it functions as p53 co-activator and positive 
regulator of its protein stability preventing the p53-MDM2 interaction (Roe et al., 2006; 
Sermeus and Michiels, 2011). In addition the affinity for binding to p300 has been 
shown to be higher for p53 compared to HIF-1α. This enables p53 to exhibit its tumour 
suppressive activities in the presence of limited amount of p300, whereas HIF-1α under 
these conditions is transcriptionally inactive (Vleugel et al., 2006).  
 
Although the molecular mechanisms involved have not been verified in details it is now 
clear that both p53 and HIF-1α regulate cellular energy production by modulating the 
gene expression of genes participating in the energy production pathways of glycolysis 
and OXPHOS. In particular, HIF-1α upregulates gene expression of the Glucose 
transporter Glut1 while p53 downregulates the expression of this gene (Chen et al., 
2001; Schwartzenberg-Bar-Yoseph et al., 2004a). Similarly, p53 downregulates HK2 
gene expression while HIF-1α upregulates it (Kim et al., 2007). In addition, p53 binding 
sites have identified in the regulatory promoter regions of the TIGAR and SCO2 genes, 
which are involved in the regulation of glycolysis and OXPHOS respectively (Bensaad 
et al., 2006; Matoba et al., 2006) and has been shown to be differentially regulated in 
hypoxic cells (Kimata et al., 2010; Sung et al., 2010).  
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1.7 TIGAR 
1.7.1 Discovery and structure 
TIGAR was discovered by Bensaad et al., in a microarray analysis of gene expression 
following p53 induction (Bensaad et al., 2006). TIGAR is located on chromosome 
12p13-3 and contains six potential coding exons and two possible p53 binding sites 
among which the one positioned within the first intron binds to p53 with higher affinity 
compared to that found upstream of the first exon (Figure 1.7.1). TIGAR mRNA 
expression was induced 6 hours after the activation of p53 following similar kinetics to 
that of the p53 anti-apoptotic target gene p21
WAF-1/CIP-1
 and faster than that of its pro-
apoptotic target gene BAX. Further studies have shown that TIGAR inhibits ROS 
mediated apoptosis (Bensaad et al., 2006).  
 
 
Figure 1.7.1: Structure of TIGAR gene 
Schematic diagram showing the structure of TIGAR gene. The two p53 binding sites are located 
upstream of the first exon (-6703 to -6679) and within the first intron (-343 to -366). The 
predicted translation start site and the positions of the six exons are also indicated. 
 
TIGAR belongs to the histidine phosphatase super-family of proteins which contain a 
strictly conserved catalytic core centred at the histidine residue and shares similarity 
with the catalytic regions of the PGM family of proteins (Bensaad et al., 2006; Li and 
Jogl, 2009). TIGAR shows highest similarity to the products of the pfkfb genes (pfkfb 
1–4) which encode for the bifunctional enzymes PFK-2/FBPase-2 (1 to 4) (Figure 1.7.2) 
and has been found to catalyze the same phosphatase reaction as these enzymes, that is 
to convert F2,6-BP to F6-P (Lehninger et al., 2005) and is phosphorylated during the 
conversion of F2,6-BP to F6-P (Li and Jogl, 2009).  
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Figure 1.7.2: The phosphatise domain of the PFKFB (1-4) enzymes is similar to TIGAR 
PFKFB bifunctional enzymes have a kinase domain in their amino terminal end and a 
phosphatase domain in their carboxy terminal end. TIGAR shares similarity with the 
phosphatase domain of PFKFB enzymes. 
 
The crystal structure of TIGAR is most closely related to the bacterial broad specificity 
phosphatase PhoE followed by phosphoglycerate mutase and F2,6-BPase (Li and Jogl, 
2009). Similar to F2,6-BPase, TIGAR catalyses the conversion of F2,6-BP to F6-P 
(Bensaad et al., 2006). However, the C-terminal region of FBPase-2 contains 25 
additional residues that are not present in TIGAR. These additional residues form two 
external loop regions that enclose the active site of FBPase-2 and restrict the access to 
the active site contributing to the high specificity of FBPase-2 for F2,6-BP. On the other 
hand, TIGAR in addition to F2,6-BP catalyzes the breakdown of F1,6-BP (Li and Jogl, 
2009). The broader TIGAR substrate specificity is currently under investigation. 
1.7.2 Role of TIGAR in regulating glycolysis 
F2,6-BP is a crucial regulator of glucose metabolism as it activates the rate limiting 
glycolytic enzyme PFK-1 and inhibits FBPase-1 an enzyme involved in 
gluconeogenesis (Pilkis et al., 1981; Uyeda et al., 1981). The level of intra-cellular 
concentration of F2,6-BP is regulated by a single bi-functional enzyme PFK-2/FBPase-
2. The N-terminal kinase activity of PFK-2/FBPase-2 catalyzes the formation of F2,6-
BP whereas the C-terminal phosphatase hydrolyses F2,6-BP to F6-P and inorganic 
phosphate (Figure 1.7.3). High levels of intracellular F2,6-BP activate PFK-1 by 
increasing its affinity for F6-P and diminishing the inhibitory effect of ATP on PFK-1 
(Lehninger et al., 2005). F2,6-BP has antagonistic effects with glucokinase (GK) and 
glucose 6-phosphatase (G6Pase) enzyme. When levels of F2,6-BP are elevated in the 
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liver, GK gene expression is up-regulated while the G6Pase is down-regulated (Wu et 
al., 2006).  
 
The molecular mechanism involved in the regulation of F2,6-BP intracellular levels by 
TIGAR has not been clearly delineated. However, since F2,6-BP is an allosteric 
activator of PFK-1, TIGAR mediated down-regulation of F2,6-BP levels render PFK-1 
in inactive state (Bensaad et al., 2006). In addition, F2,6-BP by inducing glucokinase 
gene expression and inhibiting G6Pase enzymatic activity promotes glucose 
phosphorylation (Wu et al., 2006). Consistent with the above mentioned reports TIGAR 
dependent downregulation of F2,6-BP levels results in the accumulation of F6-P which 
is diverted to metabolize via the pentose phosphate pathway (PPP) through which it 
regulates the intracellular ROS levels (Bensaad et al., 2006; Wu et al., 2006).  
1.7.3 Regulation of the intracellular ROS levels by TIGAR  
TIGAR inhibits glycolysis by dephosphorylating F2,6-BP and contributing to the 
intracellular accumulation of F6P which is initially converted to G6P by glucose 
phosphate isomerise (GPI) and then metabolized to an alternate glucose metabolic 
pathway, PPP (Bensaad et al., 2006). PPP is the major source of NADPH which 
scavenges reactive oxygen species (ROS) by promoting the conversion of reduced 
glutathione to oxidised glutathione (Figure 1.7.4). By reducing the intracellular ROS 
levels TIGAR inhibits the ROS induced apoptosis in cancer cells which suggests that it 
is a pro-survival target of the p53 tumour suppressor (Bensaad et al., 2006). 
 
The PFK-2/FBPase-2 isoform PFKFB3 has been shown to be induced in hypoxic 
conditions and exhibits kinase to phosphatase activity ratio of 700:1. (Minchenko et al., 
2002). TIGAR, which shares structural and functional similarities with the phosphatase 
domain of PFK-2/FBPase-2, has also been found to be induced in hypoxic cardiac 
myocytes (Kimata et al., 2010) in a p53 dependent manner. Elevated TIGAR levels 
inhibit glycolysis and hypoxia induced apoptosis in these cells (Kimata et al., 2010) 
suggesting that TIGAR upregulation in hypoxic conditions might be a result of the 
crosstalk between HIF-1α, and p53 determining the cellular fate under these conditions. 
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Figure 1.7.3: TIGAR regulates glucose metabolism 
TIGAR catalyses F2,6-BP de-phosphorylation mimicking the enzymatic activity of the 
phosphatase domain of PFK-2/FBPase-2 with which it shares structural similarity. F2,6-BP is 
an allosteric activator of PFK-1, a rate limiting enzyme of glycolysis. Low F2,6-BP intracellular 
levels render PFK-1 inactive and glycolysis cannot proceed, thus explaining the mechanism by 
which TIGAR reduces the glycolytic rate. 
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Figure 1.7.4: TIGAR inhibits intracellular ROS levels by promoting pentose phosphate pathway 
TIGAR contributes to F6P accumulation, which diverts glycolysis to pentose phosphate 
pathway. In the presence of NADPH produced by PPP the reduced glutathione absorbs H2O2 
and releases water becoming oxidised glutathione. GSH: Glutathione (reduced form); GSSH: 
Glutathione (oxidised form); NADP: Nicotinamide adenine dinucleotide phosphate; NADPH: 
Nicotinamide dinucleotide phosphate (reduced form) 
 
In addition, since PFKFB3 and TIGAR are both induced in hypoxia and antagonise 
each other’s function (PFKFB3 has positive effect on glycolysis whereas TIGAR 
inhibits it) the final outcome in terms of whether glycolysis will proceed or not in 
hypoxia might be a result of the balance of the intracellular levels of these two enzymes. 
This model however requires experimental evidence. 
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1.8 Synthesis of cytochrome c oxidase 2 (SCO2) 
1.8.1 Introduction 
The cytochrome c oxidase (COX) complex is the terminal enzyme of the energy 
transducing electron transport chain within the mitochondrial inner membrane. COX 
catalyzes the terminal step in electron transport chain reducing the molecular oxygen 
and coupling this reduction with proton translocation across the inner membrane. COX 
complex is composed of 13 polypeptide subunits three of which are encoded by 
mitochondrial DNA and form the catalytic core of the complex and the remaining ten 
are encoded by nuclear DNA. The catalytic cofactors of the COX complex include 
copper ions and heme moieties (Horng et al., 2005). COX I and II subunits contain 
copper centres CuB and CuA respectively. SCO2 was discovered in 1994 in an yeast 
sequencing project (Smits et al., 1994). COX17 delivers copper ions to SCO2 which 
subsequently transfers them to COX II subunit thus facilitating the assembly of the 
COX complex (Figure 1.8.1). SCO2 has also been shown to be involved in the 
maintenance of cellular copper homeostasis (Leary et al., 2007).  
 
 
Figure 1.8.1: SCO2 is involved in the transport of copper ions to the COX 2 subunit 
A. Domain structure of SCO2 protein. MTS- mitochondrial target sequences; TM- Trans 
membrane helics; CXXXC- Essential CXXXC motif. B. Copper ions are delivered to SCO2 by 
COX17. SCO2 transfers these copper ions to the COX II subunit. Figure adapted from Baylor 
college of Medicine website.  
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1.8.2 Regulation of SCO2 gene expression by p53 
 
Figure 1.8.2: Regulation of cellular energy metabolism by p53 
p53 modulates cellular energy metabolism by regulating its transcription target genes. p53 
induces TIGAR gene expression inhibiting glycolysis (A) and SCO2 promoting mitochondrial 
respiration (B). 
 
Cellular energy production is regulated by p53 through transcriptional regulation of its 
target genes involved in OXPHOS. Decreased OXPHOS has been observed in p53 
deficient cell lines that could be rescued by the ectopic expression of SCO2 indicating 
that wild type p53 regulates OXPHOS by inducing SCO2 gene expression (Figure 
1.8.2). Additional evidence supporting this notion has been lent by the observation that 
disruption of SCO2 gene expression in wild type p53 expressing cells recapitulates the 
phenotype of defective mitochondrial respiration (Matoba et al., 2006).  
 
 
 60 
Furthermore, the fact that disruption of SCO2 gene expression did not affect the total 
ATP production suggested that the cells adapt to glycolysis as their primary source of 
energy production under these conditions. This view was confirmed by the increased 
lactate production observed in cell lines deficient in either SCO2 or p53 (Sung et al., 
2010). Low SCO2 gene expression has shown to result in poor prognosis of breast 
cancers (Won et al., 2011). Although, it has been shown that both TIGAR and SCO2 
gene expression are mediated by p53, the significant expression of these proteins in 
very low p53 expression and p53 null cell lines indicate that other factors are also 
involved in the regulation of TIGAR and SCO2 gene expression (Won et al., 2011). 
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2 Project aims and hypothesis  
Transcriptional cofactors such as p300 and PCAF regulate the cross talk between HIF-1 
and p53 by modulating protein stability and transcriptional activity of both transcription 
factors under diverse types of cellular stress (Arany et al., 1996; Liu et al., 1999; 
Schmid et al., 2004; Xenaki et al., 2008). We have recently reported that under hypoxic 
conditions PCAF orchestrates cellular survival or death by differentially recruiting p53 
and HIF-1α to either the pro-survival gene p21WAF-1/CIP-1 or the pro-apoptotic member of 
the Bcl-2 family BID (Xenaki et al., 2008). It is known that p53 and HIF-1 regulate the 
levels of enzymes involved in glucose metabolism and OXPHOS (Chen et al., 2001; 
Kim et al., 2007; Mathupala et al., 1997; Schwartzenberg-Bar-Yoseph et al., 2004a) 
thereby determining the pathway of cellular energy metabolism.  
 
In particular p53 has been shown recently to inhibit glycolysis by inducing the inhibitor 
of glycolysis enzyme TIGAR and promote OXPHOS by upregulating the expression of 
the cytochrome c oxidase assembly gene SCO2. Since TIGAR has been shown recently 
to be upregulated in hypoxia (Kimata et al., 2010), and several cytochrome c oxidase 
subunits as well as mitochondrial biogenesis are under HIF-1α transcriptional control 
(Fukuda et al., 2007) we hypothesised that TIGAR and SCO2 might be transcriptionally 
regulated apart from p53 by hypoxia responsive transcription factors and PCAF could 
act as a coordinator in the decision of the pathway of cellular energy metabolism the 
same way as it has been shown for survival/death (Xenaki et al., 2008) in hypoxic 
conditions.  
 
Thus the aim of this project is to investigate the role of HIF-1α in the regulation of gene 
expression of TIGAR and SCO2 in hypoxic conditions and dissect the molecular 
mechanism(s) implicating the HAT activity of PCAF in the regulation of these genes by 
p53 and/or HIF-1α. In addition, this project aims to characterise the role of the HAT 
activity of PCAF in the regulation of TIGAR and SCO2 gene expression and hence on 
the choice of the pathway of cellular energy metabolism and intracellular ROS 
generation.  The hypothesis of the project and its aims are summarised in Figure 1.8.1. 
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Figure 1.8.1: Hypothesis and aims of the project 
In normoxia, in response to genotoxic stress, p53 is recruited to the regulatory region of the 
promoters of TIGAR and SCO2 genes. Upregulation of TIGAR gene expression by p53 leads to 
decreased intracellular ROS levels, lactate production and increased NAD
+
/NADH levels, 
whereas, upregulation of SCO2 gene expression by p53 leads to increased oxygen consumption 
as a consequence of efficient assembly of the COX complex in the mitochondria (upper panel). 
Given the crosstalk between p53 and HIF-1 we hypothesised that under hypoxia the HIF-1 
transcription factor might be recruited to TIGAR and SCO2 promoters and regulate their gene 
expression. Since PCAF is a common cofactor for both p53 and HIF-1α, we also hypothesised 
that PCAF might play an important role in facilitating p53 and/or HIF-1 to selectivity modulate 
TIGAR and SCO2 gene expression under diverse types of stress. We propose that differential 
regulation of TIGAR and/or SCO2 in hypoxia mimicking conditions determine the pathway by 
which cells produce energy (OXPHOS or glycolysis) (lower panel).  
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To study whether the TIGAR and SCO2 gene expression were under HIF-1 
transcriptional control in hypoxia mimicking conditions we followed protein and 
mRNA levels of these genes in DSFX treated cells bearing wild type or mutant p53. 
The involvement of HIF-1 transcriptional activity in the regulation of TIGAR and SCO2 
gene expression was followed with chromatin immunoprecipitation and luciferase 
reporter assays. 
 
The protein and mRNA levels of TIGAR and SCO2 were also monitored in cells 
overexpressing PCAFwt or PCAFΔHAT to investigate the role that PCAF plays in the 
regulation of the cellular levels of those genes. The functional consequences of the 
differential regulation of TIGAR and SCO2 gene expression was assessed by assays 
measuring lactate production, NAD
+
/NADH ratio, intracellular ROS levels and cellular 
oxygen consumption in PCAF wild type and PCAFΔHAT overexpressing cells.   
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3 Materials and Methods 
3.1 Materials 
3.1.1 Chemicals 
All the chemicals and general reagents used in this study and their supplier details are 
listed in Table 3.1.1 
Serial 
No 
Materials  Supplier Product code 
1 2-Mercaptoethanol  Sigma, UK M3148 
2 Acetic acid glacial Fisher, UK A/0400/PB15 
3 Acrylamide/Bis-acrylamide 
(37.5:1)  
Sigma, UK A6050 
4 Agarose low melting  Melford, UK A1201 
5 Ammonium per sulphate 
(APS)  
Flowgen, UK H17423 
6 Calcium chloride  VWR Prolabo, UK 1.02379.1000 
7 Chemiluminescent substrate 
(ECL reagent)  
Chembio Ltd, UK 16031 
8 Cryovials Scientific laboratory 
supplies, UK 
G122263 
9 Cyclohexamide Sigma, UK C4859 
10 Desferrioxamine (DSFX)  Sigma, UK D9533 
11 Dimethylsulphoxide (DMSO)  Sigma, UK D8418 
12 Di sodium hydrogen phosphate  Fisher, UK S/P525/53 
13 dNTPs  Bioline, UK Bio-39025 
14 Dithiothreitol (DTT) Sigma, UK D0632 
15 Magnetic beads (Dynabeads)  Invitrogen, UK 100-01D 
16 Ethylene diamine tetra acetatic 
acid  
Sigma, UK EDS 
17 Ethanol absolute Fisher E/0600/05 
18 Ethidium bromide Mo Bio, USA 15006-10 
19 Etoposide Sigma, UK E1383 
20 Formaldehyde (36-38%)  Sigma, UK F8775 
21 Gel loading tips Star labs, UK.  I1010-3000 
22 Glucose  Sigma, UK 158968 
23 Glycerol  VWR BDH Prolabo, 
UK 
24387.361 
24 Glycine  Fisher, UK BPE381-1 
25 HEPES  Sigma, UK 54457 
26 Isopropanol Fisher, UK P/7490/15 
27 Magnesium chloride 6 hydrate  VWR BDH Prolabo, 
UK 
436994U 
28 Methanol  Fisher, UK BPE1105-1 
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Serial 
No 
Materials  Supplier Product code 
29 Nicotinamide  Sigma, UK 72340 
30 Nonidet P40  VWR BDH Prolabo, 
UK 
A2239.0100 
31 Ortho boric acid  VWR BDH Prolabo, 
UK 
443905T 
32 PageRuler Prestained protein 
ladder 
Fermentas, UK SM0672 
33 Phenylmethylsulphonylfluoride 
(PMSF) 
Sigma, UK P7626 
34 Potassium chloride VWR BDH Prolabo, 
UK 
26759.291 
35 PVDF membrane Millipore, UK IPVH00010 
36 Rotenone  Sigma, UK R8875 
37 Sodium acetate 3 hydrate  VWR BDH Prolabo, 
UK 
27652.298 
38 Sodium butyrate  Sigma, UK B5887 
39 Sodium carbonate  VWR BDH Prolabo, 
UK 
27766.292 
40 Sodium chloride  Fisher, UK BPE358-1 
41 Sodium dihydrogen phosphate  Fisher, UK S/4480/60 
42 Sodium dodecyl sulphate 
(SDS) 
Fisher, UK S/P530/48 
43 Sodium hydroxide  VWR BDH Prolabo, 
UK 
28244.262 
44 Sodium hydrogen carbonate  VWR BDH Prolabo, 
UK 
27778.293 
45 Sodium ortho vandate  Sigma, UK S6508 
46 Sodium pyrophosphate Sigma, UK 221368 
47 SYBR Green I Sigma, UK S9430 
48 Tetra methyl ethylene diamine 
(TEMED)  
VWR BDH Prolabo, 
UK 
443083G 
49 Trichostatin A  Sigma, UK T8552 
50 Tris base  Fisher, UK BPE152-1 
51 Triton X100  Sigma, UK T8787 
52 Tween 20  Sigma, UK P9416 
53 X-Ray film Fuji Films, UK Super Rx 
 
Table 3.1.1: Suppliers of chemicals and general laboratory reagents. 
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3.1.2 Media and other biological materials 
Cell culture media, other biological materials used in this study and their sources are 
listed in Table 3.1.2 
Sl No Materials  Supplier Product code 
1 Ampicillin Sigma, UK A1593 
2 Bovine serum albumin Roche, UK 10711454001 
3 Dissociation buffer Gibco, UK 13151014 
4 Dulbecco’s Modified Eagle’s 
Medium (DMEM) 
Lonza, UK BE12-604F 
5 Foetal calf serum (FCS) Lonza, UK 14-416F 
6 HyperLadder 1 (DNA ladder) Bioline, UK BIO-33025 
7 Kanamycin Sigma, UK K1876 
8 LB agar Sigma, UK L2897 
9 LB broth Invitrogen, UK 12780029 
10 Penicillin/Streptomycin Lonza, UK DE17-602E 
11 Polyfect transfection reagent Qiagen (UK) 301107 
12 Reporter lysis buffer 5X Promega, UK E3971  
13 Salmon sperm DNA Sigma, UK D7656 
14 SOC media Invitrogen, UK 15544034 
15 Trypsin with EDTA Lonza, UK BE17-161E 
Table 3.1.2: Suppliers of media and other biological materials 
3.1.3 Enzymes, antibodies and kits 
All the enzymes, antibodies and ready-made kits used in this study and their supplier 
details are listed in Table 3.1.3 
Sl No Product Catalog 
number 
 Supplier 
1 Anti-Flag M2 F3165  Sigma (UK) 
2 Anti HIF-1α (H1α)67 400080  Calbiochem 
3 Anti HIF-1α  (AB2185)  Abcam, UK 
4 Anti p53 (DO1) SC-126  Santa Cruz Biotechnology 
5 Anti PCAF (E8) SC-13124  Santa Cruz Biotechnology 
6 Anti SCO2 (CT) 4045  ProSci Incorporated 
7 Anti TIGAR (IN1) 4049  ProSci Incorporated 
8 β-actin antibody ab8227  Abcam (UK) 
9 Bio-Rad protein assay 
kit 
500-0001  Bio-Rad (UK) 
10 CD-20 (APC-H7) 641396  BD Biosciences 
11 ECL mouse IgG NA931  Amersham Biosciences (UK) 
12 ECL Rabbit IgG NXA931  Amersham Biosciences (UK) 
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Sl No Product Catalog 
number 
 Supplier 
13 GFX genomic Blood 
DNA purification kit 
N/A  GE healthcare (UK) 
14 HA antibody MMS-101P  Covance (New Jersey) 
15 Kpn1 10 899 186 
001 
 Roche Diagnostics 
(Germany) 
16 Lactate reagent  73510-
10x10mls 
 Trinity Biotech (Ireland) 
17 NAD N0632  Sigma (UK) 
18 NADH N4505  Sigma (UK) 
19 PCAF (E-8) antibody Sc-13124  Santa Cruz (Santa Cruz) 
20 PFKFB3 antibody  AP8145a  Abgent (San Diego) 
21 Proteinase K 03115879001  Roche (UK) 
22 Reverse Transcriptase 
(Bioscript) 
BIO-27036  Bioline 
23 Sac1 10 669 792 
001 
 Roche Diagnostics 
(Germany) 
24 T4 DNA ligase 481 220  Roche Diagnostics 
(Germany) 
25 Taq DNA polymerase M0273S  New England Biolabs (UK) 
26 Xho1 10 899 194 
001 
 Roche Diagnostics 
(Germany) 
 
Table 3.1.3: Suppliers of antibodies and enzymes. 
 
3.1.4 Buffers and general solutions 
All the solutions and general buffers used in this study and their compositions are listed 
in Table 3.1.4 
Sl No Buffer Composition 
1 2X HBS 25mM HEPES, 0.75mM Na2HPO4.12H2O, 
140mM NaCl pH: 7.1 
2 3X SDS sample buffer 187mM Tris, 30% Glycerol, 6% SDS,  
15% 2-mercapto ethanol, 0.01% 
bromophenolblue. 
3 β-gal buffer 200mM Sodium phosphate pH: 7.3, 2mM 
MgCl2, 100mM β-mercaptoethanol, 4.5mM 
ONPG. 
4 Blocking solution (ChIP) 0.5% BSA w/v in PBS.  
5 Blocking solution 
(western) 
5% Milk in PBS 0.1% Tween-20 
6 ChIP buffer 1 50mM Hepes-KOH; pH: 7.5, 140mM NaCl, 
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Sl No Buffer Composition 
1mM EDTA, 10% glycerol, 0.5% Igepal 
CA-630, 0.25% Triton X-100. 
7 ChIP buffer 2 10mM Tris-HCl; pH: 8.0, 200mM NaCl, 
1mM EDTA, 0.5mM EGTA. 
8 ChIP buffer 3 10mM Tris-HCl; pH: 8.0, 100mM NaCl, 
1mM EDTA, 0.5mM EGTA, 0.1% Na-
Deoxycholate, 0.5% N-lauroylsarcosine. 
9 Cycling buffer 100mM Tris-HCl (pH:8), 5mM EDTA and 
0.5mM MTT 
10 Elution buffer (ChIP) 50mM Tris-HCl; pH:8, 100mM EDTA and 
1% SDS w/v.  
11 Elution buffer (Maxiprep) 100mM Tris-HCl; pH: 8.5, 125mM NaCl. 
12 Extraction buffer 
(NAD+/NADH) 
20mM Sodium bicarbonate, 100mM 
Sodium carbonate, 10mM Nicotinamide and 
0.05% Triton-X-100. 
13 Formaldehyde solution 50mM Hepes-KOH, 100mM NaCl, 1mM 
EDTA, 0.5mM EGTA and 11% 
formaldehyde 
14 Lysis buffer (Miniprep and 
Maxiprep) 
200mM NaOH, 1% w/v SDS. 
15 PBS Tween PBS + 0.1% Tween-20 
16 Phosphate buffered saline 
(PBS) 
170mM NaCl, 3.3 mM KCl,  
1.8 mM Na2HPO4, 10.6 mM KH2PO4; pH 
7.4. 
17 Precipitation buffer 3.1M Potassium acetate pH 5.5. 
18 Resuspension buffer  50 mM Tris HCl pH 8.0, 10 nM EDTA. 
19  RIPA buffer 50mM Hepes-KOH; pH: 7.5, 500mM LiCl, 
1mM EDTA, 1% Igepal CA-630, 0.7% Na-
Deoxycholate.  
20 Stripping buffer 100 mM 2-Mercaptoethanol, 2% SDS,  
62.5 mM Tris-HCl pH 6.7. 
21 TAE buffer 40 mM Tris-acetate, 1 mM EDTA. 
22 TE buffer 10 mM Tris-HCl pH 7.5, 1 mM EDTA. 
23 TNN buffer 120 mM 50 mM Tris-HCl pH 7.4, 120 mM NaCl,  
5 mM EDTA, 0.5% NP-40. 
24 TNN buffer 240mM 50 mM Tris-HCl pH 7.4, 240 mM NaCl,  
5 mM EDTA, 0.5% NP-40.  
25 Tris buffered saline (TBS) 20mM Tris-HCl; pH: 7.6, 150mM NaCl. 
26 Western transfer buffer 150 mM Glycine, 25 mM Tris-HCl pH 8.3, 
20% Methanol.  
 
Table 3.1.4: Composition of buffers and general solutions. 
 69 
3.2 Cell culture and maintenance  
3.2.1 Cell lines and culturing medium 
Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% (v/v) heat 
inactivated fetal bovine serum (FBS), 1% 10,000 U/ml penicillin and streptomycin (P/S) 
and 2 mM L-Glutamine was used to maintain the human osteosarcoma cell lines U2OS 
(p53
+/+
), SaOS2 (p53
-/-
) and breast cancer cell lines MCF- 7 (p53
+/+
) and MDA-MB-231 
(p53
mutated
). The variations in the p53 status of these cell lines provides a suitable system 
to study gene expression in the presence (fully or partially) or absence of p53 and also 
to study the crosstalk between p53 and other transcription factors such as HIF-1α. 
3.2.2 Cell maintenance 
Cells were maintained in 75 cm
2
 vented tissue culture flasks and subcultured every 2-3 
days when they were 70 - 80% confluent. Cell culture work was carried out in class II 
microbiological safety cabinets to provide safe and sterile environment. During 
subculture, the cells were rinsed briefly with 3ml of Trypsin-EDTA and incubated with 
1ml Trypsin-EDTA for 3min in 37
°
C to detach cells from the flask. Fresh DMEM 
medium with FBS and P/S was added to dilute trypsin and the cells were passaged at a 
ratio of 1:5. Cells were incubated at 37
°
C in a humidified atmosphere of 21% O2, 5% 
CO2 and 74% N2. Cells were seeded into 12 well plates for luciferase assays, 6 well 
plates for immuno-blotting and RNA extraction and 100mm plates for Chromatin 
immuno-precipitation assays and oxygen consumption measurement.  
3.2.3 Cell counting 
Cell counting was performed under a light microscope using a ruled haemocytometer 
(Bright-line, Hausser scientific, USA). The cells were detached from the flask and 
suspended well in order to avoid cell clumps. 100µl of cell suspension was mixed with 
100µl of trypan blue solution. 10µl of cell suspension was loaded into the 
haemocytometer and the cell count was performed according to manufacturer’s 
instructions.  
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Figure 3.2.1: Haemocytometer Figure adapted from Sigma website. 
The cells in areas A, B, C and D were counted and the total number of cells was calculated 
according to the formula mentioned in the text. 
 
The number of cells was calculated from  
C = N x 10
4
 
where C is cells per ml, N is average cells counted and 10
4 
is the volume conversion 
factor for 1mm
2
.  The total number of cells is calculated from  
Total number of cells = C x V 
where C is cells per ml and V is the total volume of cells. The cell counting was carried 
out before the experiments in order to use the appropriate number of cells (Figure 
3.2.1). 
3.2.4 Freezing the cells 
To freeze the cells, first they were pelleted by centrifugation at 1,200 rpm for 4 minutes 
(Centaur-2, Sanyo, UK) and resuspended in 1ml of FBS and 1ml of 20% DMSO in 
FBS. DMSO prevents the formation of intracellular ice crystals. FBS + DMSO was 
added drop-wise through the wall of the tube to avoid the osmotic shock to the cells and 
to minimize the heating that occurs when DMSO is added. The cell suspension was then 
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aliquoted into cryovials, transferred to a cryofreeze container (Nalgene) and stored at -
80
°
C overnight, before transferred for storage in liquid nitrogen (-196
0
C).  
3.2.5 Thawing the cells 
To restore the cell culture, the frozen cells were thawed rapidly by the addition of 1ml 
warm DMEM media. This rapid thawing reduces or prevents the formation of damaging 
ice crystals within the cells during rehydration (Ryan, 2004). 9 ml of warm DMEM 
media was added slowly to the cells and transferred to a sterile 25 cm
2
 culture flask and 
the cells were incubated for 3-4 hours. After the cells were attached to the surface of the 
flask the media was changed to fresh media containing 10% FBS and 1% 
penicillin/streptomycin. After they reach 70 - 80% confluency, the cells were 
transferred to 75cm
2
 flasks.  
3.2.6 Cell treatments 
HIF-1α protein is hydroxylated by prolyl hydroxylase enzymes (PHDs 1-4). PHDs are 
non-heme Fe (II) and 2-oxoglutorate dependent dioxygenases (2-OG oxygenases) that 
utilize molecular oxygen as a co-substrate (Epstein et al., 2001) therefore their function 
is inhibited by iron chelators such as desferrioxamine (DSFX) and creates a hypoxia 
mimicking condition (Wang and Semenza, 1993b). 250µM final concentration of 
desferrioxamine (DSFX) was used to mimic hypoxia, a condition in which HIF-1α is 
stabilized. Etoposide is a topoisomerase II inhibitor, induces DNA strand breaks by 
trapping the enzyme in a complex with cleaved DNA (Zhou et al., 1999). As DNA 
damage conditions induce p53, 10µM final concentration of etoposide was used to 
induce p53. The cells were treated with DSFX or etoposide 16 hours before harvesting. 
3.3 Molecular Biology 
3.3.1 Extraction of genomic DNA 
Genomic DNA from U2OS and SaOS2 cells was extracted using GFX genomic blood 
DNA purification kit (Amersham Biosciences). The cells were grown in a 75cm
2
 flask 
and collected by trypsinization and resuspended in the residual fluid by vigorous 
vortexing. 500ml of the extraction solution (buffered solution containing a chaotropic 
agent and detergent) was added and incubated for 5 minutes at room temperature. The 
mixture was transferred to a micro spin column (Amersham Biosciences) and 
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centrifuged at 5,000g. The chaotropic agent used in the extraction buffer facilitated the 
lysis of nucleated cells and the binding of genomic DNA to a glass fibre prepacked in 
the micro spin column. The column was then washed once with 500µl of extraction 
buffer and 500µl of wash buffer (TE buffer with ethanol). The DNA retained on the 
micro spin column was eluted with 200µl of distilled water. 
3.3.2 Measurement of DNA concentration 
Determination of nucleic acid concentration is achieved by following the absorption of 
UV light by nucleicacids. UV light analysis may be utilised not only to quantify the 
nucleic acid content of a sample, but also used to measure its purity. DNA yield 
determination is based on its ability to absorb light maximally at 260nm. The DNA 
concentration was calculated by the following formulae 
[DNA] mg/ml = A
260
 x dilution x 50,  
Where A
260
 = absorbance at 260 nm, dilution = dilution factor, 50 = the DNA extinction 
coefficient. Although this calculation provides information about the amount of DNA 
yield, it does not determine the quality and purity of the sample, which can be affected 
by the presence of excess salt, contaminating proteins and/or organic solvents. To 
provide an estimation of the sample purity, the ratio of the absorbance at 260nm divided 
with the absorbance at 280nm (A
260
/A
280
) is calculated. For the DNA sample to be 
considered pure the A
260
/A
280
 ratio should be close to 1.8±0.05.  
 
The DNA concentration and purity was determined using NanoDrop ND-1000 UV 
visible spectrophotometer. The calibration of the instrument was performed using 1.0μl 
of distilled water. To determine DNA concentration, 1.0 µl of the sample was pipetted 
onto the end of a fibre optic cable (the receiving fibre). To determine DNA 
concentration, a second fibre optic cable (the source fibre) is brought into contact with 
the liquid sample and the gap between the fibre optic ends is then bridged through the 
sample. A light emitted by a pulsed xenon lamp passes through the sample, which is 
then analyzed by the spectrometer utilizing a linear charge coupled device (CCD) array. 
The PC software displays the sample concentration in ng/μl based on the absorbance at 
260nm. The ratio of absorbance at 260nm and 280nm to assess nucleic acid purity is 
also calculated. 
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3.3.3 Polymerase chain reaction  
Polymerase chain reaction (PCR) allows the enzymatic amplification of a double-
stranded DNA region flanked by two known sequences. These two short 
oligonucleotide sequences (primers) can hybridise to their complementary sequence. In 
the first step of the reaction (denaturation) the DNA is heated at 95ºC for 5 minutes 
which separates the two strands of the DNA into single strands. In the second step of the 
reaction (primer annealing) the PCR mixture is cooled down to an optimum temperature 
which is known as the melting temperature in which the primers hybridise with their 
complementary DNA sequence to form a double-stranded region. In the third step 
(primer extension), DNA polymerase enzyme is used to extend the primer region to 
synthesize full-length complementary DNA strands. This step requires the presence of 
deoxynucleoside triphosphates (dNTPs), which serve as substrates for the polymerase. 
The process of denaturation, primer annealing, and primer extension (known as a cycle) 
is repeated with the new double strands since they also contain the primer binding sites. 
This cycle is repeated for 30 to 35 times to obtain an exponential amplification of the 
DNA sequence between the forward and the reverse primers (Figure 3.3.1) 
 
Genomic DNA of U2OS cells was extracted using GFX genomic DNA purification kit 
(Section 3.3.1). To amplify the TIGAR and SCO2 promoter regions, suitable primers 
(Table 3.3.1) were designed using Primer 3 software which amplify a specific region 
containing the HRE 5, 6 and p53 binding site 2 within the TIGAR promoter or HRE 1 
to 5 and p53 binding site in the SCO2 promoter (Figure 4.2.4 and Figure 4.2.5) 
Polymerase chain reaction (PCR) was performed using Phusion high fidelity DNA 
polymerase (Finnzymes, Finland) which synthesizes blunt end PCR product.  
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Figure 3.3.1: Principle of PCR reaction. 
Schematic diagram demonstrating the principle of PCR reaction. The DNA undergoes 
denaturation, primer annealing and primer extension processes to produce an amplified target 
region of DNA. The figure is adapted from (Mullis, 1983) 
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Gene 
name 
Forward primer Reverse primer 
TIGAR 5’- 
CTCGAGGGGTGGGTGGGTC
TAAGTCT 
 -3’ 
5’- 
GAGCTCGGACGAGCAATTCTGCA
AAC 
 -3’ 
SCO2 5’- ACCGTGGAGCTGGTCC 
 -3’ 
5’- CAGCAAGGTGAACCTCT 
 -3’ 
Table 3.3.1: Luciferase primer sequences 
The following mixture was prepared in the tissue culture hood in order to avoid 
contamination. 
Component Volume (50µl) Final concentration 
5X Phusion HF buffer 10µl 1X 
10mM dNTPs 1µl 200µM each 
Forward primer (20µM) 1µl 100nM 
Reverse primer 1µl 100nM 
DNA template 
(100ng/1µl) 
1µl - 
Phusion DNA 
polymerase 
0.5µl 0.02U/µl 
Distilled water 35.5µl - 
Table 3.3.2: Composition of PCR mixture 
The following PCR set-up was employed to amplify TIGAR and SCO2 promoter regions 
Segment Number of cycles Temperature Duration 
1 1 95°C 5 minutes 
2 35 95°C 1 minute 
3 55-66°C 1 minute 
4 72°C 1 minute 
5 1 72°C 10 minutes 
Table 3.3.3: PCR set-up for the amplification of genomic DNA  
The PCR products synthesized using different annealing temperatures ran in a 1% 
agarose gel and purified using QIAquick Gel extraction Kit (Qiagen, UK) (Figure 3.3.3 
A and Figure 3.3.4 A).   
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3.3.4 Construction of luciferase vectors 
The purified DNA was ligated to pCR-Blunt II-TOPO vector using Blunt TOPO PCR 
Cloning Kit (Invitrogen, UK). TOPO cloning is based on DNA TOPO isomerase 1 
enzyme which functions both as a restriction enzyme and as a ligase. TOPO vectors are 
linearized with DNA TOPO isomerase 1 enzyme attached to it. While it cleaves the 
DNA strand and enables DNA unwinding it religates the ends of cleaved stands. When 
incubated with PCR product, the enzyme ligates the compatible ends of PCR product 
and TOPO vector (Invitrogen, 2007). Figure 1.5.2 schematically explains the principle 
of TOPO cloning. 
 
Figure 3.3.2: Principle of TOPO cloning.  
Schematic diagram explain the principle involved in TOPO cloning. The figure is adapted from 
(Invitrogen, 2007). 
 
The ligated TIGAR-HRE5,6-p53BS2-TOPO vector was then transformed into 
chemically competent DH5α and plated on agar plates containing 50µg/ml final 
concentration of kanamycin and incubated for 16 hours in 37°C. Eight individual 
colonies from the agar-kanamycin plates were picked up and inoculated into 2ml of LB 
broth containing 50 µg/ml final concentration of kanamycin and incubated in a shaker at 
37ºC for 16 hours as the bacteria reach the stationary phase of their growth at 16 hours.  
 
The DNA from the cultured bacterial cells was extracted by alkaline lysis miniprep 
method (Section 3.4.3.1) and digested using Kpn1 restriction enzyme and ran in a 1% 
agarose gel (Figure 3.3.3 B and Figure 3.3.4 B). The linear DNA fragment then ligated 
into pre-digested pGL3 promoter vector (Promega, UK) using T4 DNA ligase (New 
England Biolabs, UK). The ligated vector was then transformed into chemically 
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competent DH5α cells and plated on agar plate containing 50µg/ml final concentration 
of ampicillin and incubated at 37°C for 16 hours.  
 
Four individual colonies were selected and inoculated in 2ml of LB broth containing 
50µg/ml final concentration of ampicillin and incubated in a shaker at 37ºC for 16 
hours. After alkaline miniprep the DNAs from different colonies digested with Kpn1 
restriction enzyme and ran in 1% agarose gel (Figure 3.3.3 C and Figure 3.3.4 C). The 
glycerol stock was inoculated in 200ml LB broth with ampicillin and the DNA was 
extracted using PureLink HiPure Plasmid Maxiprep Kit (Invitrogen, UK). 
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Figure 3.3.3: Construction of TIGAR-HRE5,6-p53BS2-luc vector 
A. Genomic DNA from U2OS cells was used in the PCR reaction to amplify the region of the 
TIGAR promoter containing HREs 5, 6 and p53 binding site 2 (approximate molecular weight 
910bp). B. The amplified DNA was cloned into pCR-Blunt II-TOPO vector. The cloned vector 
was digested using Kpn1 restriction enzyme and ran in a 1% agarose gel. C. The PCR product 
extracted from TOPO vector was ligated into pGL3 vector (pre-digested with Kpn1) and the 
ligated vector was digested using Kpn1 and ran in a 1% agarose gel. 
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Figure 3.3.4: Construction of SCO2-HRE1-5,p53-luc vector 
A. Genomic DNA from U2OS cells were used in the PCR reaction to amplify the region of the 
SCO2 promoter containing HREs 5, 6 and p53 binding site 2 (approximate molecular weight 
1425 base pairs). B. The amplified DNA was cloned into pCR-Blunt II-TOPO vector. The 
cloned vector was digested using Kpn1 restriction enzyme and ran in a 1% agarose gel. C.The 
PCR product extracted from TOPO vector was ligated into pGL3 vector (pre-digested with 
Kpn1) and the ligated vector was digested using Kpn1 and ran in a 1% agarose gel. 
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3.4 Microbiology 
3.4.1 Preparation of LB broth and LB agar plates 
LB broth was prepared by dissolving 20 grams of Luria Bertani (LB) powder in one 
litre of distilled water which was then autoclaved at 15psi and 121°C for 15 minutes. 
After the solution was cooled down to room temperature, ampicillin (100µg/ml) or 
kanamycin (50µg/ml) was added under aseptic conditions. 
 
LB agar plates were prepared by dissolving 20 grams of LB agar in one litre of distilled 
water which was then autoclaved at 15psi and 121°C. After the solution was cooled 
down to 50°C, under aseptic condition, ampicillin (100µg/ml) or kanamycin (50µg/ml) 
was added. Approximately 10ml of the mixture was poured in sterile 90cm petri dishes 
and stored at 4°C. 
3.4.2 Preparation of competent bacteria and transformation 
Transformation is the process by which the bacterial cells take up the naked DNA 
molecules. Since the bacterial genome is made up of circular DNAs and plasmids, the 
bacteria will replicate the foreign DNA along with their own DNA if the foreign 
plasmid DNA has an origin of replication recognized by the host cell DNA 
polymerases. In order for the bacteria to be able to uptake foreign DNA they should first 
be submitted to a process that transforms them to competent bacteria. To prepare 
competent bacteria, DH5α (non-competent bacteria) were grown in LB broth. The cells 
were collected by centrifuging at 5000 rpm for 10 minutes at 4°C and resuspended in 
500ml of ice cold 100mM calcium chloride and incubated on ice for 30 minutes with 
occasional swirling. The cells were pelleted again by centrifuging at 5000rpm for 10 
minutes at 4°C. The pellet was resuspended in 40ml of ice cold 100mM calcium 
chloride with 15% glycerol. The bacterial suspension was aliquoted into 600µl in sterile 
eppendorf tubes and kept in 4°C for 12 hours. The cells were frozen down rapidly in 
liquid nitrogen and immediately transferred to -80°C.  
 
The bacterial cell membrane is permeable to chloride ions, but not to calcium ions. 
When the chloride ions enter the cell, it will be accompanied by water molecules which 
cause the cells to swell which facilitate the cells to uptake the DNA. The calcium 
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chloride treatment is followed by heat shock at 42°C for 45 seconds during which a set 
of genes aiding the bacteria to survive in high temperatures are expressed. These so 
called heat shock genes are believed to be involved in the uptake of foreign DNA by the 
bacteria. 
 
Briefly, 200µl of chemically competent DH5α bacterial suspension was thawed on ice 
and approximately 100ng of plasmid DNA was added to it and mixed well. This 
mixture was kept on ice for 30 minutes and then heat shocked at 42°C for 45 seconds 
and placed on ice for 2 minutes. 500µl of SOC medium was added to bacterial mixture 
and incubated in a shaker at 37°C for 1 hour. 200µl of the resultant mixture was 
streaked on an LB agar plate containing the appropriate antibiotics. The plate was 
incubated at 37°C for 16 hours. 
3.4.3 Preparation of plasmid DNA 
3.4.3.1 Miniprep 
A single colony from the LB agar plate was inoculated in 2ml of LB broth with 
appropriate antibiotic and allowed to grow overnight in a shaking incubator at 200 rpm 
and 37°C for 16 hours. The bacterial cell pellet was collected by centrifuging the cells at 
6,000g for 15 minutes and resuspended in 100µl of ice cold resuspension buffer 
(containing 20µg/µl RNAse A) by vortexing. 200µl of miniprep lysis buffer was added 
and mixed well by inverting the tube rapidly five times (to ensure proper lysis of the 
cells) and kept on ice for 2 minutes. 150µl of ice cold precipitation buffer was added 
and vortexed gently for 10 seconds to disperse precipitation buffer through the viscous 
bacterial lysate. This mixture was incubated on ice for 5 minutes and centrifuged at 
12,000g for 5 minutes at 4
0
C and the supernatant was transferred to a fresh Eppendorf 
tube. 400µl of phenol:chloroform was added and mixed by vortexing. The mixture was 
centrifuged at 12,000g for 5 minutes at 4
0
C and the supernatant was transferred to a 
fresh Eppendorf tube. The DNA dissolved in the aquatic phase was then precipitated 
with 800µl of absolute ethanol, and washed with 70% ethanol. The remaining ethanol 
was removed carefully and the precipitated double stranded DNA was dissolved in 50µl 
of TE buffer and stored at -20
0
C for future use. In some occasions, the miniprep was 
carried out using Qiagen Miniprep Kit following the manufacturer's instructions. 
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3.4.3.2 Maxiprep 
To isolate high quality plasmid DNA which was used for transfection of mammalian 
cells, PCR reactions and cloning, the PureLink HiPure Plasmid Filter Purification Kit 
(Invitrogen) was used. This kit contains columns which have an anion-exchange resin, 
which selectively binds plasmid DNA and enzymes that remove endotoxins. A single 
colony was picked up from a transformation plate and inoculated into a sterilised 
conical flask containing 150 ml of sterile LB broth supplemented with the appropriate 
antibiotic. Bacteria were incubated for 16 hours at 37°C with shaking (200 rpm), 
harvested by centrifugation for 10 min at 4,000g, resuspended, lysed, precipitated and 
the precipitated mixture was loaded on the HiPure Filter Columns that contain filtration 
cartridges. During this process, the negatively charged phosphates of the DNA 
backbone are bound to the positively-charged surface of the resin and while DNA is 
retained on the resin, RNA, proteins, carbohydrates and other impurities are washed 
with the wash buffer. The plasmid DNA was then eluted in high salt concentration by 
applying the elution buffer. The DNA was precipitated with isopropanol by 
centrifugation (12,000g, 30min, 4°C) and the DNA pellet was washed with 70% ethanol 
and resuspended in 250-400 µl of TE buffer.   
3.5 Transfection Studies 
3.5.1 Plasmids 
The details of the plasmids used in this study are listed in Table 3.5.1 
Sl No Plasmid Source 
1 CA-IX-HRE Luc (Wykoff et al., 2000) 
2 CMV-p53 T Halazonetis, University of Geneva 
3 CMV- -Gal (Zamanian and La Thangue, 1992) 
4 Flag-PCAF (Barbacci et al., 2004) 
5 Flag-PCAFΔHAT (Barbacci et al., 2004) 
6 HA-HIF-1α (Huang et al., 1998) 
7 HA-HIF-1αK389R (Xenaki et al., 2008) 
8 HA-HIF-1αK532R (Xenaki et al., 2008) 
9 HA-p53K320R T Halazonetis, University of Geneva 
10 pcDNA3 Invitrogen 
11 RNAi-HIF-1α (Xenaki et al., 2008) 
12 pcDNA3-SCO2 (Matoba et al., 2006) 
13 SCO2-p53-HRE-Luc Part of promoter region of SCO2 gene 
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Sl No Plasmid Source 
cloned into pGL3 promoter vector 
14 pcDNA3-Flag-TIGAR (Bensaad et al., 2006) 
15 TIGAR-p53-HRE5,6-Luc Part of promoter region of TIGAR  gene 
cloned into pGL3 promoter vector 
Table 3.5.1: List of plasmids used in this study and their sources 
3.5.2 Transfection methods 
3.5.2.1 Calcium phosphate method 
The principle of calcium phosphate transfection involves the slow mixing of HEPES 
buffered saline containing sodium phosphate with a calcium chloride solution 
containing the DNA. The resulting calcium-phosphate DNA complex adheres to the cell 
membrane and enters the cytoplasm possibly by endocytosis. Briefly, the cells were 
subcultured in 100mm culture plates at least 24 hours before transfection. A fresh media 
was added to the cells just before transfection. A total of 10µg of plasmids listed in 
Table 3.5.1 (also as described in the Figure legends), were diluted to 360µl with sterile 
distilled water. 120µl of 1M calcium chloride was added to the diluted DNA and 
vortexed for 15 secs. This mixture was incubated at room temperature for 10 minutes. 
480µl of 2X HBS was added to the mixture and immediately vortexed for 15 seconds. 
The mixture was incubated in room temperature for 20 minutes (at the end of 20 
minutes a faint precipitate formed by calcium phosphate was visible). The whole 
mixture was added drop wise to the cells with swirling. The cells were incubated in 
37°C incubator for 16 hours and then washed twice with sterile PBS and changed to 
fresh media. The cells were harvested 36-48 hours after transfection.  
3.5.2.2 Polyfect transfection method 
For luciferase reporter assays, mRNA analysis and estimation of lactate production, 
oxygen consumption, NAD
+
/NADH ratio and intra-cellular ROS levels the cells were 
transfected using Polyfect transfection reagent. A recommended amount of plasmid 
DNA was diluted in DMEM without serum and antibiotics as the presence of serum, 
proteins and antibiotics in this step would interfere with the complex formation and 
significantly reduce the transfection efficiency. A specified amount of Polyfect 
transfection reagent was added to the DNA solution and the mixture was vortexed for 
10 seconds (Polyfect reagent possesses a specific spherical structure, with branches 
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radiating a central core and terminating at charged amino groups. Polyfect reagent 
assembles DNA into compact structures, facilitating the entry of DNA into the cells 
(Qiagen, 2000)). The mixture was then incubated at room temperature for 5-10 minutes 
to allow Polyfect-DNA complex formation. Meanwhile, the cells were washed once 
with PBS and the fresh media containing FBS and P/S was added. DMEM with FBS 
and P/S was added to the Polyfect-DNA complex and mixed well and the mixture was 
added to the cells with swirling to ensure the uniform distribution of the complexes 
(Polyfect-DNA complex possesses a net positive charge, which allows them to bind to 
negatively charged receptors on the surface of the eukaryotic cells. Inside the cells, 
Polyfect reagent buffers the lysosome after it has fused with the endosome, leading to 
the pH inhibition of lysosomal nuclease. This ensures the stability of Polyfect-DNA 
complexes and the transport of intact DNA into the nucleus (Qiagen, 2000)). The cells 
with the complexes were incubated at 37°C and 5% CO2 and harvested after 24 - 48 
hours. 
3.6 Luciferase assay 
This assay is based on the principle that luciferase enzyme catalyzes the transformation 
of D-luciferin into oxyluciferin in an oxygen and ATP dependent process, leading to the 
emission of photons which can be detected at 500 to 620nm wavelength (Figure 3.6.1 
A) (Baert, 2008). The luciferase reporter vectors have been designed to report the 
binding activity of an individual transcription factor. The pGL3 Luciferase Reporter 
Vectors provide a basis for the quantitative analysis of factors that potentially regulate 
mammalian gene expression. These factors may be cis-acting, such as promoters and 
enhancers, or trans-acting, such as various DNA-binding factors (Figure 3.6.1 B) (Baert, 
2008).  
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Figure 3.6.1: Principle of luciferase assay 
A. In the presence of oxygen, ATP and Mg
2+
 ions luciferase enzyme converts luciferin into 
oxyluciferin and produces light. B. Transcription factors bind to regulatory sequences cloned 
directly adjacent to the luciferase gene, and the expression of luciferase which can be measured 
by the conversion of luciferin into oxyluciferin and light (Baert, 2008).. 
  
The cells were grown in 6 well plates and transfected with PCDNA3 or PCAF or 
PCAFΔHAT using Polyfect transfection reagent. 24 hours after transfection the cells 
were left untreated or treated with DSFX for 16 hours. The cells were harvested using 
Reporter lysis buffer (Promega, UK) and centrifuged at 13,000 rpm for 15 minutes at 
4°C. 10µl of this cleared lysate was added to 100µl of luciferin reagent (Promega, UK) 
and briefly vortexed and the luminescence produced was immediately measured in a 
luminometer at 560nm.  
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Figure 3.6.2: pGL3 promoter vector circle map (Promega, 2007) 
Schematic diagram showing the vector map of pGL3 promoter vector. 
3.6.1 β-galactosidase assay 
β-galactosidase assay was performed to measure the transfection efficiency of the cells. 
β-galactosidase is an enzyme encoded by the lacZ gene of the lac operon in E.Coli. β-
galactosidase cleaves lactose to glucose and galactose. The synthetic compound o-
nitrophenyl-β-D-galactoside (ONPG) is also recognized as a substrate and cleaved to 
yield galactose and o-nitrophenol which has a yellow colour whose absorbance can be 
measured at 420nm. The conversion of ONPG to o-nitrophenol is proportional to the 
concentration of β-galactosidase enzyme. 
 
The cells were grown in 6 well plates and transfected with PCDNA3 or PCAF or 
PCAFΔHAT using Polyfect transfection reagent. 24 hours after transfection the cells 
were left untreated or treated with DSFX for 16 hours. The cells were harvested using 
Reporter lysis buffer (Promega, UK) and centrifuged at 13,000 rpm for 15 minutes at 
4°C. 30µl of this supernatant was added to 300µl of β-gal buffer (Table 3.1.4) and 
incubated at 37°C for 1 hour. 500µl of distilled water was added to the mixture and the 
absorbance was measured at 420nm.  
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3.7 Immunoblotting 
3.7.1 Preparation of whole cell extract 
For western blotting, the cells were seeded at 60 - 70% confluency in 100mm culture 
plates and were incubated overnight in 37°C incubator. Wherever necessary the cells 
were transfected with calcium phosphate method or with Polyfect transfection reagent. 
Fresh media was added to the cells after 16 hours of transfection and the cells were 
treated with appropriate chemicals for the periods mentioned in each experiment. Then 
the media was removed and the cells were washed twice with 1X cold PBS. 250µl of 
240 mM TNN buffer (Table 3.1.4) (with freshly added protease and phosphatase 
inhibitors) was added to the cells and the cells were scraped in the cold room using a 
rubber policeman.  
 
The extracts were collected in 1.5ml centrifuge tubes and rotated for 20 minutes at 4
0
C 
followed by centrifugation at 4
0
C for 30 minutes at 13,000rpm. The pellets were 
discarded and the supernatants were carefully transferred to a fresh centrifuge tube kept 
on ice.  
3.7.2 Determination of protein concentration 
The concentration of proteins present in the whole cell extract was measured using Bio-
Rad Protein Assay reagent. This assay is based on the Bradford method for protein 
quantification (Bradford, 1976). The Bradford's assay relies on a colour change of the 
dye Coomassie Brilliant Blue G-250 after binding to different concentrations of protein. 
The Coomassie Blue dye readily binds to arginyl and lysyl residues of the protein. In 
acidic conditions, binding of the dye to the protein results in shifting of the maximum 
absorbance of the dye from 465 nm to 595 nm. The concentration of the protein is then 
determined by measuring the absorbance at 595 nm. 
 
The Bio-Rad working solution was prepared by 1 part of the dye with 4 parts of distilled 
and de-ionized water in a 1.6 ml, 1 cm path visible cuvette. 2µl of distilled and de-
ionised water was used to calibrate the spectrophotometer that was set at 595 nm and 
was used as blank. To normalise the protein concentrations of samples used for Western 
Blotting or co-immunoprecipitation, 2µl of sample was added to the diluted dye, mixed 
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well and incubated for five minutes at room temperature before the absorbance of the 
resultant solution was measured. After determining the protein concentration equal 
amount of proteins were mixed with 3X SDS sample buffer (Table 1.1.4) and subjected 
to SDS PAGE. 
3.7.3 SDS-PAGE 
Electrophoresis is a process in which the macromolecules are separated in an electric 
field. A common method for separating proteins by electrophoresis uses a poly 
acrylamide gel as a supporting medium and SDS to denature the proteins. This method 
is called SDS-poly acrylamide gel electrophoresis (SDS-PAGE).  
Polypeptides are amphoteric and their net charge is determined by the pH of the 
suspension they are in. SDS is an anionic detergent and in solution form it possesses 
negative charge in a wide pH range. When added to the proteins, the amount of SDS 
binds with the polypeptide chain is directly proportional to the molecular mass of the 
polypeptide. The SDS denatures the proteins by wrapping around the polypeptide 
backbone and binds to proteins fairly specifically in a mass ratio of 1.4:1 thus 
conferring negative charge to the polypeptide in proportion to its length which leads 
them to move towards the positively charged electrode in an electric field.   
Poly acrylamide gels have pores which allow the smaller molecules to move faster and 
restrain the larger molecules from moving as fast as the smaller molecules. In an electric 
field, when the charge to mass ratio is nearly the same among SDS denatured 
polypeptides, the movement of the proteins are almost entirely dependent on the 
molecular mass of the polypeptides. To ensure that the proteins are fully denatured and 
attain a random-coil configuration which is necessary for separation by size, a 
disulphide reducing agent, 2-mercapto ethanol is used. 
SDS-PAGE was performed using 7.5% and 10% gels according to the size of the 
proteins of interest. The compositions of the gels are listed in Table 3.7.1. 
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Solutions  
 
7.5% 10% 
Resolving Stacking Resolving Stacking 
Distilled water 13.3 ml 6.73 ml 10.94 ml 6.73 ml 
Acrylamide 7 ml 1.67 ml 9.33 ml 1.67 ml 
1.5M Tris pH 8.95 7 ml - 7 ml - 
1M Tris pH 6.95 - 1.25 ml - 1.25 ml 
0.2M EDTA 280µl 100µl 280µl 100µl 
10% SDS 280µl 100µl 280µl 100µl 
10% APS 157µl 100µl 157µl 100µl 
TEMED 17µl 10µl 17µl 10µl 
Table 3.7.1: Composition of poly acrylamide gels 
 
The gel casting apparatus (Mini-PROTEAN 3 - Bio-Rad, UK) was set-up according to 
the manufacturer’s guidelines. The components mentioned in Table 3.7.1 were mixed 
together and TEMED and APS were added at the end before pouring the mixture 
between the plates. Once the resolving gel was poured into the gel casting apparatus, 
500 µl of isopropanol was added on top of it to ensure that the gel was evenly flat on top 
and to remove any air bubbles. Once the resolving gel was set isopropanol was removed 
and the stacking gel was poured and 1.5 mm wide well combs were inserted into the 
stacking gel solution. The stacking gel was used to get the optimal resolution of the 
proteins. It has lower percentage of acrylamide and pH compared to the resolving gel, 
which allows the proteins to be stacked before they enter the resolving gel. After the 
stacking gel was set, the gels were fitted into the electrophoresis mini buffer tank (Bio-
Rad) and the tank was filled with SDS-PAGE running buffer (Table 3.1.4) and the 
combs were removed. 
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The protein samples were boiled at 95ºC for 5 minutes, centrifuged at 13,000 rpm for 1 
minute and loaded into the wells using gel loading tips (Star Labs, UK). 5µl of 
PageRuler Prestained protein ladder (Fermentas, UK) was loaded in every gel and the 
samples were run at 80V until they enter the resolving gel and then at 110V. 
3.7.4 Western transfer and detection of proteins 
The proteins resolved on the gels were transferred to a polyvinylidene fluoride PVDF 
membrane (Millipore, UK) using western transfer method. Electroblotting is a 
commonly used method that uses an electric current and a transfer buffer solution to 
transfer proteins from the gel onto the membrane. Western transfer apparatus (Bio-Rad, 
UK) was set-up according to manufacturer’s guidelines and filled with western transfer 
buffer (Table 3.1.4). The transfer was carried out in 0.4amps for 90 minutes with the ice 
pack changed at 45 minutes. After the proteins were transferred, the PVDF membranes 
were blocked in 5% dried milk powder in PBS for 1 hour. The membrane was then 
incubated with specific primary antibody (Table 3.1.3) in 2.5% milk/PBS/0.1% Tween 
solution on a rocking platform overnight at 4ºC.  
 
Membranes were washed 3 times with PBS/0.1% Tween for 10 minutes and incubated 
for 1 hour with relevant anti-rabbit or anti-mouse IgG horseradish peroxidise conjugated 
secondary antibody (Table 3.1.3) in 2.5% milk/PBS/0.1% tween. The membranes were 
washed 3 times with PBS/0.1% Tween for 10 minutes. 500µl of One Step ECL 
(Chembio, UK) was sprayed on each membrane and the proteins were visualised on 
medical X-ray films (Fujifilm, UK) developed using the Compact X4, Xograph imaging 
system according to the manufacturer’s guidelines.  
3.7.5 Densitometric analysis 
To quantify blots, densitometric scanning was performed using the Image J 1.38e 
software. Three readings of each band were recorded and then each band was 
normalised to its correspondent Actin band intensity. The average of the three readings 
were calculated, and presented as chart bars. The final average and standard deviation 
readings were measured by taking the values of three sets of independent experiments.  
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3.7.6 Stripping the membrane 
After detecting the first protein, the membranes were subjected to antibody striping, 
wherever necessary, to detect the second protein whose molecular weight is close to the 
first protein. To remove the antibody, the membranes were incubated in stripping buffer 
(Table 3.1.4) for 30 minutes at 55ºC and washed three times in 10ml of PBS with 0.1% 
tween-20 for 10 minutes. After stripping the membranes were blocked with the desired 
primary antibody. 
3.8 Measurement of mRNA level 
3.8.1 RNA isolation 
The total RNA was extracted using RNeasy plus mini kit (Qiagen, UK). This kit is 
specially designed to extract all RNA molecules which are longer than 200 nucleotides. 
The procedure offers enrichment for mRNA as most RNAs less than 200 nucleotides 
such as rRNA and tRNA are selectively excluded. Briefly, the cells were lysed and 
homogenised in a highly denaturing guanidine-isothiocyanate containing buffer which 
immediately inactivates RNase to ensure the isolation of intact RNA. Since numerous 
disulfide bonds make ribonucleases very stable enzymes 2-mercaptoethanol was added 
to the lysis buffer to reduce these disulfide bonds and denature the enzymes. A high salt 
buffer along with a spin column eliminates the gDNA from the sample. The binding 
capacity of RNA is improved by the addition of ethanol. Then the solution was passed 
through a specially designed column which retains only the RNA and the retained RNA 
is then eluted in distilled water. 
 
U2OS and SaOS2 cells were grown in 6 well plates, transfected and treated as described 
in the figure legends. The cells were lysed using RLT plus buffer containing 1%  
mercaptoethanol. The lysates were homogenised using Qia-shredder spin column and 
centrifugation. The gDNA eliminator was used to remove the genomic DNA and one 
volume of 70% ethanol was added to the flow through. RNA was recovered from the 
solution with the RNeasy column, which was washed once with RW1 buffer and once 
with the RPE buffer. The RNA captured on the column was eluted with 30µl of RNase-
free water and its concentration was determined using NanoDrop ND-1000 UV-Vis 
spectrophotometer. 
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3.8.2 Reverse transcription 
The cDNA was generated from the isolated RNA by a process called reverse 
transcription. In eukaryotic mRNA, poly-A tail is present at the 3’ ends, therefore a 
poly-T oligonucleotide (anchored oligo) is used as a primer to anneal to the 3’ end of 
the mRNA. This primer is then extended with the reverse transcriptase using mRNA 
strand as a template.  
 
500ng of anchored oligo dT was added to 1µg of the isolated total RNA (section 3.8.1) 
and the total volume of the mixture was made up to 12µl using RNase free water. This 
mixture was incubated at 70°C for 5 minutes to remove any secondary structure and 
then chilled on ice. dNTPs and reverse transcriptase enzyme were added along with the 
reaction buffer to this mixture. This mixture was incubated at 37°C for 1 hour and 
heated at 75°C for 10 minutes to stop the reaction. The cDNA synthesised in this 
process was used in qRT-PCR to measure gene expression using specific primers that 
amplify the genes of interest. 
3.8.3 Quantitative Real Time PCR (qRT-PCR) 
cDNA levels corresponding to mRNA content of specific genes were determined by 
quantitative real-time PCR. qRT-PCR is a method that allows continuous data logging 
with plate read-outs at each DNA amplification cycle throughout the assay. RT-PCR 
was first described by Higuchi and colleagues (Higuchi et al., 1992) and was developed 
to quantify the levels of amplified DNA which represent the transcribed RNA. The 
SYBR Green I double-stranded binding dye (Sigma, UK) intercalates only to double 
stranded PCR products, so that the fluorescence signal is proportional to the number of 
amplified copies. SYBR Green I has an excitation and emission maxima of 494 nm and 
521 nm, respectively. It binds to all double stranded DNA so there is no need for 
adaptation to individual samples and it is a very sensitive method as multiple molecules 
of the dye bind to a single amplification product. Primers listed in Table 3.8.1 were used 
to amplify cDNA and the cycling parameters are described in Table 3.3.3. A melting 
curve is calculated from 72°C to 95°C with 1°C increase in every 30 secs. 
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Gene Orientation Primer sequence Product size 
TIGAR Forward 5’- ATGGAATTTTGGAGAGAA-3’ 84 
Reverse 5’-CCATGGCCCTCAGCTCAC-3’ 
SCO2 Forward 5’-TCACTCACTGCCCTGACATC-3’ 149 
Reverse 5’-CGGTCAGACCCAACAGTCTT-3’ 
Rpl19 Forward 5’-ATGTATCACAGCCTGTACCTG-3’ 122 
Reverse 5’-TTCTTGGTCTCTTCCTCCTTG-3’ 
Table 3.8.1: qPCR primer sequences 
The components used for qRT-PCR reactions are listed in table 2.6.  
Component Amount per reaction 
Nuclease free water 11.93µl 
10X Thermopol buffer (NEB, UK) 2µl 
MgCl2 50mM  0.4µl 
dNTPs (10mM) 0.6µl 
SYBR Green I (1X) 0.75µl 
Forward primer (100µM) 0.06µl 
Reverse primer 0.06µl 
Taq polymerase (NEB, UK) 0.2µl 
cDNA template 4µl 
Total reaction volume 20µl 
Table 3.8.2: Components of qPCR reaction 
Opticon Monitor 2 System (MJ Research) was used for qRT-PCR assay. Data was 
analysed with Opticon Monitor Analysis Software, version 2.02. The principle of qPCR 
analysis is demonstrated in Figure 3.8.1 
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Figure 3.8.1: Principle involved in qPCR assay 
The threshold cycle (Ct value) determines the cycle at which there is a significant increase in 
fluorescence. On the contrary, the baseline area represents the noise level in early cycles and 
therefore at this stage there is no significant fluorescence. The log- linear phase is the linear 
portion of the amplification plot that represents the exponential phase of amplification. The 
intensity of the intercalated SYBR green fluorescence is measured at the end of every cycle and 
this determines the copy number of the amplified DNA. In this case, sample A reaches the Ct 
value at 21 cycles, whereas sample B at 31 cycles. Figure adapted from (Qiagen, 2006).  
 
3.9 Chromatin immuno-precipitation (ChIP) assay 
DNA-protein interactions mediate critical nuclear and cellular functions. Chromatin 
immunoprecipitation is a powerful tool for studying protein/DNA interactions hence 
very useful to study the transcription factors that are bound to specific DNA regions. In 
this method the cells are fixed with formaldehyde which facilitates the formation of 
covalent bond between DNA and specific protein located on it and preserves the 
protein/DNA interactions. The DNA is then sheared to small fragments and the specific 
protein/DNA complex is pulled down using an antibody directed against the DNA 
binding protein of interest. Following pull down, the cross link between DNA and 
protein is reversed, and the DNA is recovered. The DNA is then analysed to determine 
which fragments of the DNA were bound by the protein of interest (Motif, 2009). A 
schematic diagram of the ChIP protocol is shown Figure 3.9.1.  
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Figure 3.9.1: Principle of Chromatin immunoprecipitation (ChIP). 
DNA and binding proteins are cross-linked and the chromatin-DNA complex is immuno-
precipitated using a primary antibody specific for the protein of interest, and magnetic beads for 
easy separation. The protein-DNA cross-links are then reversed, to release DNA fragments that 
are ready for direct PCR. Figure adapted from Clontech website. 
Approximately 10 million cells were grown for each treatment point. The cells were left 
untreated or treated with 250µM DSFX for 16 hours. The chromatin was cross-linked to 
DNA by the addition of 1ml of formaldehyde solution Table 3.1.4. After incubating at 
room temperature for 10 minutes, the effect of formaldehyde was quenched by 
incubating the cells with 125mM final concentration of glycine for 5 minutes at room 
temperature. The cells were washed twice with 10mls of ice-cold PBS and harvested 
with 2mls of ice cold ChIP buffer 1 containing 100µM PMSF and 1X protease inhibitor 
cocktail (PIC). The cell pellet was obtained by centrifuging at 4,700 rpm for 5 minutes 
at 4°C. The supernatant was discarded and the cell pellet was washed once with 10ml of 
ChIP buffer 2 which was supplemented with 100µM PMSF, 1X protease inhibitor 
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complex. After centrifugation at 4700 rpm for 5 minutes the cells were resuspended in 
3ml of ChIP buffer 3. The cell suspension was aliquoted as 500µls into fresh eppendorf 
tubes, and subjected to sonication in Bio-ruptor UCD 200, set 30 seconds ON/OFF 
pulse for 5 minutes. This setup will produce 0.5kb to 1kb size of DNA fragments 
(Figure 3.9.2). The sonicated lysate was cleared by centrifugation at 11,400 rpm for 10 
minutes at 4°C and the supernatant was transferred to fresh sterile eppendorf tubes. 
100µl of this whole cell lysate was taken for input and 1ml of lysate was used for 
immuno-precipitation. 
 
Meanwhile, 100µl of magnetic beads were washed three times in 1ml of blocking 
solution and resuspended in 250µl of blocking solution. 2µg of mouse IgG or anti-HIF-
1α antibody was added and rotated in the cold room for 16 hours. The magnetic beads 
were washed three times in 1ml blocking solution and resuspended in 100µl of blocking 
solution 1 ml of whole cell extract was added to the beads and rotated overnight in the 
cold room.  
 
The magnetic beads were collected and washed 5 times in 1ml of RIPA buffer (Table 
3.1.4) and once in 1ml of Tris buffered saline (TBS). The residual TBS was removed 
after brief centrifugation and the beads were resuspended in 200µl of elution buffer 
(Table 3.1.4) and incubated at 65°C for 16 hours. 200µl of the supernatant was 
transferred to new tubes. 200µl of TE buffer was added to IP and input samples along 
with 8µl of 1mg/ml of RNase A and incubated at 37°C for 30 minutes. 4µl of 20mg/ml 
of Proteinase K was added and the mixture was incubated at 55°C for 2 hours. 400µl of 
phenol-chloroform-isoamyl alcohol (25:24:1) was added and vortexed. The aqueous 
phase was separated after centrifugation at 13,000 rpm for 5 minutes at 4°C and 
transferred to fresh tube. 16µl of 5M NaCl (200mM final concentration) and 1µl of 
20mg/ml of glycogen was added to the mixture along with 800µl of 100% ethanol and 
incubated at -80°C for 30 minutes. The DNA pellet was collected after centrifugation at 
13,000rpm for 30 minutes at 4°C. The pellets were washed with 500µl of 70% ethanol 
and air dried for 10 minutes at 45°C and finally resuspended in 50µl of distilled water 
and isolated DNA fragments were submitted to PCR using the TIGAR and SCO2 
primers flanking the HREs within their promoter regions (Table 3.9.1 and Table 3.9.2).  
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The equal shearing of DNA is necessary for all samples as it affects the 
immunoprecipitation efficiency. The shearing efficiency was checked by 2% agarose 
gel electrophoresis of 10µl of the input samples (Figure 3.9.2) 
 
Figure 3.9.2: Equal shearing of DNA in all samples. 
The untreated and DSFX treated samples were sheared equally to produce DNA fragment sized 
between 200 and 700 base pairs. 
The sequences of the primers used to enrich the region of TIGAR and SCO2 promoters 
which contain HREs are listed in Table 3.9.1 and Table 3.9.2 
TIGAR Forward Reverse 
HRE 1 GTGTTGGAATCTCGGCTCAC CAAGGCAGGTCAGGAGAATC 
HRE 2 CCGTGTTAGCCAAAATGGTC CACATTTGGCCTTCTGAACA 
HRE 3 
and E2F1 
CTATAGAAGGGTGCGTCCTT TGACTCCTTCCCATTACCTA 
HRE 4 ACACGGTGAAACCCTGTCTC AGTGCAGTGGTGTGATCTCG 
HRE 5 CACAGTCTGTTGGTCGCTG GATTCCTTCCCTCGATAGCC 
HRE 6 AGGAATCCTACCGCGGACT CTACCTCCCCCACACCACT 
Table 3.9.1: Sequences of the TIGAR primers used in ChIP assay. 
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SCO2 Forward Reverse 
HRE 1 TGGTGCTGCACGAGCTCGG CTCACCACGGCGCAGCCTC 
HRE 2 CTCTGCAGGGACCCCCTGGC GCGGTCGGAGAGTACGAGCG 
HRE 3 CAGGAGGCGCTCGTACTCT GACAGGCTCTCAGCGCGTGC 
HRE 4 CATGCGCAGCTCCGGGGAC ACGAGAGGAAGCGCCGACCT 
HRE 5 
and p53 
GCCAGAGAGTTACCCACCTCC
TTTTAA 
CTGTCACCGCACCCTGCCC 
HRE 6 GTGTGGTTGCCCAGGTGTGGA GGCTGCCCCTGCGACTTGAG 
Table 3.9.2: Sequences of the SCO2 primers used in ChIP assay. 
3.10 Glycolysis OXPHOS and ROS generation analysis 
3.10.1 Lactate measurement 
Lactic acid is a by-product of carbohydrate metabolism under hypoxic conditions. 
Lactic acid is converted to pyruvate and hydrogen peroxide (H2O2) by lactate oxidase. 
In the presence of the H2O2 formed, peroxidase catalyzes the oxidative condensation of 
chromogen precursors present in lactate reagent (Trinity Biotech, Ireland) to produce a 
coloured dye with an absorption maximum at 540 nm. The increase in absorbance at 
540 nm is directly proportional to the lactate concentration in the sample.  
 
U2OS and SaOS2 cells were seeded at 60-70% confluency in 6 well plates and 
transfected with appropriate plasmids using Polyfect transfection reagent. Fresh media 
without phenol red pH indicator (Sigma, UK) was added to the cells after 16 hours of 
transfection and the cells were treated with 250µM DSFX for 16 hours. 300µl of the 
media was collected in a 96 well plate before and 16 hours after treating with DSFX. 
2µl of this media was mixed with 200µl of lactate reagent and incubated at room 
temperature for 5 to 10 minutes and the absorbance was recorded at 540nm. Lactic acid 
standard solutions (Trinity Biotech, Ireland) were used to plot the standard curve and 
the concentration of lactic acid present in the media was calculated accordingly. 
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3.10.2 NAD+/NADH measurement 
The NAD
+
/NADH ratio is an indication of the metabolic and redox state of a cell. The 
NAD
+
/NADH measurement assay utilizes a cycling mixture composed of MTT (3- (4, 
5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide), phenazine ethosulfate 
(PES), ethanol and alcohol dehydrogenase. When NAD
+
 is added to a suitably buffered 
mixture of PES, MTT, alcohol dehydrogenase and its substrate ethanol an enzymatic 
cycling is initiated (Nisselbaum and Green, 1969). The rate of reduction of MTT (from 
a yellow tetrazole to purple formazan) is proportional to the concentration of the co-
enzyme NAD
+
.  Since NAD
+
 is not thermo stable the NAD
+
 and NADH amounts were 
determined from the heated and unheated samples. NADt (NAD and NADH) or NADH 
can be quantified by comparison with the amount of standard NADH.  
 
U2OS and SaOS2 cells were seeded at 60-70% confluency in 100mm plates and 
transfected with appropriate plasmids using Polyfect transfection reagent and treated 
with 250µM DSFX for 16 hours. The cells were washed twice with PBS and 1 ml of 
extraction buffer (Table 3.1.4) was added. The plates were swirled until the cells were 
lysed and the jelly like lysate was transferred to 15ml universal tubes and sonicated 
briefly on ice. 200µl of these lysates was transferred to fresh eppendorf tubes and 
incubated at 60ºC for 30 minutes. 5µl of both the heated and unheated samples were 
mixed with 83µl cycling buffer (Table 3.1.4) 1µl of 200mM phenazine ethosulfate 
(PES) and 1µl of 20mg/ml alcohol dehydrogenase enzyme. This mixture was incubated 
at 25ºC for 5 minutes. 20µl of 6M ethanol was added and the absorbance was measured 
at 570nm for 2 minutes (7 cycling points). The standard curves for NAD
+
 and NADH 
were plotted using the NAD
+
 and NADH standards (Sigma, UK). 
3.10.3 Measurement of oxygen consumption 
The amount of oxygen consumed by U2OS and SaOS2 cells under normoxic and 
hypoxic conditions were measured using the Clark-type polarographic electrodes. A 
Clark type oxygen electrode consists of a platinum electrode (cathode) and a silver 
electrode (anode). To maintain the chamber temperature stable at 37°C, there is an 
additional surrounding chamber filled with water and connected with a water circulation 
system. The electrode is located at the bottom of the chamber. The platinum cathode is 
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located on top of a dome-like centre which is surrounded by the silver anode. These two 
electrodes are connected with each other by a thin layer of 50% saturated KCl 
electrolyte. The dome is covered by an oxygen permeable Teflon membrane which is 
attached by an O-ring that surrounds the electrodes. When current is given to the 
electrodes, the platinum electrode is negatively charged while the silver electrode is 
positively charged. Oxygen diffuses through the Teflon membrane to the platinum 
electrode and is reduced there while the silver electrode is oxidised and accumulates 
silver chloride. The oxygen monitor holds a constant voltage difference across the two 
electrodes so that the platinum electrode is negatively charged with respect to the silver 
electrode. The current which is produced by the electrode is proportional to the oxygen 
tension in the solution. The Clark-type electrode is diagrammatically presented in 
Figure 3.10.1. The chemical reaction that occurs at the electrodes is shown below 
(Heimburg et al., 2005) 
  
At the anode (positive electrode) 
4Ag + 4Cl
-
   4AgCl + 4e
-
 
At the cathode (Negative electrode) 
4H
+
 + 4e
-
 +O2   2H2O 
Overall 
4Ag + 4Cl
-
 +4H
+
 +O2   4AgCl +2H2O 
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Figure 3.10.1: Clark type electrode system. 
A. Schematic diagram of Clark-type electrode system. B. The electrode is located at the bottom 
of the chamber. The platinum cathode is located on top of a dome-like centre which is 
surrounded by the silver anode. These two electrodes are connected with each other by a thin 
layer of 50% saturated KCl electrolyte. The dome is covered by an oxygen permeable Teflon 
membrane. When current is given to the electrodes, the platinum electrode is negatively charged 
while the silver electrode is positively charged. Oxygen diffuses through the Teflon membrane 
to the platinum electrode and is reduced there while the silver electrode is oxidised and 
accumulates silver chloride. The current which is produced by the electrode is proportional to 
the oxygen tension in the solution. The figure is adapted from Rank Brothers company website.  
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U2OS and SaOS2 cells were grown in 100mm plates and transfected with PCDNA3, or 
PCAF, or PCAFΔHAT along with PCDNA3 or SCO2 expression vector and left 
untreated or treated with DSFX for 16 hours. The Clark-type electrode system was set 
up and calibrated using 1ml of air saturated PBS and sodium dithionite which 
completely reduced the oxygen in the measuring solution. The cells were counted after 
collection and 2 million cells were loaded into the measuring chamber. A magnetic 
stirrer was positioned at the bottom of the measuring chamber. Using a 1ml pipette, the 
cell suspension was saturated with air and the chamber was closed using a plastic nob. 
The amount of oxygen consumed by the cells was calculated from the measurable units 
displayed in the computer monitor.   
3.10.4 ROS measurement 
The mixed isomers of 5-(and-6)-chloromethyl-2',7' dichlorodihydrofluorescein diacetate 
(H2-DCFDA) are probes for intracellular oxidants (Macey, 2007).  
 
 
Figure 3.10.2: Principle of ROS measurement by H2-DCFDA (Macey, 2007) 
The uptake and conversion of 2',7' dichlorodihydrofluorescein diacetate (He-DCFDA) to the 
fluorescent product 2',7' dichlorofluorescein (DCF) this is retained within the cell. 
 
H2-DCFDA is a cell permeant non-fluorescent precursor that on oxidation is converted 
to a cell impermeable fluorescent form (Chen et al., 2010). Esterases first convert 
H2DCFH-DA to a non-fluorescent intermediate, 2’,7’-dichlorofluorescin (DCFH), that 
is retained in the cell. Then during the respiratory burst, the intermediate is further 
converted by H2O2 and superoxide (O
-
2) together with peroxidase action to fluorescent 
2’,7’-dichlorofluorescein (DCF), which is also well retained in cells (Figure 3.10.2).  
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U2OS and SaOS2 cells were transfected with appropriate plasmids and left untreated or 
treated with DSFX for 16 hours. The cells were collected in a 15 ml universal tube 
using dissociation buffer (Invitrogen, UK) washed twice with sterile PBS and 
resuspended in 10ml DMEM media with FBS and penicillin /streptomycin and 
incubated in 37°C incubator with 5% CO2 for 30 minutes. 100µM final concentration of 
H2-DCFDA was added to the cells and incubated in 37°C with 5% CO2 for 30 minutes. 
The cells were washed twice in PBS and resuspended in 500µl of PBS and subjected to 
FACS analysis. The excitation and emission of the H2-DCFDA fluorescence was 
measured at 488nm and 530 nm respectively. 
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4 Results  
4.1 HIF-1α regulates TIGAR gene expression 
Given that cellular energy metabolism plays important role in tumour growth and 
survival both oncogenes and tumour suppressors antagonistically regulate the pathways 
involved in energy production such as glycolysis and oxidative phosphorylation 
(OXPHOS) to exert their pro- survival and pro-apoptotic functions on tumour cells. 
Increase in glycolysis has been shown to be beneficial for the proliferation and survival 
of the tumour cells (Gatenby and Gillies, 2004). Among the transcription factors that 
regulate cellular energy metabolism, the tumour suppressor p53 inhibits glycolysis and 
facilitates OXPHOS by transcriptionally regulating TIGAR and SCO2 gene expression, 
which have prominent roles in glycolysis and OXPHOS respectively (Bensaad et al., 
2006; Matoba et al., 2006). Apart from p53, other transcription factors have also been 
reported to exert important functions in the regulation of cellular energy metabolism. In 
particular, the HIF-1α transcription factor increases glycolysis in tumour cells by 
inducing several of its target genes encoding enzymes involved in glycolysis including 
HK2, PFK-1 and PFKFB (Sakakibara et al., 1997). In addition, HIF-1α inhibits 
mitochondrial respiration by upregulating the gene expression of the enzyme PDK1 
which inactivates the enzyme PDH which is involved in the oxidative decarboxylation 
of pyruvate (the end product of glycolysis) to produce acetyl-coA (an essential 
component of TCA cycle) (Kim et al., 2006; Papandreou et al., 2006).  
 
Regulation of the F2,6-BP level is of critical importance for the glycolytic pathway to 
proceed further, owing to the fact that F2,6-BP is an allosteric activator of the glycolytic 
rate limiting enzyme PFK-1. The F2,6-BP levels are regulated by the bifunctional 
PFKFB enzyme, whose amino terminal kinase domain increases whereas the carboxy 
terminal bisphosphatase domain decreases the F2,6-BP intracellular levels. 
Phosphorylation of the serine 32 residue (Ser
32
) in the amino terminal domain of 
PFKFB1 (an isozyme of PFKFB found in liver) by cAMP-dependent kinase (PKA) has 
been shown to inhibit the kinase activity of the enzyme thereby decreasing the ratio of 
the kinase to phosphatase activity of this enzyme (El-Maghrabi and Pilkis, 1984). In 
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contrast, PFKFB3 (another isozyme of PFKFB overexpressed in many tumour cell 
lines) lacks the critical serine residue corresponding to Ser
32
 in PFKFB1 (Sakakibara et 
al., 1997). As a consequence, the kinase activity of this PFKFB isozyme is 
constitutively high thus explaining the high ratio of kinase to phosphatase activity (700 
to 1) in the tumour cells bearing high levels of PFKFB3 (Sakakibara et al., 1997). 
Interestingly, PFKFB3 has been shown to be upregulated in hypoxic cells in an HIF-1α 
dependent manner (Obach et al., 2004) 
 
TIGAR protein on the other hand, encoded by TIGAR gene, has been shown to bear 
structural and functional similarities with the bisphosphatase domain of PFKFB 
enzyme, hence lowering the F2,6-BP level and as a consequence inhibiting the 
glycolytic flux (Bensaad et al., 2006). TIGAR exhibits significantly high basal protein 
levels in many tumour cell lines including U2OS and MCF-7 which increase further 
upon DNA damage in these cell lines (Bensaad et al., 2006). Taken together, these 
results raise the questions whether high levels of TIGAR in tumour cells play any role 
in the regulation of F2,6-BP in hypoxia thereby modulating glycolysis under these 
conditions, and if that was the case, whether this TIGAR regulatory effect on glycolysis 
was related to the PFKFB3 phosphatase activity. In other words, we hypothesised that 
TIGAR overexpression in hypoxic cells might result in the enhancement of the PFKFB3 
phosphatase and concomitant decrease of its kinase activity, reducing the kinase to 
phosphatase ratio of the enzyme and by doing so inhibits glycolysis. 
 
Functional cross talk between p53 and HIF-1α at several levels including protein 
stability (Ravi et al., 2000), and effects of one transcription factors on the transcriptional 
activity of the other have been reported (Blagosklonny et al., 1998; Chen et al., 2003). 
However, the crosstalk between p53 and HIF-1α in metabolic pathways has not been 
well documented. In this respect, we sought to investigate the involvement of HIF-1α in 
the regulation of the glycolytic pathway through possible effects that this transcription 
factor might exert on the p53 metabolic target TIGAR.  
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4.1.1 TIGAR protein levels in cells exposed to hypoxia mimicking conditions 
PFK-1 is a rate limiting enzyme of glycolysis which is regulated by the level of the 
allosteric activator F2,6-BP which is in turn determined by the function of PFKFB and 
TIGAR (Bensaad et al., 2006; Van Schaftingen et al., 1980). Although TIGAR has been 
identified as a p53 transcriptional target, the significantly high TIGAR basal protein 
levels identified in various tumour cell lines (H1299, U2OS and RKO cells) indicate the 
existence of additional p53-independent mechanisms regulating TIGAR gene expression 
(Bensaad et al., 2006). Taking into account that F2,6-BP level is primarily regulated by 
the function of the PFKFB 1 - 4 isozymes and that these isozymes are under the control 
of HIF-1α in hypoxic conditions (Minchenko et al., 2002; Minchenko et al., 2003; 
Minchenko et al., 2004). we hypothesised that TIGAR could be a common p53 and HIF-
1α transcriptional target in the glycolytic pathway the same way as it has been shown 
for Noxa (Kim et al., 2004b; Nardinocchi et al., 2011), and Bid (Xenaki et al., 2008) in 
the apoptotic pathway.  
 
To investigate the involvement of hypoxia inducible transcription factors in the 
regulation of TIGAR, we initially followed TIGAR protein levels in untreated, DSFX or 
etoposide (Section 3.2.6; page 71) treated cell lines with different p53 status such as 
U2OS and MCF-7 cells which express wild type p53 (p53
+/+
), MDA-MB-231 cells in 
which p53 is expressed by one allele (p53
mutant
) and the p53 deficient (p53
-/-
) SaOS2 
cells using western blot analysis.  
 
Accumulation of p53 protein was observed in etoposide treated wild type p53 
expressing U2OS and MCF-7 cells (Figure 4.1.1 A and B., compare lanes 3 and 1; 
Figure 4.1.2 A and B., compare black bar 3 with black bar 1) whereas no significant 
change in p53 levels was found between etoposide treated and untreated MDA-MB-231 
cells which express mutated p53 (Figure 4.1.1 C., compare lane 3 with lane 1; Figure 
4.1.2 C., compare black bar 3 with black bar 1). In the p53 null cell line SaOS2 p53 was 
not detected (Figure 4.1.1 D).  
 
The interaction between HIF-1α and its ubiquitin E3 ligase pVHL depends on the 
hydroxylation of Pro
402
 and Pro
564
 residues of HIF-1α in which iron plays important role 
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(Yu et al., 2001). In cells treated with the iron chelator DSFX iron is not available, the 
hydroxylation reaction is  inhibited and as a consequence HIF-1α is stabilised (Figure 
4.1.1 A, B, C and D., lane 2) (Maxwell et al., 1999). Consistently with the published 
reports p53 is also stabilized in DSFX treated cells in a HIF-1α dependent manner 
(Figure 4.1.1 A and B., lane 2) (An et al., 1998). 
 
Densitometric analysis of the TIGAR and p53 protein levels using ImageJ 1.43 software 
(Figure 4.1.2) indicated that TIGAR was upregulated in all four cell lines treated with 
etoposide compared to non-treated cells (Figure 4.1.1 A, B, C and D, compare lanes 3 
with lanes 1 and Figure 4.1.2 A, B, C and D, white bar 3 with white bar 1). 
 
 
Figure 4.1.1: TIGAR protein levels in hypoxia mimicking and DNA damaged cell lines 
U2OS (A), MCF-7 (B), MDA-MB-231 (C) and SaOS2 (D) cells were left untreated or treated 
with either DSFX or etoposide as indicated and subjected to western blot analysis. Actin was 
used as loading control. Data are representative of three independent experiments. 
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On the other hand, in DSFX treated cells, the pattern of TIGAR protein levels followed 
that of p53 only in the p53 wild type cell lines U2OS and MCF-7 (Figure 4.1.1 A and B, 
compare lanes 2 with lane 1 and Figure 4.1.2 A and B, compare bars 2 with bars 1). In 
contrast, in MDA-MB-231 and SaOS2 cells treated with DSFX, TIGAR protein levels 
followed different pattern from that of p53.  
 
In particular TIGAR protein levels were upregulated in MDA-MB-231 cells (Figure 
4.1.1 C, compare lane 2 with lane 1 and Figure 4.1.2 C, white bar 2 with white bar 1) 
even though p53 protein levels were downregulated under these conditions (Figure 4.1.1 
C, compare lane 2 with lane 1 and Figure 4.1.2 C, black bar 2 with black bar 1). In 
addition, in the DSFX treated p53 deficient SaOS2 cells TIGAR was downregulated 
(Figure 4.1.1 D, compare lane 2 with lane 1 and Figure 4.1.2 D, white bar 2 with white 
bar 1). These results indicated that TIGAR protein levels in hypoxia mimicking 
conditions were regulated by other factors apart from p53. 
 
 
Figure 4.1.2: Densitometric analysis of Figure 4.1.1 
ImageJ 1.43 was used to perform the densitometric measurements of Figure 4.1.1. The band 
intensity of TIGAR protein was normalized to the band intensity of Actin. The values of 
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untreated samples were considered 1 and the values from DSFX and etoposide treated cells 
calculated accordingly. 
4.1.2 Regulation of TIGAR gene expression in hypoxia mimicking conditions 
occurs at the transcriptional level 
 
The pattern of TIGAR protein levels in DSFX treated p53 deficient cells did not follow 
that of p53 protein levels (Figure 4.1.1). This led us to investigate the factors that are 
involved in the regulation of TIGAR expression in hypoxia mimicking conditions. For 
this purpose, the TIGAR mRNA levels were determined in cells treated with either 
DSFX or etoposide employing qRT-PCR. Briefly, total mRNA from all four cell lines 
(U2OS, MCF-7, MDA-MB-231 and SaOS2) was extracted and subsequently reverse 
transcribed to cDNA and qRT-PCR reactions were performed as described in the 
Materials and Methods section 3.8.3 (Page 92). TIGAR mRNA levels were measured 
using Opticon Monitor 3 software. 
 
In etoposide treated U2OS, MCF-7 and MDA-MB-231 cells, increased TIGAR mRNA 
levels were observed (Figure 4.1.3 A, B and C, compare bars 3 to bars 1), a pattern 
similar to that observed for TIGAR protein levels (Figure 4.1.1, B and C and Figure 
4.1.2 A, B and C compare white bars 3 to bars 1). However, in etoposide treated SaOS2 
cells, decreased TIGAR mRNA level compared to the non-treated cells was evident 
(Figure 4.1.3 D, compare bar 3 with bar 1). This downregulation might be attributable 
to the recruitment of repressive transcription complexes in the TIGAR promoter by other 
p53 family members such as p73 or other transcription factors such as E2F1 and NF-κB, 
which are responsive to etoposide treatment in SaOs2 cells (Lin et al., 2001; Morotti et 
al., 2006). This notion was supported by the fact that putative binding sites for E2F1 
and NF-κB were identified within the regulatory region of TIGAR gene promoter 
(Figure 4.1.5) (page 113). 
 
In line with TIGAR protein expression pattern, TIGAR mRNA levels also increased in 
DSFX treated p53 wild type U2OS and MCF-7 cell lines and a slight increase was also 
evident in the p53
mutant
 MDA-MB-231 cell line (Figure 4.1.3 A, B and C, compare bars 
2 with bars 1).  Slightly decreased TIGAR mRNA levels were observed in DSFX 
treated SaOS2 cells (Figure 4.1.3 D, compare bar 2 with bar 1).   
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Figure 4.1.3: TIGAR mRNA levels in hypoxia mimicking and DNA damaged cell lines 
Total mRNA from U2OS (A), MCF-7 (B), MDA-MB-231 (C) and SaOS2 (D) cells untreated or 
treated with either DSFX or etoposide was extracted and reverse transcribed. The cDNAs were 
then subjected to qRTPCR using specific primers amplifying TIGAR mRNA. Rpl19 was used 
as an internal control. The data was analyzed by Opticon Monitor 3 software. The data are 
representative of three independent experiments each performed in duplicates. 
 
The difference in the TIGAR mRNA levels in DSFX versus etoposide treated U2OS, 
MCF-7 and MDA-MB231 cells (Figure 4.1.3 A, B and C, compare bars 2 to 3) as well 
as the upregulation of TIGAR mRNA levels in DSFX compared to etoposide treated 
SaOS2 cells (Figure 4.1.3 D, compare bar 2 to 3) indicated that other factors, apart from 
p53 are involved in the transcriptional regulation of TIGAR gene expression in hypoxia 
mimicking conditions. Since DSFX treatment has been shown to stabilize and induce 
HIF-1α transcriptional activity (Wang and Semenza, 1993a), we hypothesised that the 
differential regulation of TIGAR gene expression in DSFX treated cells might indicate 
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the potential involvement of HIF-1α in the modulation of TIGAR gene expression in 
hypoxia under these conditions. (Wang and Semenza, 1993a) 
4.1.3 HIF-1α regulates TIGAR cellular levels 
To investigate the potential involvement of HIF-1α in the regulation of TIGAR gene 
expression in hypoxia mimicking conditions, we followed TIGAR mRNA (Figure 4.1.4 
A) and protein levels (Figure 4.1.4 B) in DSFX treated U2OS cells in the presence or 
absence of HIF-1α. RNAi-HIF-1α (Table 3.5.1) was used to silence the HIF-1α 
expression and scrambled RNAi was used as a negative control.  
 
Figure 4.1.4: TIGAR cellular levels are regulated by HIF-1α in U2OS cells 
A. U2OS cells were transfected either with scrambled RNAi or with RNAi for HIF-1α and 
treated with DSFX (black bars) or left untreated (white bars). Total mRNA was extracted, 
reverse transcribed and the cDNA was then subjected to qRT-PCR using specific primers for 
TIGAR. Rpl19 was used as an internal control. The data were analysed by Realplex software 
(Eppendorf, UK) and are representative of three independent experiments performed in 
duplicates. B. U2OS cells were transfected with scrambled RNAi (lanes 1 and 2) or RNAi for 
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HIF-1α (lanes 3 and 4) and left untreated (lanes 1 and 3) or treated with DSFX (lanes 2 and 4). 
Cell lysates were prepared and subjected to PAGE and western transfer. Actin was used as 
loading control. Data shown are representative of 2 independent experiments 
 
Decreased TIGAR mRNA levels in U2OS cells transfected with RNAi for HIF-1α 
compared to those in cells transfected with scrambled RNAi (Figure 4.1.4 A., compare 
black bar 2 with black bar 1) suggested that in DSFX treated U2OS cells, TIGAR gene 
expression was downregulated in the absence of HIF-1α. In other words, HIF-1α 
upregulated TIGAR mRNA levels in hypoxia mimicking conditions. To investigate 
whether this HIF-1α effect was reflected in the TIGAR protein levels, cellular extracts 
from untreated or DSFX treated U2OS cells transfected with either scrambled RNAi or 
RNAi for HIF-1α were subjected to western blot analysis.  
 
Efficient silencing of HIF-1α protein was observed in cells transfected with RNAi for 
HIF-1α (Figure 4.1.4 B, compare lane 4 to lane 2). In addition, stabilization of p53 was 
also observed in DSFX treated U2OS cells transfected with either the scrambled RNAi 
or the RNAi for HIF-1α (Figure 4.1.4 B., compare lanes 2 and 4 with lanes 1 and 3 
respectively). TIGAR protein expression was downregulated in U2OS cells in which 
HIF-1α was silenced compared to those in which HIF-1α was expressed (Figure 4.1.4 B, 
compare lane 4 with lane 2). These results indicated that HIF-1α upregulated TIGAR 
gene expression, both at mRNA and protein levels in DSFX treated U2OS cells.  
4.1.4 Identification of HREs in the regulatory region of the TIGAR gene promoter 
Results shown in sections 4.1.1 and 4.1.2 indicated the potential involvement of 
transcription factors induced in hypoxia mimicking conditions, although it is known that 
TIGAR gene expression is primarily regulated by p53. Upregulation of TIGAR protein 
levels in DSFX treated cells (Figure 4.1.1 A, B and C) in combination with the 
downregulation of TIGAR mRNA and protein levels in DSFX treated U2OS cells in 
which HIF-1α had been silenced (Figure 4.1.4 A and B) indicated the potential 
involvement of HIF-1α in the modulation of TIGAR gene expression in hypoxia 
mimicking conditions. In order to exert its transcriptional effects, HIF-1α dimerizes 
with HIF-1  and this complex then is recruited to the hypoxia responsive element 
(HRE) present within the regulatory regions of the promoters of HIF target genes.  
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Figure 4.1.5: Promoter region of TIGAR gene showing the binding sites for various transcription factors 
The regulatory region of the promoter of TIGAR gene was analyzed for the presence of hypoxia 
responsive elements. The 5'-CGTG-3' sequences present within the TIGAR promoter region are 
marked and numbered. The translation start site is marked in green. The previously reported p53 
(Bensaad et al., 2006) as well as the NF-κB and the E2F1 binding sites are also indicated. 
To gain further insight in the HIF mediated TIGAR gene expression the nucleotide 
sequence of the promoter of TIGAR gene was analyzed for the presence of putative 
binding sites for HIF-1α. Six putative HREs (5'-CGTG-3') were identified within 2600 
nucleotides upstream of the translation start site (Figure 4.1.5). In addition NF-κB (-
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2569 to -2578 upstream of translation start site) and E2F-1 binding sites    (-1509 to -
1516 upstream of translation start site) were also detected within this region (Figure 
4.1.5). Figure 4.1.6 A., schematically demonstrates the presence of putative binding 
sites for various transcription factors in the regulatory region of the promoter of TIGAR 
gene. The presence of multiple binding sites for different transcription factors within the 
close proximity of the previously published p53 binding sites (p53bs1: -6680 to -6702 
upstream and p53bs2: +344 to +365 downstream of translation start site) (Bensaad et 
al., 2006) imply that TIGAR gene expression is under control of several transcription 
factors.  
 
Figure 4.1.6: HREs in the regulatory region of the promoter of TIGAR gene. 
(A) Schematic diagram of the TIGAR promoter showing the binding sites for various 
transcription factors. The regulatory region of the promoter of TIGAR gene was analyzed for 
the presence of putative binding sites for various transcription factors. The numbers shown in 
the figure are the position of the first and last nucleotide of the sequences of the putative binding 
sites calculated upstream or downstream from the translation start site. (B) TIGAR HRE 5 
followed by 5'-CACAG-3' region after 10 nucleotides is similar to the known HIF-1α 
transcriptional target genes EPO, VEGF and NOXA. 
 
Interestingly, the bio-informatics studies indicated that after 10 nucleotides of the 
TIGAR HRE 5 a consensus 5'-CACAG-3' sequence followed which has been shown to 
be present in many of the promoters of HIF-1α transcriptional target genes including 
VEGF, EPO, NOXA (Fukuda et al., 2007; Kim et al., 2004b; Semenza and Wang, 1992; 
Shima et al., 1996). The nucleotide sequences of known HIF-1α transcriptional target 
genes and the position of 5'-CACAG-3' region following the HRE are shown in Figure 
4.1.6 B.  
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4.1.5 TIGAR HRE-5 is functional HIF-1α binding site 
The transcription factor HIF-1α is upregulated in hypoxia or hypoxia mimicking 
conditions, dimerizes with HIF-1  (Aryl hydrocarbon receptor nuclear translocator – 
ARNT) to form the HIF-1 complex and this hetero-dimeric complex recognizes and 
binds to the HREs present in the promoter of HIF-1α target genes modulating their 
transcription. To investigate the functionality of the HREs present within the TIGAR 
gene promoter untreated or DSFX treated U2OS cells were subjected to chromatin 
immuno-precipitation (ChIP) assay using a specific anti-HIF-1α ChIP grade antibody to 
precipitate HIF-1α chromatin immuno-complexes (Abcam, UK). 
 
Briefly, chromatin in DSFX treated or untreated U2OS cells was cross-linked with 
transcription factors using formaldehyde as described in Materials and Methods and the 
formed chromatin complexes were immuno- precipitated using specific antibody for 
HIF-1α or Rabbit IGG.  
 
Figure 4.1.7: HIF-1α binds to TIGAR HRE-5 
A. Chromatin immuno-complexes were precipitated using a specific HIF-1α (lanes 3 and 4) or 
Rabbit IGG (lanes 5 and 6) as negative controls. The pulled down DNA was amplified with 
specific primers flanking the regions containing various HREs and p53 binding sites present in 
TIGAR promoter. The resultant PCR product was then submitted to 2% agarose gel 
electrophoresis. CA-IX was used as a positive control (lane 4). Lanes 1 and 2 are 10% of the 
input. B. ChIP assay was performed with all 6 HREs present within the TIGAR promoter. Only 
the TIGAR HRE-5 produced a specific product. Lanes 1 and 2 represent 10% of the input. 
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The precipitated DNA was sonicated, ethanol precipitated and the purified DNA was 
then amplified using specific primers flanking the region containing the different HREs 
present in the TIGAR promoter. The sequences of the primers used in ChIP assays are 
listed in Table 3.9.1 (Page 97). 10% of the input samples were used as control. Also the 
input was used as a positive control for the primers and the product size. Rabbit IgG 
which does not bind to any specific protein was used as a negative control. Since CA-IX 
is a known transcriptional target gene of HIF-1α, only in DSFX treated cells but not in 
non-treated cells, the binding of HIF-1α to the specific region of the promoter of CA-IX 
flanking the HRE sequence was observed indicating that DSFX stabilized and induced 
the transcriptional activity of HIF-1α as expected (Figure 4.1.7 A and B., lanes 4 and 3). 
HIF-1α was pulled down only with the promoter region of TIGAR which contains the 
HRE 5. This indicated that HIF-1 complex binds with HRE 5 present in the regulatory 
region of promoter of TIGAR gene (Figure 4.1.7 A and B., compare lanes 4 and 3). 
Although other HREs contain 5'-CGTG-3' sequence, HIF-1α did not bind with them. 
 
The ChIP results have indicated that the HIF-1 complex is recruited to the TIGAR gene 
promoter. To investigate whether HIF-1α was involved in the transcriptional regulation 
of TIGAR gene expression, a luciferase reporter assay was performed. For luciferase 
experiment, a specific region of TIGAR promoter consists of 908 base pairs of 
nucleotides (+400 to -508 from translation start site) contains HRE 5 which has been 
shown to bind to HIF-1α, (-423 to -430 upstream of translation start site) (Figure 4.1.7), 
HRE 6 and a p53 binding site (p53 BS2) (-188 to -195 upstream and +344 to +365 
downstream of translation start site respectively) was cloned in pGL3 promoter vector 
(Promega, UK) as described in the Materials and Methods section. It is important to 
note that the p53 binding site included in this vector is shown to be less efficient in 
binding with p53 protein compared to the other binding site for p53 (p53 BS 1; -6680 to 
-6702 upstream of translation start site) (Bensaad et al., 2006). 
 
To confirm that the TIGAR HRE-5 was functional a luciferase assay was performed in 
U2OS and SaOS2 cells as they are p53 wild type and p53 null cell lines respectively. 
Briefly, U2OS or SaOS2 cells were grown in 6 well plates and after reaching 60% 
confluency, they were transfected with TIGAR-HRE5,6-p53BS2-luc vector along with 
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-galactosidase and HIF-1α expression vector. 24 hours after transfection the cells were 
either left untreated or treated with 250µM DSFX and incubated for 16 hours at 37°C. 
The cell lysates were subjected to luciferase reporter assay. -galactosidase expression 
was used as a transfection efficiency control.  
 
 
Figure 4.1.8: HIF-1α regulates the transcription of TIGAR gene in DSFX condition 
A. U2OS and B. SaOS2 cells were transfected either with TIGAR-HRE5,6-p53BS2-Luc vector 
along with -galactosidase and HIF-1α expression vectors using Polyfect transfection reagent 
(Qiagen, UK). 24 hours after transfection, the cells were left untreated or treated with 250µM 
DSFX and incubated in 37°C for 16 hours. The cell lysates were prepared using Promega 
luciferase lysis buffer (Promega, UK) and subjected to luciferase assay. 30µl of the lysate was 
used to measure -galactosidase expression. The values from the luciferase assay were 
normalized to the values from -galactosidase experiment. C. and D. Western blots showing the 
expression level of HIF-1α protein in untreated and DSFX treated U2OS and SaOS2 cells 
respectively. Data shown are representative of three individual experiments.  
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The western blotting with U2OS and SaOS2 cells treated with DSFX showed that HIF-
1α was stabilized in DSFX treated cells (Figure 4.1.8 B and C). In contrast to the 
protein and mRNA expression pattern, in which the TIGAR expression was upregulated 
in DSFX treated U2OS cells, the luciferase experiment showed a downregulation of 
TIGAR gene transcription (approx. 13%) in DSFX treated U2OS cells (Figure 4.1.8 A). 
Although the TIGAR-HRE5,6-p53BS2-luc vector contains the HRE 5 which has been 
shown to be a binding site for HIF-1α (Figure 4.1.7), it does not contain the full length 
TIGAR promoter region which also contain binding sites for other transcription factors 
such as NF-κB and E2F1 which might  interact with HIF-1α in the regulation of TIGAR 
gene expression.  
 
Also, it is possible that the region which is necessary for the transcription cofactors 
might have not been included in the vector which might have affected the 
transcriptional activity of HIF-1α. In addition, p53 protein is also shown to be stabilized 
in DSFX treated U2OS cells (Figure 4.1.1 A, lane 2), hence the presence of p53 binding 
site 2 (Figure 4.1.5 and Figure 4.1.6 A) in the TIGAR-HRE5,6-p53BS2-luc vector 
might have facilitated p53 to exert its transcription regulatory functions in DSFX treated 
conditions. Since both p53 and HIF-1α proteins were stabilized in DSFX treated U2OS 
cells, the cross talk between these two transcription factors might have affected the gene 
expression of TIGAR.  
 
However, the upregulation of TIGAR transcription in DSFX treated p53 null SaOS2 
cells, indicate that HIF-1α upregulate TIGAR gene expression in the absence of p53 
(Figure 4.1.8 B). Together, these results suggest that HIF-1α regulate TIGAR gene 
expression both in the presence and absence of p53 in hypoxia mimicking conditions. 
Since both p53 and HIF-1α proteins were stabilized in DSFX treated U2OS cells, the 
cross talk between these two transcription factors might have affected the gene 
expression of TIGAR. 
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4.2 HIF-1α regulates SCO2 gene expression 
Maintaining the proton gradient across the inner mitochondrial membrane is necessary 
for the mitochondrial ATP synthase enzyme to drive ATP production (Sone et al., 1977; 
Yoshida et al., 2001). This proton gradient is maintained by the mitochondrial 
respiratory enzyme complex IV, also known as cytochrome c oxidase (COX), a 
multimeric protein complex that catalyzes the transfer of electrons from cytochrome c to 
molecular oxygen and pumps protons across the inner mitochondrial membrane (Fetter 
et al., 1995). Human COX complex is made up of 13 protein subunits of which 3 
subunits that form the catalytic core of the enzyme are encoded by mitochondrial DNA 
and the remaining 10 subunits are encoded by nuclear DNA (Kadenbach et al., 1983). 
The human COX complex requires several assembly components including SCO2 
protein (encoded by SCO2 gene) which transports copper to the CuA site on the 
cytochrome c oxidase subunit II (COX II) (Leary et al., 2004), a process which is 
essential for the biogenesis of COX II (Horn and Barrientos, 2008).  
 
While attenuating glycolysis by modulating the TIGAR gene expression, tumour 
suppressor p53 regulates mitochondrial respiration by fine-tuning the SCO2 gene 
expression (Bensaad et al., 2006; Matoba et al., 2006). The disruption of SCO2 gene in 
p53 wild type cell line HCT-116 has been associated with defective OXPHOS and 
increased lactate production which resembles the metabolic phenotype observed in p53 
mutant cells (HCT-116 p53
-/-
) (Matoba et al., 2006; Sung et al., 2010). In addition HCT-
116 cells lacking SCO2 gene expression (SCO2
-/-
) has been shown to have increased 
ROS and oxidative DNA damage (Sung et al., 2010). Together these results indicate 
that by regulating SCO2 gene expression, p53 not only controls mitochondrial 
respiration but also protects the cells from ROS mediated genotoxic stress. Although 
SCO2 gene expression has been shown to be regulated by p53, the significant level of 
SCO2 protein expression detected in p53
-/-
 mice and human p53 mutant cell line (HCT-
116 p53
-/-
) suggests that p53 independent pathways exist in the regulation of SCO2 gene 
expression (Matoba et al., 2006).  
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Apart from upregulating glycolysis, HIF-1α has been shown to inhibit both TCA cycle 
and OXPHOS by inducing PDK1 enzyme in tumour cells which inhibits the activity of 
PDH enzyme thereby attenuates the oxidative decarboxylation of pyruvate and inhibits 
the synthesis of acetyl-CoA which is essential for the TCA cycle to proceed (Kim et al., 
2006; Papandreou et al., 2006). In addition, prolonged hypoxia is reported to attenuate 
the mitochondrial respiration by inhibiting COX activity in intact cells and in isolated 
mitochondria (Chandel et al., 1995). Recently, Fukuda et al., demonstrated that HIF-1α 
regulate several of the mitochondrial COX complex subunits in hypoxia (Fukuda et al., 
2007). These results indicate the role of HIF-1α in the regulation of cellular 
mitochondrial respiration. However, the involvement of HIF-1α in the regulation of the 
COX complex subunit II assembly factor SCO2 gene expression has not been 
documented. Since SCO2 protein is involved in the assembly of COX complex subunit 
II and many subunits of the COX complex are regulated by HIF-1α in hypoxic 
conditions, we asked a question, whether SCO2 gene expression is modulated by HIF-
1α in hypoxic condition. Along this line, the involvement of HIF-1α in the regulation of 
SCO2 gene expression was investigated. 
4.2.1 SCO2 protein levels in hypoxic cells 
Inhibition of COX activity has been reported in hypoxic conditions (Chandel et al., 
1995). Also, recent reports provide evidence that many subunits of COX complex are 
regulated by HIF-1α in hypoxic conditions (Fukuda et al., 2007). An important 
assembly component of the subunit II of COX complex, SCO2 (encoded by SCO2 
gene) which has been shown to be regulated transcriptionally by p53, shows a high 
basal level protein expression in p53
-/-
 tumour cells (HCT-116 cells) (Matoba et al., 
2006). Together, by these results we were intrigued to investigate whether SCO2 gene 
expression is controlled by HIF-1α in hypoxic conditions. 
 
In order to study the involvement of transcription factors induced in hypoxic conditions 
in the regulation of SCO2, the SCO2 protein levels were followed in untreated or DSFX 
treated or etoposide treated cell lines with different p53 status such as U2OS and MCF-
7 cells which express wild type p53 (p53
+/+
), MDA-MB-231 cells in which p53 is 
expressed by one allele (p53
mutant
) and the p53 deficient (p53
-/-
) SaOS2 cells (Soussi, 
2007) using western blot analysis. 
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The p53 and HIF-1α protein levels in untreated, DSFX treated and etoposide treated 
conditions are the same as in Section 4.1.1. The densitometric analysis of the p53 and 
SCO2 protein levels indicated that except MCF-7 cells, the SCO2 protein expression 
was upregulated in all the three cell lines in etoposide treated conditions (Figure 4.2.1 
A, B, C and D compare lane 3 with lane 1 and Figure 4.2.2 A, B, C and D compare 
white bar 3 with white bar 1). As putative binding site for NF-κB were found on the 
SCO2 gene promoter (Result 4.2.3), the downregulation of SCO2 protein expression in 
MCF-7 cells in etoposide treated condition might attribute to the induction of NF-κB 
transcriptional activity in these conditions (Morotti et al., 2006). 
 
 
 
Figure 4.2.1: SCO2 protein is differentially regulated in hypoxia mimicking and etoposide treated conditions. 
U2OS (A), MCF-7 (B), MDA-MB-231 (C) and SaOS2 (D) cells were left untreated or treated 
either with DSFX or with etoposide for 16 hours before harvested using TNN buffer (contains 
240mM NaCl) and the lysates were subjected to western blotting. Actin was used as loading 
control and the data are representative of three independent experiments.  
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In contrast to etoposide treated conditions, the DSFX treated wild type p53 expressing 
U2OS cells showed a downregulation of SCO2 protein expression (Figure 4.2.1 A., 
compare lane 2 with lane 1; Figure 4.2.2 A., compare white bar 2 with white bar 1) 
indicating the antagonistic effect of the hypoxia induced transcription factor against p53 
in the regulation of SCO2 protein expression.  
 
However, the SCO2 protein expression was downregulated in DSFX treated MCF-7 
cells (Figure 4.2.1 B., compare lane 2 with lane 1; Figure 4.2.2 B., compare white bar 2 
with white bar 1) which is similar to etoposide treated conditions (Figure 4.2.1 B., lane 
3; Figure 4.2.2 B., white bar 3) indicating that in hypoxia mimicking conditions p53 is 
not the only regulator of SCO2 protein expression. 
 
 
Figure 4.2.2: Densitometric analysis of Figure 4.2.1 
ImageJ 1.43 was used to perform the densitometric measurements of Figure 4.2.1. The band 
intensity of SCO2 protein was normalized to the band intensity of Actin. The values of 
untreated samples of each cell line were considered as 1 and the values of treated samples were 
calculated accordingly. Measurements were made in duplicates and the standard deviations were 
used in the error bars.  
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This notion was strengthened by the upregulation of SCO2 protein expression in DSFX 
treated mutant p53 expressing MDA-MB-231 cells (Figure 4.2.1 C., compare lane 2 
with lane 1; Figure 4.2.2 C., compare white bar 2 with white bar 1) in which p53 protein 
expression was downregulated in these conditions (Figure 4.2.1 C., compare lane 2 with 
lane 1; Figure 4.2.2 C., compare black bar 2 with black bar 1). p53 null SaOS2 cells 
showed upregulation of SCO2 protein expression (Figure 4.2.1 D., compare lane 2 with 
lane 1 and Figure 4.2.2 D., compare white bar 2 with white bar 1). Together these 
results indicate that apart from p53 other transcription factors are also involved in the 
SCO2 protein expression in hypoxia mimicking conditions.  
 
4.2.2 Regulation of SCO2 gene expression in hypoxia occurs at the transcriptional 
level 
 
SCO2 protein expression studies in p53 mutant and null cell lines (Result 4.2.1) 
indicated that factors other than p53 are involved in the regulation of SCO2 gene 
expression in hypoxia mimicking conditions (Result 4.2.1). To investigate whether the 
modulation of SCO2 gene expression is under the transcriptional control of these 
factors, qRT-PCR reactions were performed in U2OS, MCF-7, MDA-MB-231 and 
SaOS2 cells treated with DSFX or etoposide to follow the SCO2 mRNA levels. 
 
In line with published reports (Matoba et al., 2006), SCO2 mRNA levels were increased 
in etoposide treated wild type p53 expressing U2OS cells (A, compare bar 3 with bar 1). 
A slight decrease in SCO2 mRNA levels was observed in etoposide treated wild type 
p53 expressing MCF7 cells (Figure 4.2.3 B, compare bar 3 with bar 1). In etoposide 
treated mutant p53 expressing MDA-MB-231 cells and p53 null cell line SaOS2 
showed increased SCO2 mRNA levels (Figure 4.2.3 C and D., compare bar 3 with bar 
1). The increase in SCO2 mRNA levels in etoposide treated MDA-MB-231 and SaOS2 
cell lines indicated the potential role of transcription factors other than p53 involved in 
the regulation of SCO2 gene expression. Since NF-κB is induced in etoposide treated 
cells (Morotti et al., 2006), the NF-κB consensus binding site which was found in the 
regulatory region of the promoter of SCO2 gene (Figure 4.2.4) allowed the hypothesis 
for a potential role of NF-κB in the modulation of SCO2 gene expression. 
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Figure 4.2.3: SCO2 mRNA levels are regulated by factors other than p53 in DSFX treated cells 
U2OS (A), MCF-7 (B), MDA-MB-231 (C) and SaOS2 (D) cells were left untreated or treated 
with either DSFX or etoposide for 16 hours before the total mRNA was extracted and reverse 
transcribed to cDNA. The cDNAs were then subjected to qRTPCR using specific primers 
amplifying SCO2 mRNA. Rpl19 was used as an internal control. The data was analyzed by 
Opticon Monitor 3 or Realplex 2.2.4. software. The data is representative of three independent 
experiments. 
 
In DSFX treated conditions, in line with the pattern of SCO2 protein levels (Figure 
4.2.1 and Figure 4.2.2) the SCO2 mRNA levels decreased in p53 wild type expressing 
U2OS and MCF-7 cell lines (Figure 4.2.3 A and B., compare bar 2 with bar 1) and 
increased in p53 mutant cell line MDA-MB-231 and p53 null cell line SaOS2 (Figure 
4.2.3 C and D., compare bar 2 with bar1). This indicated that in hypoxia mimicking 
conditions, the regulation of SCO2 gene expression is under the transcriptional control 
of factors other than p53. In view of the fact that HIF-1α is the major transcription 
factor activated in DSFX treated cells (Wang and Semenza, 1993a), the increase in 
SCO2 mRNA levels in SaOS2 and MDA-MB-231 cells might be an indication of the 
potential role of HIF-1α in the regulation of SCO2 gene expression. 
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4.2.3 Identification of HREs in the regulatory region of the promoter of SCO2 gene 
Although SCO2 gene expression has been shown to be regulated by p53, the SCO2 
protein and mRNA levels in DSFX treated cells (Result 4.2.1 and 4.2.2) indicated the 
potential involvement of other transcription factors induced in hypoxia in the regulation 
of SCO2 gene expression. Since HIF-1α is transcriptionally activated in DSFX treated 
cells, to explore the possibility that SCO2 gene expression is regulated by HIF-1α, the 
regulatory region of the promoter of SCO2 gene was subjected to bio-informatics 
analysis to find the putative binding sites for HIF-1α and other transcription factors 
induced in hypoxia mimicking conditions.   
 
Figure 4.2.4: Presence of putative binding sites for various transcription factors in the promoter of SCO2 gene 
The regulatory region of the promoter of SCO2 gene was analyzed for the presence of putative 
binding sites for transcription factors induced in hypoxia mimicking conditions. The putative 
binding sites for HIF-1α are marked and numbered as HRE 1 -6 along with p53 binding site 
(Matoba et al., 2006) and putative NF-κB binding site. The translation start site is marked in 
green. 
The presence of multiple binding sites for different transcription factors within 1700 
base pairs from the translation start site and within the close proximity of the previously 
published p53 binding site (Matoba et al., 2006) imply that SCO2 gene expression is 
under control of multiple transcription factors. Figure 4.2.5 schematically demonstrates 
the putative binding sites for various transcription factors present in the SCO2 promoter 
region.  
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Figure 4.2.5: Schematic diagram showing the putative binding sites for various transcription factors in the SCO2 
promoter region. 
Cartoon showing the putative binding sites for various transcription factors found in the regulatory region 
of the promoter of SCO2 gene. The translation start site was marked with the arrow.  
 
4.2.4 Potential role of HIF-1α in SCO2 gene expression 
 
The bio-informatics studies indicated the presence of 8 putative binding sites for HIF-1α 
in the regulatory region of the promoter of SCO2 gene. To investigate the involvement 
of HIF-1α in the transcriptional regulation of SCO2 gene expression, a luciferase 
reporter assay was performed. A specific region of SCO2 promoter which contain the 
putative HREs 1 to 5 (Figure 4.2.4 and Figure 4.2.5) and the previously published p53 
binding site (Matoba et al., 2006) was cloned into pGL3 promoter vector (Promega, 
UK) as described in the Materials and Methods. 
 
Briefly, in luciferase assay, U2OS and SaOS2 cells were grown in 6 well plates and 
after reaching 60% confluency, they were transfected either with SCO2-HRE(1-5)-p53-
luc vector or with CA-IX(HRE)3 along with -galactosidase and HIF-1α expression 
vectors. 24 hours after transfection the cells were either left untreated or treated with 
250µM DSFX and incubated for 16 hours at 37°C. The cell lysates were subjected to 
luciferase reporter assay. -galactosidase expression was used as a transfection 
efficiency control.  
 
Since CA-IX(HRE)3 has three HREs inserted into the pGL3 promoter vector, it has 
been transcribed efficiently in DSFX treated U2OS and SaOS2 cells (Figure 4.2.6 A and 
B, compare black bar 2 with white bar 2). A western blot was performed to confirm the 
stabilization of HIF-1α in DSFX treated cell (Figure 4.2.6 C and D). Together, these 
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experiments have confirmed that HIF-1α is stabilized and transcriptionally active in 
DSFX treated U2OS and SaOS2 cells.  
 
In line with the protein and mRNA levels, SCO2 gene expression was downregulated in 
wild type p53 expressing U2OS cells (Figure 4.2.6 A., compare black bar 1 with white 
bar 1) while  upregulated in p53 null SaOS2 cell line in hypoxia mimicking conditions 
(Figure 4.2.6 B., compare black bar 1 with white bar 1). The increase in SCO2-HRE(1-
5)-p53-luc expression in SaOS2 cells indicate that HIF-1α increases SCO2 transcription 
in the absence of p53. 
  
 
Figure 4.2.6: Role of HIF-1α in SCO2 gene expression 
A. U2OS and B. SaOS2 cells were transfected either with SCO2-HRE(1-5)-p53-Luc vector or 
CA-IX(HRE)3 along with -galactosidase and HIF-1α expression vectors using Polyfect 
transfection reagent (Qiagen, UK). 24 hours after transfection, the cells were left untreated or 
treated with 250µM DSFX and incubated in 37°C for 16 hours. The cell lysates were prepared 
using Promega luciferase lysis buffer (Promega, UK) and subjected to luciferase assay. 30µl of 
the lysate was used to measure -galactosidase expression. The values from the luciferase assay 
were normalized to the values from -galactosidase experiment. C. and D. Western blots 
showing the expression level of HIF-1α protein in untreated and DSFX treated U2OS and 
SaOS2 cells respectively. Data shown are representative of three individual experiments 
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The decrease in the SCO2-HRE(1-5)-p53-luc expression in U2OS cells indicated the 
possible involvement of interaction between p53 and HIF-1α in the regulation of SCO2 
gene expression in hypoxia mimicking conditions. However, the huge increase in the 
induction of CA-IX(HRE)3-luc expression in both U2OS (~19 fold) and SaOS2 (~25 
fold) in DSFX treated conditions raised a question that the changes observed in SCO2-
HRE(1-5)-p53-luc transfected DSFX treated U2OS and SaOS2 cells (~1.4 fold 
induction) whether reflecting the transcriptional activity of HIF-1α or not. 
 
 
Figure 4.2.7: SCO2 gene expression in DSFX treated condition is HIF-1α independent 
A. U2OS and B. SaOS2 cells were transfected with pcDNA3 or increasing amounts of HIF-1α 
expression vector along with SCO2-HRE(1-5)-p53-luc vector and -galactosidase vector using 
Polyfect transfection reagent. 24 hours after transfection, the cells were treated with DSFX and 
incubated at 37° C for 16 hours. The cells were lysed using Promega luciferase lysis buffer 
(Promega., UK) and subjected to luciferase assay. 30µl of cell lysate was used to measure -
galactosidase expression. The values from the luciferase assay were normalized to the values 
from -galactosidase experiment. C. and D. Western blots showing the expression level of HIF-
1α protein in pcDNA or increasing amount of HIF-1α transfected and DSFX treated U2OS and 
SaOS2 cells respectively. Data shown are representative of three independent experiments. 
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To verify that the changes observed in the luciferase reporter assay is due to the 
transcriptional activity of HIF-1α, we performed a luciferase reporter assay with 
increased amounts of ectopically expressed HIF-1α expecting to magnify the changes 
observed in Figure 4.2.6. The transfection efficiency of the increased amounts of 
ectopically transfected HIF-1α in U2OS and SaOS2 cells were observed in the increased 
accumulation of HIF-1α protein in the western blotting of DSFX treated U2OS and 
SaOS2 cells (Figure 4.2.7 C and D).  
 
Although the SCO2-HRE(1-5)-p53-luc expression has been increased with the 
increased accumulation of HIF-1α in DSFX treated U2OS and SaOS2 cells (Figure 
4.2.7 A and B., compare black bars 4, 3 2 and 1), no significant changes in luciferase 
expression were observed between the DSFX treated and untreated cells (Figure 4.2.7 A 
and B., compare black bar with white bar in all the 4 lanes). This indicated that the 
increase in SCO2-HRE(1-5)-p53-luc expression was not due to the increased 
transcriptional activity of HIF-1α but could be due to the regulation of SCO2 
transcription by other factors such as p53 and NF-κB whose binding sites are present in 
the luciferase vector (Figure 4.2.4 and Figure 4.2.5). However this notion needs further 
investigation of the HREs present in the SCO2 promoter region 
 
4.2.5 Functional analysis of SCO2 HREs 
 
In order to exhibit the transcriptional activation functions, HIF-1α needs to form a 
complex with HIF-  and the complex should be recruited to the HREs present in the 
regulatory region of the promoter of its target genes (Semenza, 1998). To investigate the 
functionality of the HREs present within the SCO2 gene promoter untreated or DSFX 
treated U2OS cells were subjected to chromatin immuno-precipitation (ChIP) assay as 
mentioned in Materials and Methods, using a specific anti-HIF-1α ChIP grade antibody 
to precipitate HIF-1α chromatin immuno-complexes (Abcam, UK). The sequence of the 
primers used in this assay are listed in Table 3.9.2. 
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Figure 4.2.8: Functional analysis of HREs present in SCO2 promoter 
Chromatin immuno-complexes were precipitated using a specific HIF-1α (lanes 3 and 4) or 
Rabbit IGG (lanes 5 and 6) as negative controls. The pulled down DNA was amplified with 
specific primers flanking the regions containing various HREs present in SCO2 promoter. The 
resultant PCR product was then submitted to 2% agarose gel electrophoresis. CA-IX was used 
as a positive control (lane 4). Lanes 1 and 2 are 10% of the input. 
 
10% of the input samples were used as control. Also the input was used as a positive 
control for the primers and the product size. Rabbit IGG which does not bind to any 
specific protein was used as a negative control and CA-IX was used as a positive 
control for the binding ability of HIF-1α to its target gene promoter in hypoxia 
mimicking conditions. As expected the binding of HIF-1α to the specific promoter of 
CA-IX flanking the HRE sequence was observed only in the DSFX treated cells but not 
in the untreated cells (Figure 4.2.8, compare lane 4 with lane 3). This indicated that 
HIF-1α was stabilized and the transcriptionally activity was induced in hypoxia 
mimicking conditions.  
 
However, HIF-1α did not bind to any of the 6 tested HREs present in the SCO2 
promoter region in hypoxia mimicking conditions (Figure 4.2.8., compare lane 4 and 3 
with lane 2 and 1) indicated that HIF-1α might have not involved directly in the 
regulation of SCO2 gene expression. However, HIF-1α has been shown to interact with 
other transcription factors such as p53 and NF-κB and modulate their stability and 
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transcriptional functions (An et al., 1998; BelAiba et al., 2007; Bendinelli et al., 2009; 
Chen et al., 2003). In addition, HIF-1α has been reported to compete for transcription 
cofactors with p53 and NF-κB in hypoxic conditions (Arany et al., 1996; Mendonça et 
al., 2011; Schmid et al., 2004; Xenaki et al., 2008). Since p53 and NF-κB binding sites 
are found in the SCO2 promoter (Figure 4.2.4 and Figure 4.2.5) HIF-1α could 
potentially interact with these transcription factors and indirectly regulate the SCO2 
gene expression. 
4.3 Role of transcriptional co-factors in the regulation of TIGAR and 
SCO2 gene expression 
While the contribution of the p53 tumour suppressor in the regulation of TIGAR gene 
expression under conditions of genotoxic stress has been shown (Bensaad et al., 2006), 
the transcriptional network modulating TIGAR gene expression in hypoxia has not been 
elucidated. The determination of the TIGAR protein and mRNA levels (Results 
presented in Section 1) indicated that factors other than p53 might be involved in the 
regulation of TIGAR gene expression in hypoxia mimicking conditions (Results 4.1.1, 
4.1.2). Furthermore, experiments in cells where HIF-1α had been silenced by RNAi, 
supported the view that HIF-1α might be a potential candidate regulating TIGAR gene 
expression in hypoxia mimicking conditions (Result 4.1.3). This notion was 
strengthened by bio-informatics studies revealing the existence of putative HREs in the 
regulatory region of TIGAR gene promoter (Result 4.1.4). In addition, ChIP and 
luciferase experiments identified the HRE5 as a functional HIF-1α binding site and 
under hypoxia mimicking conditions HIF-1 binds to TIGAR gene promoter and 
regulates its gene expression (Result 4.1.5).  
 
Results described in sections 4.1.1, 4.1.2 and 4.1.3 indicated that TIGAR protein and 
mRNA levels were differentially regulated in U2OS and SaOS2 cells treated with 
DSFX. In particular, upregulation of TIGAR gene expression was evident only in the 
presence of p53 (U2OS cells), whereas in its absence (SaOS2 cells) TIGAR gene 
expression was downregulated in hypoxia mimicking conditions. Furthermore, there 
was a difference in the TIGAR induction pattern when it was assessed in DSFX treated 
U2OS cells, using the TIGAR-HRE5,6-p53-luc luciferase reporter (Figure 4.1.8) 
compared to that observed in protein and mRNA levels (Figure 4.1.1, 4.1.2 and 4.1.3), 
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implying that the second p53 binding site (that was not included in the TIGAR-HRE5,6-
p53-luc reporter) might be essential for p53 to exert its transcriptional activity on 
TIGAR gene expression. Another explanation for this difference could be provided by 
the fact that the fragment of the TIGAR promoter that was included in the TIGAR-
HRE5,6-p53-luc reporter contained a putative binding site for E2F1 (Figure 4.1.6 A). It 
is known that while U2OS express wild type pRb tumour suppressor, SaOS2 cells 
express a non-functional form of pRb (p95) (Shew et al., 1990). Given the fact that pRb 
represses E2F1 transcriptional activity by preventing its binding to the promoters of its 
transcriptional targets (Trimarchi and Lees, 2002) the difference observed in the 
TIGAR-HRE5,6-p53-luc reporter activity in DSFX treated U2OS and SaOS2 cells 
could be due to the diverse E2F1 transcriptional activity in the two cell lines. In 
addition, the potential role of common p53, HIF-1α and E2F1 transcriptional co-factors 
in the regulation of TIGAR gene expression in DSFX treated U2OS and SaOS2 cells 
cannot be excluded.  
 
On the other hand, SCO2 gene expression has been shown to be regulated by p53 
(Matoba et al., 2006). However, the SCO2 protein (Figure 4.2.1 and Figure 4.2.1) and 
mRNA levels (Figure 4.2.3) in hypoxia mimicking conditions indicated the possible 
involvement of factors other than p53 in the regulation of SCO2 gene expression. 
Although bio-informatics studies revealed the presence of putative binding sites for 
HIF-1α and NF- B in the regulatory region of the SCO2 gene promoter (Figure 4.2.4 
and Figure 4.2.5), the luciferase experiments indicated that the regulation of SCO2 gene 
expression in hypoxia mimicking conditions is independent of the HIF-1α 
transcriptional activity. This conclusion is supported by ChIP assays showing that HIF-
1α did not bind to the SCO2 promoter under hypoxia mimicking conditions (Figure 
4.2.8). Nevertheless, the significant difference in the SCO2 luciferase expression 
between DSFX treated U2OS and SaOS2 cells suggested that HIF-1α was indirectly 
involved in the regulation of SCO2 gene expression potentially either through 
interaction with other transcription factors such as p53 (An et al., 1998; Blagosklonny et 
al., 1998; Schmid et al., 2004),  NF- B (Mendonça et al., 2011), or competition for p53 
and HIF-1α common transcriptional co-factors such as p300/CBP and PCAF 
(Blagosklonny et al., 1998; Xenaki et al., 2008).  
 133 
Under diverse stress conditions, both p53 and HIF-1α undergo post-translational 
modifications that alter their protein stability and transcriptional activity (Arany et al., 
1996; Xenaki et al., 2008). Transcriptional co-factors such as p300/CBP (Arany et al., 
1996; Gu and Roeder, 1997; Kallio et al., 1998; Liu et al., 1999), SRC-1 (Carrero et al., 
2000; Lee et al., 1999) and PCAF (Liu et al., 1999; Xenaki et al., 2008) are among the 
co-factors shared between p53, p73, NF- B and HIF-1α and modify their protein 
stability and transcriptional activity under diverse stress conditions. The role of PCAF 
as common transcriptional co-factor for p53 and HIF-1α in the regulation of genes 
involved in cell cycle arrest and apoptosis has been reported in the past (Xenaki et al., 
2008). Since TIGAR and SCO2 genes are p53 transcription targets (Bensaad et al., 
2006; Matoba et al., 2006) and HIF-1α is directly involved in the regulation of TIGAR 
gene expression and indirectly in the case of SCO2 (Results described in Chapters 1 and 
2), we were interested to test the hypothesis whether PCAF determined the cellular 
energy production pathway by selectively acetylating p53 and HIF-1α, thereby 
differentially regulating TIGAR and SCO2 gene expression and hence the balance 
between glycolysis and OXPHOS.  
4.3.1 TIGAR and SCO2 protein levels are affected by the HAT activity of PCAF  
To investigate the involvement of PCAF in the regulation of TIGAR and SCO2 gene 
expression, the TIGAR and SCO2 protein levels were followed in U2OS cells 
transfected with PCDNA3, Flag-PCAFwt or Flag-PCAF-ΔHAT expression vectors. The 
Flag-PCAF-ΔHAT expresses a HAT defective mutant of PCAF which lacks histone 
acetyl transferase activity (Barbacci et al., 2004).  
 
Accumulation of p53 protein was observed in etoposide treated U2OS cells (Figure 
4.3.1 A and Figure 4.3.2 A., compare lanes 3, 6 and 9 with lanes 1, 4 and 7 
respectively). Also, HIF-1α was stabilized in DSFX treated conditions (Figure 4.3.1 A 
and Figure 4.3.2 A., compare lanes 2, 5 and 8 with lanes 1, 4 and 7 respectively). The 
anti-flag antibody was used to show the transfection efficiency of PCAF and 
PCAFΔHAT in U2OS and SaOS2 cells (Figure 4.3.1 A and Figure 4.3.2 A). 
Densitometric analysis of the TIGAR and SCO2 proteins was carried out using ImageJ 
1.43 software (Figure 4.3.1 B and Figure 4.3.2 B). 
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Figure 4.3.1: Role of PCAF in TIGAR protein expression 
A. U2OS cells were transfected with either PCDNA3 (lanes 1 to 3) or Flag-PCAFwt (lanes 4 to 
6) or Flag-PCAF-ΔHAT (lanes 7 to 9). 24 hours after transfection the cells were left untreated 
or treated with either DSFX or etoposide. 16 hours after treatment the cells were harvested and 
subjected to western blotting. B. Densitometric analysis of the TIGAR protein from Figure 4.3.1 
A., was carried out using ImageJ 1.43. The data are representative of two independent 
experiments. 
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Downregulation of TIGAR protein expression in DSFX treated U2OS cells ectopically 
expressing PCAFwt was reversed in cells transfected with PCAF-ΔHAT (Figure 4.3.1 
A., compare lanes 5 and 8 with lanes 4 and 7 respectively; Figure 4.3.1 B., compare 
black bar 2 and 3 with white bars 2 and 3 respectively). This indicated the repressive 
effect of the HAT activity of PCAF in TIGAR protein levels in hypoxia mimicking 
conditions. At the same time, in etoposide treated cells overexpression of PCAFwt did 
not downregulate TIGAR protein level (Figure 4.3.1 A., compare lane 6 with lane 4; 
Figure 4.3.1 B., compare grey bar 2 with white bar 2). TIGAR protein level was 
upregulated in etoposide treated U2OS cells transfected with PCAF-ΔHAT (Figure 
4.3.1 A., compare lane 9 with lane 6; Figure 4.3.1 B., compare gray bar 3 with white bar 
3). While PCAFwt downregulated the TIGAR protein level only in DSFX treated cells, 
PCAF-ΔHAT upregulated TIGAR protein level in cells treated with either DSFX or 
etoposide. Given that HIF-1α and p53 are recruited to TIGAR promoter in DSFX and 
etoposide treated cells ((Bensaad et al., 2006) and Figure 4.1.7) the results presented in 
Figure 4.3.1 imply that the HAT activity of PCAF might facilitate the selective 
recruitment of HIF-1α and/or p53 in the TIGAR promoter in DSFX and etoposide 
treated cells. This observation is in line with our previous finding indicating that p53 
and HIF-1α compete for PCAF in the regulation of anti and pro-apoptotic gene 
expression (Xenaki et al., 2008). 
 
SCO2 protein levels, on the other hand, were downregulated in DSFX treated U2OS 
cells ectopically expressing PCAFwt, which was reversed in cells transfected with 
PCAF-ΔHAT mutant vector (Figure 4.3.2 A., compare lanes 5 and 8 with lanes 4 and 7 
respectively; Figure 4.3.2 B., compare black bars 2 and 3 with white bars 2 and 3 
respectively). Downregulation of SCO2 protein levels was also observed in etoposide 
treated cells transfected with PCAFwt (Figure 4.3.2 A., compare lane 3 to lane 6 and 
Figure 4.3.2 B., compare gray bar 2 to grey bar 1). This downregulation was reversed 
when PCAF-ΔHAT was transfected in etoposide treated U2OS cells (Figure 4.3.2 A., 
compare lane 3 to lane 9 and Figure 4.3.2 B., compare gray bar 3 to grey bar 1). 
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Figure 4.3.2: Role of PCAF in SCO2 protein expression 
A. U2OS cells were transfected with either PCDNA3 (lanes 1 to 3) or Flag-PCAFwt (lanes 4 to 
6) or Flag-PCAF-ΔHAT (lanes 7 to 9). 24 hours after transfection the cells were left untreated 
or treated with either DSFX or etoposide. 16 hours after treatment the cells were harvested and 
subjected to western blotting. B. Densitometric analysis of the SCO2 protein from Figure 4.3.2 
A., was carried out using ImageJ 1.43. The data are representative of two independent 
experiments. 
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This result implies that the HAT activity of PCAF plays a role in the modulation of 
SCO2 protein levels in U2OS cells treated with either DSFX or etoposide. Results 
shown in Figure 4.2.8 indicated that HIF-1α was not recruited to the regulatory region 
of the SCO2 promoter in DSFX treated U2OS cells conditions while p53 has been 
shown to bind SCO2 promoter under DNA damage conditions (Matoba et al., 2006). 
Taken together these observations indicate that the HAT activity of PCAF plays an 
important role in the regulation of SCO2 gene expression under DSFX and etoposide 
treated conditions. However, this conclusion requires further experimental support since 
the half-life of the SCO2 protein could be affected by various factors under different 
stress conditions. To investigate whether the fluctuation of the SCO2 protein levels 
under different stress conditions was due to transcriptional regulation of its gene 
expression, the SCO2 mRNA levels were investigated in cells after DSFX and 
etoposide treatment. 
4.3.2 Role of PCAF HAT activity in the regulation of TIGAR and SCO2 mRNA levels 
To investigate whether PCAF mediated regulation of TIGAR and SCO2 gene 
expression occurs at the transcriptional level, TIGAR and SCO2 mRNA levels were 
followed in U2OS cells transfected with PCDNA3 empty, PCAFwt or PCAF-ΔHAT 
expression vectors and treated with DSFX or etoposide or left untreated for 16 hours. 
Total mRNA from these cells was extracted and reverse transcribed to cDNA, which 
was then subjected to qRT-PCR to estimate TIGAR and SCO2 mRNA levels. 
 
The low level of TIGAR mRNA expressed in PCAFwt transfected and DSFX treated 
cells (Figure 4.3.3 A., compare black bar 2 with black bar 1) comply with the protein 
expression pattern observed in U2OS cells (Figure 4.3.1 A and B). Similar to TIGAR 
protein levels (Figure 4.3.1), transfection of the PCAF-ΔHAT mutant which lacks 
acetylation activity, resulted in the reversion of the repressive effect exerted by the 
PCAFwt ectopic expression in DSFX treated cells (Figure 4.3.3 A., compare black bar 3 
with black bar 2). These results indicated that the HAT activity of PCAF exerted 
suppressive effect on the regulation of TIGAR gene expression in hypoxia mimicking 
conditions.  
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Figure 4.3.3: Regulation of TIGAR gene expression by PCAF, occurs at the transcriptional level 
U2OS cells were transfected with either PCDNA3 (bars 1) or PCAF (bars 2) or PCAFΔHAT 
(bars 3). 24 hours after transfection the cells were left untreated or treated with either DSFX or 
etoposide. 16 hours after treatment the total mRNA from the cells were extracted and 
subsequently reverse transcribed. The resultant cDNA was then subjected to qRT-PCR using 
specific primers flanking TIGAR (A) or SCO2 (B) mRNA sequences. The equal expression of 
PCAF and PCAFΔHAT in U2OS under DSFX and etoposide treated conditions are shown in 
Figure 4.3.1 A and Figure 4.3.2 A. The data are representative of three independent 
experiments. 
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On the other hand, in line with the pattern of protein levels in DSFX treated conditions 
(Figure 4.3.1 A lanes 2, 5, 6  and Figure 4.3.1 B, black bars), PCAFwt transfection had 
repressive effect on SCO2 mRNA in DSFX treated U2OS cells (Figure 4.3.3 B., 
compare black bar 2 with black bar 1), which was reversed in cells transfected with 
PCAF-ΔHAT (Figure 4.3.3 B., compare black bar 3 with black bar 2) indicating that 
SCO2 gene expression was suppressed by the HAT activity of PCAF in hypoxia 
mimicking conditions. Although this suppressive effect was not observed in PCAFwt 
transfected cells in etoposide treated conditions, the high mRNA levels  observed in 
PCAF-ΔHAT transfected cells (Figure 4.3.3 B., compare gray bar 3 with gray bar 2) 
implied potential involvement of the HAT activity of PCAF in the regulation of SCO2 
gene expression in etoposide treated conditions. 
4.3.3 Role of PCAF in the transcriptional regulation of TIGAR and SCO2 gene 
expression 
To further explore the role of PCAF in the transcriptional regulation of TIGAR and 
SCO2 gene expression, luciferase reporter assays were performed using TIGAR-
HRE5,6-p53-luc and SCO2-HRE(1-5)-p53-luc reporter vectors containing specific 
HREs and p53 binding sites identified within the regulatory region of the promoter of 
TIGAR and SCO2 genes respectively. U2OS and SaOS2 cells were transfected with 
TIGAR or SCO2 luciferase reporter vector, -galactosidase, and HIF-1α along with 
PCDNA3 or increasing amounts of PCAFwt or PCAF-ΔHAT (Figure 4.3.4 and Figure 
4.3.5). 24 hours after transfection the cells were treated with DSFX for further 16 hours 
at 37°C. The cell lysates were subjected to luciferase reporter assay. -galactosidase 
expression was used as a transfection efficiency control.  
 
TIGAR-HRE5,6-p53-luc reporter activity was progressively downregulated in response 
to increasing amounts of PCAFwt transfected cells (Figure 4.3.4 A., compare bars 2 and 
3 to bar 1). This trend was gradually reversed in cells overexpressing increasing 
amounts of PCAF-ΔHAT in a dose dependent manner (Figure 4.3.4 A., compare bars 4 
and 5 to bars 2, and 3 respectively).  
 140 
 
Figure 4.3.4: The involvement of PCAF HAT activity in the regulation of TIGAR gene expression 
A. U2OS and B. SaOS2 cells were co-transfected with TIGAR-HRE5,6-p53BS2-Luc, -
galactosidase and HIF-1α expression vector along with either PCDNA3 or increasing amounts 
of PCAFwt or PCAF-ΔHAT and treated with DSFX as shown in the Figure 4.3.6 A and Figure 
4.3.6 B respectively. Data shown are representative of two independent experiments in 
duplicates.  
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These results support the conclusions presented in Result sections 4.3.1 and 4.3.2 
demonstrating that the HAT activity of PCAF exhibits repressive role in the regulation 
of TIGAR gene expression in hypoxia mimicking conditions. In DSFX treated SaOS2 
cells transfection of increasing amounts of PCAFwt resulted in the gradual increase of 
the TIGAR-HRE5,6-p53-luc reporter activity (Figure 4.3.4 B., compare bars 2 and 3 to 
bar 1) whereas transfection of gradually increasing amounts of PCAF-ΔHAT exhibited 
the opposite trend (Figure 4.3.4 B., compare bars 4 and 5 to bars 2, and 3 respectively). 
The effect of the HAT activity of PCAF in SaOS2 cells was the opposite of that 
observed in U2OS cells (compare Figure 4.3.4 B., to Figure 4.3.4 A). 
 
Luciferase reporter assays performed in U2OS (Figure 4.3.5 A and SaOS2 cells (Figure 
4.3.5 B) using the SCO2-HRE(1-5)-p53-luc reporter in hypoxia mimicking conditions 
showed that increasing amounts of PCAFwt gradually downregulated the activity of this 
reporter in U2OS cells (Figure 4.3.5 A., compare bars 2 and 3 to bar 1) whereas the 
opposite was the case for the SaOS2 cells under the same conditions where gradually 
increasing quantities of PCAFwt transfection upregulated the activity of the SCO2-
HRE(1-5)-p53-luc reporter  (Figure 4.3.5 B., compare bars 2 and 3 to bar 1). In DSFX 
treated U2OS cells transfected with increasing amounts of PCAF-ΔHAT a slight 
reversion of the repressive effect of the PCAFwt was evident (Figure 4.3.5 A, compare 
bars 4 and 5 to bars 2, and 3 respectively). Reversion of the upregulating effect of 
PCAFwt in the luciferase activity of the SCO2-HRE(1-5)-p53-luc reporter was 
observed in DSFX treated SaOs2 cells transfected with increasing amounts of PCAF-
ΔHAT (Figure 4.3.5 B, compare bars 4 and 5 to bars 2, and 3 respectively). Taken 
together these results provided evidence for the involvement of the HAT activity of 
PCAF in the regulation of TIGAR and SCO2 gene expression.  
 
Furthermore the fact that the suppressive role of PCAFwt in TIGAR and SCO2 gene 
expression was observed only in U2OS cells and not in SaOS2 cells suggests that this 
cofactor mediates a complex regulatory effect on the activity of both HIF-1α and p53 
transcription factors. 
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Figure 4.3.5: Role of PCAF in the transcriptional regulation of SCO2 gene expression 
A. U2OS and B. SaOS2 cells were transfected with TIGAR-HRE5,6-p53BS2-Luc vector, -
galactosidase and HIF-1α expression vector along with either PCDNA3 or increasing amounts 
of PCAF or PCAFΔHAT expression vectors. 24 hours after transfection, the cells were treated 
with DSFX and incubated in 37°C for 16 hours. The cell lysates were subjected to luciferase 
assay. 30µl of the lysate was used to measure -galactosidase expression. The values from the 
luciferase assay were normalized to the values from -galactosidase experiment. Data shown 
are representative of two independent experiments in duplicates.  
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The differential effects of the HAT activity of PCAF in the presence or absence of p53 
in hypoxic conditions on the TIGAR and SCO2 gene expression could be exemplified 
by competition events occurring between the two transcription factors for the limiting 
amounts of PCAF in U2OS cells which results in preferential co-activation between 
HIF-1α and p53 (Xenaki et al., 2008). This notion is supported by the upregulation of 
TIGAR and SCO2 gene expression in SaOS2 cells (Figure 4.3.4 B and Figure 4.3.5 B) 
where there is no competition between p53 and HIF-1α due to the absence of p53 in 
SaOS2 cell. This could have led to more acetylation of HIF-1α by PCAF in SaOS2 cells 
compared to U2OS cells. However, PCAF is a common co-factor for HIF-1α and p53, 
in DSFX treated U2OS cells where both HIF-1α and p53 are stabilized, the expression 
of luciferase reporters which include binding sites for both HIF-1α and p53 did not give 
clear indication that whether PCAF binds to HIF-1α or p53 in order to recruit them to 
their binding sites in TIGAR and SCO2 gene promoters. Further experiments such as 
ChIP, co-immunoprecipitation are required to find out whether PCAF recruits HIF-1α 
or p53 to the promoters of TIGAR and SCO2 genes. 
 
To investigate whether this suppressive role of PCAF was reflected at the protein level, 
we followed the TIGAR and SCO2 protein expression in DSFX treated U2OS and 
SaOS2 cells, transfected with PCDNA3 or Flag-PCAF or Flag-PCAF-ΔHAT expression 
vectors and treated with DSFX for 16 hours. Anti-Flag antibody was used to estimate 
the transfection efficiency of these plasmids in U2OS and SaOS2 cells.  Actin was used 
as a loading control. 
 
As seen in the luciferase expression, the TIGAR protein expression was also 
downregulated gradually in DSFX treated U2OS cells in response to the increasing 
amount of PCAF (Figure 4.3.6 A., compare lanes 2, 3 and 4 with lane 1) which was 
reversed gradually in a dose dependent manner as ectopic expression of PCAF-ΔHAT 
increases (Figure 4.3.6 A., compare lanes 5, 6 and 7 with lane 1) indicated the 
repressive role of PCAF HAT activity in the regulation of TIGAR protein expression in 
hypoxia mimicking conditions.  
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Figure 4.3.6: Role of PCAf in the regulation of TIGAR and SCO2 protein expression 
A. U2OS and B. SaOS2 cells were transfected with PCDNA3 or Flag-PCAF or Flag-
PCAFΔHAT and 24 hours after transfection treated with DSFX. 16 hours after treatment the 
cell lysates were subjected to western blot analysis. Anti-flag antibody was used to measure the 
amounts of PCAF and PCAFΔHAT transfection. Actin was used as a loading control. The data 
are representative of two independent experiments. 
 145 
Also in line with the luciferase expression pattern, in DSFX treated p53 null SaOS2 
cells showed gradual upregulation of TIGAR protein expression as the ectopic 
expression of PCAF went up (Figure 4.3.6 B., compare bars 2, 3 and 4 with bar 1) 
which was reversed gradually in response to increasing amount of PCAF-ΔHAT 
transfection (Figure 4.3.6 B., compare lanes 5, 6 and 7 with bar 1) indicated the 
inductive role of PCAF HAT activity in the TIGAR protein expression in the absence of 
p53 in hypoxia mimicking conditions.  
 
Together, these experiments suggest that PCAF HAT activity plays an important role in 
the regulation of TIGAR and SCO2 gene expression in hypoxia mimicking conditions. 
PCAF downregulates TIGAR and SCO2 gene expression when it acetylates both HIF-1α 
and p53 and it upregulates TIGAR and SCO2 gene expression when it acetylates HIF-
1α alone (in the absence of p53).  
 
As evidenced in previous reports (Xenaki et al., 2008), both HIF-1α and p53 might 
compete for PCAF in hypoxia mimicking conditions, in U2OS cells where both HIF-1α 
and p53 are present, only limited amount of PCAF will be available for HIF-1α 
acetylation. On the other hand, since p53 is absent in SaOS2 cells, more PCAF will be 
available for HIF-1α acetylation. In SaOS2 cells, the more acetylated HIF-1α might 
upregulate the TIGAR gene expression and in U2OS cells, the less acetylated HIF-1α 
might downregulate the TIGAR gene expression.  
 
Similarly, the acetylated p53 in U2OS cells, might down-regulate the SCO2 gene 
expression. Also, in SaOS2S which express non-functional form of pRb thus having 
increased E2F1 transcriptional activity (Shew et al., 1990), and PCAF is the major 
acetyl transferase involved in E2F1 acetylation (Pillai et al., 2010), the upregulation of 
SCO2 gene expression in SaOS2 cells in hypoxia mimicking conditions might involve a 
complex network of transcriptional regulation by HIF-1α and E2F1 mediated by PCAF 
HAT activity.  
 146 
4.4 Functional consequences of PCAF mediated TIGAR and SCO2 gene 
expression 
Recent reports have demonstrated that the regulation of TIGAR gene expression is under 
the transcriptional control of p53 (Bensaad et al., 2006). Our results described in 
Section 4.1 indicated that under hypoxia mimicking conditions, HIF-1α plays an 
important regulatory role in TIGAR gene expression. Results presented in Section 4.3 
showed that the regulation of TIGAR gene expression in hypoxia is controlled by a 
complex network of transcription factors involving HIF-1α and p53 and implicating the 
HAT activity of PCAF as a crucial regulatory factor. Results shown in Section 4.3 also 
pointed out that in PCAF-ΔHAT ectopically expressing and DSFX treated U2OS cells, 
TIGAR is downregulated at both protein and mRNA levels. Moreover, results in 
Section 4.3 demonstrated that in DSFX treated SaOS2 cells, PCAFΔHAT 
overexpression resulted in the upregulation of TIGAR gene expression. The differential 
regulation of TIGAR gene expression in the presence or absence of p53 in hypoxia 
mimicking conditions coordinated by the HAT activity of PCAF implied that PCAF 
mediated acetylation of p53 and/or HIF-1α allows selective recruitment of one or the 
other transcription factor to the TIGAR promoter in a manner dependent on the 
environmental conditions. 
 
Results shown in Section 4.2 revealed that the gene expression of the known p53 
transcriptional target SCO2 (Matoba et al., 2006), in hypoxia mimicking conditions is 
regulated independently of the p53 status. This suggested that, a hypoxia responsive 
transcription factor might be involved in the regulation of SCO2 gene expression in 
hypoxia. However, further studies demonstrated that HIF-1α was not directly involved 
in the regulation of SCO2 gene expression (Section 4.2.4 and 4.2.5). Nevertheless, the 
differential SCO2 protein and mRNA levels in cells bearing wild type or defective p53 
in hypoxia mimicking conditions, indicated that HIF-1α might be involved in the 
regulation of SCO2 gene expression indirectly by other transcription factors such as 
E2F1 or NF-κB associated with HIF-1α and for which DNA binding sites have been 
identified within the SCO2 promoter, or could be a result of competition for binding 
with transcriptional co-factors such as p300/CBP or PCAF, which are common for HIF-
1α (Lim et al., 2010), E2F1 (Pediconi et al., 2009) and NF-κB (Zhong et al., 1998). 
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Support to the latter is provided by the observations described in Section 5.3 indicating 
that the HAT activity of PCAF plays a major role in the regulation of SCO2 gene 
expression by acetylating p53 and/or HIF-1α thereby regulating their transcriptional 
activity and selectively targeting these transcription factors to a specific subset of their 
promoters. 
 
TIGAR and SCO2 are involved in the regulation of cellular energy metabolism by 
modulating glycolysis (Bensaad et al., 2006) and OXPHOS (Bensaad et al., 2006; 
Matoba et al., 2006) respectively. In particular TIGAR has been shown to inhibit 
glycolysis -therefore lactic acid production as well- whereas SCO2 to increase 
OXPHOS and hence oxygen consumption. Given that PCAF plays important role in the 
regulation of TIGAR and SCO2 gene expression in hypoxia mimicking conditions as 
demonstrated in Section 4.3 we were intrigued to assess its role in the regulation of 
TIGAR and SCO2 mediated glycolysis and OXPHOS. 
4.4.1 Lactate Production 
HIF-1α has been shown to increase the lactate production by inducing the expression of 
genes encoding glycolytic enzymes such as aldolase-A, phosphoglycerate kinase-1, 
pyruvate kinase M, lactate dehydrogenase A, phosphofructokinase (PFK), and glucose 
transporter-1 (Glut-1) which are induced in hypoxic conditions (Firth et al., 1994; Firth 
et al., 1995; Minchenko et al., 2002; Semenza et al., 1994). To confirm that lactate 
production was affected in our experimental conditions we silenced the expression of 
HIF-1α in DSFX treated U2OS cells using specific RNAi against HIF-1α and 
determined the lactate production in the media the cells were cultured collected at 0 
minutes and 16 hours after treatment. 10µl of the media was then added to 60µl of 
lactate reagent (Trinity Biotech, Dublin) and the absorbance of the resultant mixture 
was measured at 540nM. A standard curve was prepared using lactate standard solutions 
(Trinity Biotech, Dublin). 
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Figure 4.4.1: HIF-1α regulates lactate production 
U2OS cells were transfected with scrambled RNAi (Control RNAi) or RNAi-HIF-1α and left 
untreated or treated with DSFX for 16 hours. Media from these cells was collected before, 0 
min and 16 hours after the addition of DSFX. Lactate reagent (Trinity Biotech, Dublin) was 
added to the media and the absorbance at 540nm was measured. A standard curve was prepared 
using lactate standards (Trinity Biotech, Dublin). The efficiency of HIF-1α silencing is shown in 
Figure 4.1.4. Data shown are representative of three independent experiments.  
 
The involvement of HIF-1α in the regulation of lactate production was evident as DSFX 
treated U2OS cells transfected with scramble RNAi exhibited increased lactate 
production compared to those transfected with RNAi against HIF-1α under the same 
conditions (Figure 4.4.1, compare black bar 2 with black bar 1). Still, even in the 
absence of HIF-1α, DSFX treated cells produced higher lactate levels compared to the 
untreated cells (Figure 4.4.1, compare black bar 2 with white bar 2). 
 
TIGAR has been shown to inhibit glycolysis and reduce lactate production (Bensaad et 
al., 2006). Results shown in Figure 4.1.1 and Figure 4.1.3 indicated that in hypoxia 
mimicking conditions, TIGAR protein levels were differentially regulated in DSFX 
treated cells in the presence or in the absence of HIF-1α. Since decrease in glycolysis is 
one of the major consequences of TIGAR induction (Bensaad et al., 2006) we were 
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intrigued to investigate whether TIGAR overexpression reduces lactate production in 
DSFX treated U2OS cells. To this direction we analysed lactate production in DSFX 
treated U2OS cells transfected with either empty vector (PCDNA3) or a TIGAR 
expressing construct. In accord with previously published observations (Kimata et al., 
2010), TIGAR overexpression in DSFX treated cells, reduced the lactate production 
compared to PCDNA3 transfected cells (Figure 4.4.2.), compare black bar 2 with black 
bar 1) signifying the ability of TIGAR to inhibit glycolysis and hence lactate production 
(Bensaad et al., 2006). 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.2: TIGAR overexpression reduces lactate production in hypoxic conditions 
U2OS cells were transfected with either PCDNA3 or Flag-TIGAR expressing vector and left 
untreated or treated with DSFX for 16 hours. The media was collected at 0 minute and 16 hours 
after treatment and lactate production was measured. The data is representative of 3 independent 
experiments. 
 
To investigate the role of the HAT activity of PCAF in the regulation of lactate 
production, lactate levels were determined in DSFX treated or untreated cells 
transfected with either empty (PCDNA3) or PCAFwt, or PCAF-ΔHAT expression 
vectors. Consistently with TIGAR cellular levels increased lactate production was 
observed in PCAFwt transfected cells and decreased in those ectopically expressing 
PCAF-ΔHAT (Figure 4.4.3 A, compare black bar 2 with black bars 1 and 3) indicating 
that the HAT activity of PCAF promoted upregulation of glycolysis in hypoxia 
mimicking conditions. 
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Figure 4.4.3: Role of PCAF in the regulation of lactate production mediated by TIGAR 
A. U2OS cells were transfected with either PCDNA3 or PCAFwt or PCAFΔHAT expression 
vectors and left untreated or treated with DSFX. Media was collected immediately and 16 hours 
after treatment and lactate production was determined as described in Materials and Methods. 
Lactate production values normalized to the number of cells. The data are representative of 
three independent experiments. B. U2OS cells transfected with either PCAFwt or PCAFΔHAT 
and untreated or treated with DSFX as indicated, were subjected to western blot analysis. Actin 
was used as a loading control. Equal PCAFwt and PCAF-ΔHAT transfection was confirmed 
blotting with the anti-Flag antibody. Data shown are representative of two independent 
experiments. 
 
The results shown in Figure 4.4.3 might be a consequence of PCAF mediated 
acetylation of HIF-1α and subsequent prevention of the recruitment of the acetylated 
transcription factor to the TIGAR promoter Figure 4.1.7 and subsequent inhibitory effect 
on TIGAR gene expression and promotion of glycolysis.  
 
TIGAR has been shown to share structural and functional similarities with the 
phosphatase domain of the bi-functional enzyme PFK2/FBPase-2 (Bensaad et al., 
2006). PFKFB3, an isozyme of PFK2/FBPase-2 has 700 times higher kinase compared 
to its phosphatase activity (Obach et al., 2004; Sakakibara et al., 1997). Given that 
PFKFB3 is a HIF-1α transcription target and its expression is induced in hypoxic 
conditions the formation of F2,6-BP is induced under these conditions leading to 
increased glycolytic rate (Lehninger et al., 2005; Obach et al., 2004). As the inhibitory 
effect of PCAF on TIGAR gene expression resulted in the upregulation of glycolysis, 
we explored the possibility that PCAF mediated acetylation of HIF-1α selectively 
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targets this transcription factor to the promoter of the glycolytic PFKFB3 and 
concurrently prevents the recruitment of this transcription factor to the glycolytic 
inhibitor TIGAR. This assumption was tested in not treated or DSFX treated U2OS cells 
over expressing PCAFwt or PCAF-ΔHAT. Decreased PFKFB3 and concomitant 
increased TIGAR protein levels were observed in DSFX treated U2OS cells 
overexpressing PCAF-ΔHAT (Figure 4.4.3 B, compare lane 4 with lane 2). These 
findings might support the notion that the HAT activity of PCAF is crucial in the 
regulation of glycolysis in hypoxia mimicking conditions by regulating TIGAR and 
PFKFB3 gene expression, but further experiments in other cell lines are required to 
confirm this assumption.  
4.4.2 Oxygen consumption 
SCO2 plays an important role in the assembly of the COX complex, the major site of 
oxygen utilization in eukaryotic cells (Matoba et al., 2006). The disruption of SCO2 
gene expression in wild type p53 expressing cells leads to down-regulation of oxygen 
consumption which resembles the metabolic phenotype observed in p53
-/- 
cells (Matoba 
et al., 2006). However, the total ATP production in SCO2wt and SCO2 defective cells 
did not change implying that cells bearing mutant SCO2 compensate their energy 
requirements by upregulating the glycolytic pathway. Support to this view was provided 
by observations indicating elevated lactate production in these cells (Kimata et al., 
2010; Matoba et al., 2006). 
 
Results presented in Section 4.3 allowed the hypothesis that the HAT activity of PCAF 
might be involved in the regulation of SCO2 gene expression in hypoxia mimicking 
conditions (Figure 4.3.6). These results triggered our interest to study the role of PCAF 
in oxygen consumption and OXPHOS regulation in hypoxic cells. To this direction 
oxygen consumption was monitored in untreated and DSFX treated U2OS cells 
transfected with PCDNA3, TIGAR or SCO2 along with PCDNA3, PCAFwt or PCAF-
ΔHAT expression vectors.  
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Figure 4.4.4: Role of PCAF in the regulation of oxygen consumption 
U2OS cells were transfected with PCDNA3 (white bars), TIGAR (black bars) or SCO2 (grey 
bars) expression vectors along with PCDNA3 (1), PCAFwt (2) and PCAF-ΔHAT (3) and left 
untreated or treated with DSFX for 16 hours. Oxygen consumption was monitored in these cells 
using a Clark-type polarographic oxygen electrode instrument as described in Materials and 
Methods. 
 
No significant changes were observed in the DSFX treated versus the untreated cells 
overexpressing PCAFwt (Figure 4.4.4 , compare white bar 2 to white bar 1) whereas 
increased oxygen consumption was exhibited by DSFX treated compared to untreated 
cells ectopically expressing PCAF-ΔHAT (Figure 4.4.4), compare white bar 3 to white 
bars 1 and 2) suggesting that the HAT activity of PCAF decreased oxygen consumption 
in hypoxia mimicking conditions. 
  
The potential combinatory effect of the HAT activity of PCAF with TIGAR and SCO2 
overexpression on oxygen consumption was investigated in untreated or DSFX treated 
U2OS cells cotransfected with PCAFwt or PCAF-ΔHAT together with TIGAR or 
SCO2 expressing constructs. Reduced oxygen consumption was detected in DSFX 
treated versus untreated cells overxpressing PCAFwt together with TIGAR (Figure 
4.4.4., compare black bar 2 to black bar 1). On the contrary increased oxygen 
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consumption was measured in DSFX treated versus untreated cells overxpressing 
PCAF-ΔHAT together with TIGAR (Figure 4.4.4., compare black bar 3 with black bars 
1 and 2). Although TIGAR has been shown to inhibit glycolysis, its involvement in the 
regulation of OXPHOS has not been documented and in order to reach firm conclusions 
further investigation is required.  
 
Increased oxygen consumption was demonstrated by DSFX treated versus untreated 
U2OS cells overexpressing SCO2 together with PCAFwt and PCAF-ΔHAT (Figure 
4.4.4., compare grey bar 2 to grey bar 1 and grey bar 3 to grey bar 1) suggesting that 
overexpressing SCO2 cells promote oxygen uptake in hypoxic conditions. Taken 
together, results shown in Figure 4.4.3 and Figure 4.4.4., supported the view that the 
HAT activity of PCAF promoted glycolysis and inhibited OXPHOS in hypoxic cells 
possibly by coordinating the transcriptional activity of HIF-1α and/or other hypoxia 
responsive transcription factors.  
4.4.3 NAD+/NADH ratio 
Nicotinamide adenine dinucleotide (NAD
+
) participates in many biological processes 
including the regulation of energy metabolism. In particular, during glycolysis and citric 
acid cycle energy from nutrients is transferred to NAD
+
 which is reduced to NADH. 
NADH is then oxidized back to NAD
+
 by transferring its reducing electrons to electron 
acceptors and ultimately to oxygen and the energy released during this process is 
coupled to ATP generation through OXPHOS (Murray et al., 2003). The NAD
+
/NADH 
ratio is an indicator of intracellular redox and metabolic state as the NAD
+
/NADH ratio 
fluctuates in response to changes in metabolism (Schwartz et al., 1974); (Lin and 
Guarente, 2003) (MacDonald and Marshall, 2000; Mongan et al., 2002; Ramasamy et 
al., 1998; Sanni et al., 2001). Therefore, the NAD
+
/NADH ratio plays an important role 
in the regulation of intracellular redox state. Also, NAD
+
/NADH ratio has been shown 
to affect cellular energy metabolism by regulating enzymes such as glyceraldehyde 3-
phosphate dehydrogenase and pyruvate dehydrogenase complex (Lin and Guarente, 
2003). 
 
To investigate the possibility that the HAT activity of PCAF is involved in the 
regulation of NAD
+
/NADH ratio, the amounts of NAD
+
 and NADH were estimated in 
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untreated and DSFX treated U2OS and SaOS2 cells transfected with PCDNA3, 
PCAFwt or PCAF-ΔHAT as described in the Materials and Methods section. The 
standard curves for NAD
+
 and NADH were prepared using the standard solutions 
provided by the supplier (Sigma, UK).  
 
Reduced NAD+/NADH ratio was observed in the DSFX treated versus untreated U2OS 
cells transfected with PCAFwt (Figure 4.4.5, compare black bar 2 with black bar 1). In 
other words there was higher NADH production in the DSFX treated cells compared to 
the untreated ones. Considering that the glycolytic pathway utilizes NAD+ and 
produces NADH which is re-oxidized to NAD
+
 in ETC and when pyruvate is converted 
to lactate (Lehninger et al., 2005), the low NAD+ and high NADH levels observed in 
PCAFwt transfected cells compared to the untransfected cells could be explained by 
increased glycolytic rate, which is in agreement with the lactate production results 
(Figure 4.4.3 A., compare black bar 2 with black bar 1). In contrast decreased 
NAD+/NADH ratio was observed in the NAD+/NADH ratio in DSFX treated versus 
untreated U2OS cells ectopically expressing PCAF-ΔHAT (Figure 4.4.5, compare black 
bar 3 with black bar 1).  
  
 
 
 
 
 
 
 
 
 
 
Figure 4.4.5: Role of PCAF in the regulation of NAD+/NADH ratio 
The NAD
+
 and NADH levels were estimated in untreated or DSFX treated U2OS and SaOS2 
cells transfected with PCDNA3, PCAFwt or PCAF-ΔHAT. A standard curve was prepared 
using NAD
+ 
and NADH standards (Sigma, UK). The data are representive of three independent 
experiments. 
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In the p53 null SaOS2 cells on the other hand, slightly downregulated NAD
+
/NADH 
ratio was observed in DSFX treated versus untreated PCAFwt and PCAF-ΔHAT 
transfected cells (Figure 4.4.5, compare white bars 2 and 3 with white bar 1). Results 
shown in Figure 4.4.5 implied that the PCAF mediated regulation of the NAD
+
/NADH 
ratio depends on the presence of p53. 
4.4.4 ROS production 
TIGAR has been shown to inhibit intracellular ROS levels by diverting fructose 6-
phosphate from glycolysis into pentose phosphate pathway that leads to increased 
NADPH production, which contributes to the scavenging of ROS by reduced 
glutathione (Bensaad et al., 2009; Bensaad et al., 2006). To investigate whether the 
inhibitory role of HAT activity of PCAF on TIGAR gene expression played any role in 
the regulation of intracellular ROS levels mediated by TIGAR, we followed 
intracellular ROS levels in untreated or DSFX treated U2OS cells transfected with 
PCDNA3, PCAFwt and PCAFΔHAT. The intracellular ROS levels were estimated by 
FACS analysis as described in the Materials and Methods section. 
 
Figure 4.4.6: Role of PCAF in the regulation of intracellular ROS levels 
U2OS cells were transfected with PCDNA3 or TIGAR expression vectors along with PCDNA3 
or PCAFwt or PCAFΔHAT vectors and left untreated or treated with DSFX for 16 hours. The 
cells were treated with H2DCF-DA for 30 minutes and subjected to FACS analysis for the 
measurement of intracellular ROS levels. The data represents two independent experiments.  
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Under hypoxia mimicking conditions, PCAF exerted a suppressive role in the regulation 
of TIGAR gene expression at protein and mRNA levels (Section 4.3). The suppression 
of TIGAR gene expression should result in increased intracellular ROS levels (Bensaad 
et al., 2006). However, the suppressive effect of PCAF on TIGAR gene expression was 
not reflected in intracellular ROS levels (Figure 4.4.6 compare white bar 2 with white 
bar 1). At the same time, the difference in intracellular ROS levels between PCAF and 
PCAFΔHAT transfected cells (Figure 4.4.6 compare white bar 2 with white bar 3) 
indicated that the HAT activity of PCAF might  regulate intracellular ROS levels. 
 
However, when TIGAR was overexpressed in U2OS cells, both PCAF and 
PCAFΔHAT transfected cells showed a slight reduction in intracellular ROS levels 
(Figure 4.4.6 compare black bar 2 and 3 with black bar 1) indicating that TIGAR 
overexpression abolished the effects of the HAT activity of PCAF on intracellular ROS 
generation. Together these results indicate the potential role of PCAF in the regulation 
of intracellular ROS levels and oxidative stress. 
 
 157 
5 Discussion 
5.1 Significance and key findings 
Otto Warburg has discovered that cancer cells prefer to produce energy through the low 
energy yielding glycolysis pathway irrespectively of the presence of oxygen supply, 
whereas in the presence of oxygen, their normal counterparts produce energy 
preferentially through OXPHOS which is a highly efficient energy producing pathway 
(Warburg et al., 1924). Although it is now clear that the so called Warburg effect 
provides tumour cells survival and proliferative advantages, the molecular mechanism 
involved in this metabolic shift is not clear. However, numerous oncogenes and tumour 
suppressors have been shown to act as inducers or inhibitors of this metabolic shift. The 
oncogenes HIF-1α, AKT and MYC, for example, have been shown to promote 
glycolysis and inhibit OXPHOS by differentially regulating the gene expression of 
genes encoding enzymes that are involved in glycolysis and OXPHOS (Elstrom et al., 
2004; Kim et al., 2004a; Papandreou et al., 2006; Semenza et al., 1994). Conversely, the 
tumour suppressor p53 inhibits glycolysis and promotes mitochondrial respiration by 
transcriptionally modulating its target genes involved in these metabolic pathways to 
prevent proliferation of transformed cells (Bensaad et al., 2006; Matoba et al., 2006; 
Yeung et al., 2008). Reversing Warburg Effect (decreased glycolysis and elevated 
OXPHOS) might selectively kill tumour cells as these cells rely mainly on glycolysis 
for their energy production, survival and proliferation. Since the metabolic phenotype is 
the Achilles’ heel of cancer, this model has been proposed by many researchers as a 
potential therapy for cancer (Chen et al., 2007; Jones and Thompson, 2009; Kroemer 
and Pouyssegur, 2008).  
 
The role of transcriptional cofactors such as p300 and PCAF in the regulation of the 
functional cross talk between HIF-1α and p53 has been investigated in the past and it is 
known that p300 and PCAF modulate the stability and transcriptional activity of both 
transcription factors (Arany et al., 1996; Liu et al., 1999; Schmid et al., 2004; Xenaki et 
al., 2008). Under hypoxic conditions p300 and PCAF orchestrate cellular homeostasis 
by differentially recruiting p53 and HIF-1α to their target genes (Xenaki et al., 2008). 
Both transcription factors intervene in the determination of the pathway of cellular 
 158 
energy production regulating the levels of enzymes involved in glucose metabolism 
such as GLUT-1 and HK2 which are modulated by both p53 and HIF-1α (Chen et al., 
2001; Kim et al., 2007; Mathupala et al., 1997; Schwartzenberg-Bar-Yoseph et al., 
2004a). In addition, TIGAR and SCO2 gene expression has been shown to be under p53 
transcriptional control whereby p53 regulates glycolysis and OXPHOS (Bensaad et al., 
2006; Matoba et al., 2006).   
 
TIGAR has been shown recently to be upregulated in hypoxic myocytes and inhibits 
glycolysis (Kimata et al., 2010), however the molecular mechanism involved in the 
regulation of TIGAR in hypoxic conditions has not yet been elucidated. Given the 
important role of HIF-1α in the regulation of cellular energy metabolism, we were 
interested to test whether TIGAR and SCO2 gene expression was HIF-1α dependent 
under hypoxic conditions. To this direction we followed TIGAR and SCO2 protein and 
mRNA levels in cell lines with variable p53 status treated with the hypoxia mimicking 
agent DSFX. We found evidence to suggest that under hypoxic conditions HIF-1α is 
recruited to one of the HREs identified within the TIGAR promoter using bioinformatic 
tools thereby regulating its cellular levels. On the other side although SCO2 was 
observed to be differentially regulated in hypoxic conditions and the presence of HREs 
within its regulatory region was identified there was no evidence for direct involvement 
of HIF-1α in the regulation of its gene expression. Next we studied the role of the acetyl 
transferase activity of PCAF in the regulation of TIGAR and SCO2 gene expression 
knowing that PCAF dependent acetylation of p53 and HIF-1α plays important role in 
their protein stability as well as in targeting these transcription factors to a specific 
subset of their transcription target genes. Our results suggested that the HAT activity of 
PCAF was important in determining the pathway of cellular energy production in 
hypoxic conditions by regulating the cellular levels of both TIGAR and SCO2 which 
are to be involved in the regulation of glycolysis and OXPHOS respectively (Bensaad et 
al., 2006; Matoba et al., 2006). To verify this assumption we followed lactate 
production, oxygen consumption, NAD/NADH ratio and ROS generation in cells 
treated with the hypoxia mimicking agent DSFX and ectopically overexpressing wild 
type PCAF or PCAF-ΔHAT mutant.  
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5.2 Detailed analysis of the results 
5.2.1 TIGAR protein and mRNA levels are upregulated in DSFX treated cells 
To study whether TIGAR was differentially regulated in hypoxia mimicking conditions, 
we followed both its protein and mRNA levels in DSFX treated cell lines with different 
p53 status. TIGAR protein and mRNA levels increased in hypoxia mimicking 
conditions in wild type p53 expressing U2OS and MCF-7 as well as in MDA-MB-231 
cells expressing mutated p53 which was not stabilized in hypoxic conditions (Figure 
4.1.1 A, B, and C, Figure 4.1.2 A, B, and C and Figure 4.1.3 A, B, and C). Furthermore 
in DSFX treated p53 null SaOS2 cells, TIGAR protein and mRNA levels were 
downregulated compared to untreated cells (Figure 4.1.1  D, Figure 4.1.2 D and Figure 
4.1.3 D). As expected in etoposide treated U2OS and MCF-7 cells TIGAR protein and 
mRNA levels were elevated compared to untreated and DSFX treated cells. 
Interestingly etoposide treatment of MDA-MB-231 and SaOS2 cells resulted in 
upregulation of TIGAR protein levels compared to non-treated and DSFX treated cells 
(Figure 4.1.1 C and D, Figure 4.1.2 C and D and Figure 4.1.3) whereas TIGAR mRNA 
levels increased slightly in etoposide treated MDA-MB-231 and downregulated 
significantly in SaOS2 cells under the same conditions (Figure 4.1.1 D, Figure 4.1.2 D 
and Figure 4.1.3 D).  
 
These results are in agreement with previously published observations indicating that 
p53 upregulates TIGAR in response to DNA damage (Bensaad et al., 2006) and in 
addition they implied that TIGAR was regulated in a similar manner in hypoxia 
mimicking conditions. Although, in p53 wild type cells the increase of TIGAR protein 
and mRNA levels after DSFX treatment can be explained by the stabilisation of p53 in 
these conditions, the results obtained in p53 defective cell lines indicated that TIGAR 
expression in hypoxia mimicking conditions was independent of p53 activation and 
other hypoxia responsive transcription factors such as MYC (Knies-Bamforth et al., 
2004), NF-κB (Koong et al., 1994)  and FOXO-3a (Bakker et al., 2007) possibly 
determine TIGAR levels under these conditions.    
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5.2.2 TIGAR gene expression is regulated by HIF-1α 
HIF-1α is the master regulator of cellular response to hypoxia (Semenza, 1998) and has 
been shown to regulate most of the glycolytic enzymes (Obach et al., 2004; Semenza et 
al., 1994). To study whether HIF-1α was involved in the regulation of TIGAR gene 
expression in hypoxic conditions, we followed TIGAR protein and mRNA levels in 
U2OS cells in the presence and absence of HIF-1α. In the latter case RNAi against HIF-
1α was used to silence its expression in U2OS cells. Decreased TIGAR mRNA and 
protein levels were evident in DSFX treated U2OS cells in which HIF-1α had been 
silenced compared to those in DSFX treated cells that had been transfected with 
scrambled RNAi (Figure 4.1.4 A and B) indicating potential involvement of HIF-1α in 
the regulation TIGAR gene expression.  
 
HIF-1α exhibits its transcriptional activity by binding to the cis- responsive elements 
present in the promoters of its target genes. To investigate, whether HIF-1α binding 
sites existed within the regulatory region of the TIGAR promoter, we used 
bioinformatics tools which identified the presence of six putative HREs numbered from 
1 to 6 (HRE 1-6) where the HRE-6 is the closer one to the translation start site (Figure 
4.1.5 and Figure 4.1.6 A). The DNA sequence of the consensus HRE is 5’-RCGTG-3’ 
(where R is A or G) (Wenger et al., 2005), although the sequence 5’-CCGTG-3’ has 
also been found in some of the HIF-1α transcription target genes. In addition the 
sequence 5’-CACAG-3’ has been detected in the HIF-1α includible genes EPO, VEGF 
and NOXA (Figure 4.1.6 B) (Fukuda et al., 2007). The functionality of the TIGAR 
HREs was assessed using chromatin immunoprecipitation assays, which indicated that 
HIF-1α was recruited to the HRE5 of the TIGAR promoter (Figure 4.1.7) implying that 
this transcription factor regulates TIGAR gene expression.   
 
Luciferase reporter assays using the pGL3 reporter constructs containing the HRE5 
alongside the p53 binding site (Materials and methods 3.3.4) were employed to verify 
the results observed with ChIP assays. No significant changes in luciferase expression 
were observed in DSFX treated versus non-treated U2OS cells whereas an approximate 
1.5 fold upregulation was observed in DSFX treated versus untreated SaOS2 cells 
(Figure 4.1.8 A).  
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The luciferase assay results could be explained by the fact that the luciferase reporter 
used in these assays contained only a short fragment of the TIGAR promoter region 
bearing the p53 and HIF-1α binding sites. Apart from p53 and HIF-1α, binding sites for 
other transcription factors such as NF-κB and E2F1 have been identified within the 
TIGAR promoter, which were not included in the luciferase reporter construct and 
might play crucial role in the modulation of TIGAR gene expression. The induction of 
the TIGAR luciferase reporter in SaOS2 cells however indicated that HIF-1α 
contributes to the modulation of TIGAR gene expression in hypoxia mimicking 
conditions. Taken together these results provide evidence that HIF-1α is recruited to the 
TIGAR promoter and transcriptionally regulates its gene expression.  
5.2.3 SCO2 protein and mRNA levels are regulated in a p53 independent mode in 
hypoxia mimicking conditions 
SCO2 plays important role in the mitochondrial respiration by facilitating the assembly 
of the subunit II of the complex IV of the COX holoenzyme (Figure 1.8.1).  p53 
regulates mitochondrial respiration by modulating SCO2 gene expression (Matoba et 
al., 2006). Mitochondrial respiration is also affected by HIF-1α which regulates gene 
expression of several COX subunits in many different types of cancer (Fukuda et al., 
2007). To investigate the possibility that SCO2 was transcriptional target of both p53 
and HIF-1α, protein and mRNA levels of this enzyme were followed in four cell lines 
with different p53 status treated with either the hypoxia mimicking agent DSFX or 
etoposide.  
 
Upregulation of SCO2 protein and mRNA levels was observed in etoposide treated 
U2OS, MDA-MB-231 and SaOS2 cells, whereas in MCF-7 cells SCO2 was 
downregulated under the same conditions (Figure 4.2.1, Figure 4.2.2 and Figure 4.2.3). 
This downregulation could be due to factors other than p53 that are induced in 
etoposide treated MCF-7 cells such as NF-κB (Morotti et al., 2006) for which consensus 
binding sites have been identified within the regulatory region of the SCO2 promoter 
(Figure 4.2.4).  
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In contrast to etoposide treated cells, SCO2 gene expression was upregulated in DSFX 
treated p53 mutant MDA-MB-231 and p53 null SaOS2 cells and downregulated in wild 
type p53 expressing U2OS and MCF-7 cells (Figure 4.2.1, Figure 4.2.2, Figure 4.2.3). 
These cell type dependent differences could be due to the involvement of hypoxia 
responsive transcription factors other than p53 in the regulation of SCO2 gene 
expression. Moreover, the difference in SCO2 gene expression between etoposide and 
DSFX treated U2OS cells indicate the possible participation of hypoxia responsive 
factors affecting p53 transcriptional activity. In addition results presented in Figure 
4.2.1, Figure 4.2.2, Figure 4.2.3 implied that SCO2 gene expression in hypoxia 
mimicking conditions is independent of p53.       
5.2.4 SCO2 gene expression in hypoxia mimicking conditions is not regulated by 
HIF-1α  
Results indicating that HIF-1α regulates many subunits of the COX complex (Fukuda et 
al., 2007) together with the observations described above presenting evidence that 
SCO2 protein and mRNA levels in hypoxia mimicking conditions were regulated in a 
p53 independent manner, triggered our interest to investigate whether HIF-1α was 
involved in the regulation of SCO2 gene expression in hypoxic conditions. To that end, 
we used bioinformatic tools to analyse the regulatory region of the SCO2 promoter to 
identify putative binding sites for HIF-1α. Six putative HREs were detected within 1700 
base pairs upstream of the translational start site (Figure 4.2.4 and Figure 4.2.5) 
implying that HIF-1α might play a role in SCO2 gene expression. To this end, a 
luciferase reporter containing 5 of the identified putative HREs, one p53 and one NF-κB 
binding sites was constructed (Materials and methods - Figure 3.3.4) 
 
Luciferase reporter assay performed with this reporter in hypoxia mimicking conditions, 
showed that SCO2 reporter was downregulated in SaOS2 cells and moderately 
upregulated in U2OS cells (Figure 4.2.6). The same experiment performed with 
gradually increasing amounts of transfected HIF-1α indicated that although there was a 
slight increase in luciferase activity following the increase of HIF-1α no significant 
changes were observed between untreated and DSFX treated cells (Figure 4.2.8 A and 
B) implying that the differences in SCO2 luciferase activity monitored in U2OS and 
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SaOS2 cells were not due to HIF-1α but to other factors such as p53 and NF-κB for 
which binding sites were included in the luciferase reporter construct.  
 
ChIP assays carried out to investigate whether HIF-1α was recruited to any of the 
putative HREs present within the SCO2 promoter confirmed this conclusion as HIF-1α 
was not recruited to any of the identified putative HREs within the SCO2 promoter 
(Figure 4.2.8). Together these results indicated that HIF-1α does not regulate SCO2 
gene expression. 
5.2.5 PCAF regulates TIGAR and SCO2 gene expression in hypoxic conditions 
We have recently demonstrated that PCAF is a common cofactor for both p53 and HIF-
1α playing important role in the regulation of the stability and transcriptional activity of 
both transcription factors thereby determining cellular life and death in hypoxic 
conditions (Xenaki et al., 2008). In particular we have shown that in hypoxic conditions 
the PCAF mediated acetylation of p53 at K320 (Liu et al., 1999) is compromised and 
the limited amount of acetylated p53 at K320 is preferentially recruited to the 
prosurvival p21
WAF-1/CIP-1 
promoter and not to the proapoptotic BID promoter leading to 
cell cycle arrest in the G1 phase and hence cell survival (Xenaki et al., 2008). Along 
with published reports the results presented in sections 4.1.1and 4.1.2 have shown that 
TIGAR gene expression is regulated by both p53 and HIF-1α (Bensaad et al., 2006). On 
the other hand, although evidence for HIF-1α direct involvement in the regulation of 
SCO2 gene expression has not been found in sections 4.2.1and 4.2.2 it has been shown 
that SCO2 gene expression is modulated in hypoxic conditions in a p53 independent 
manner (Matoba et al., 2006).  
 
To test whether the HAT activity of PCAF was involved in the regulation of TIGAR 
and SCO2 gene expression, we monitored protein and mRNA levels of these two 
enzymes in DSFX treated U2OS cells transfected with wild type PCAF or the HAT 
defective mutant PCAFΔHAT. TIGAR protein levels were downregulated in PCAFwt 
transfected cells in hypoxia mimicking conditions, whereas no significant changes were 
observed in etoposide treated cells (Figure 4.1.1). In contrast increased TIGAR protein 
levels were detected in both DSFX and etoposide treated cells transfected with 
PCDNA3 and PCAFΔHAT (Figure 4.1.1) suggesting that the HAT activity of PCAF 
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exerts negative effect on TIGAR protein levels in hypoxia mimicking conditions. 
Although it is evident from this experiment that the HAT activity of PCAF is involved 
in the regulation of TIGAR protein levels, the molecular mechanisms engaged in the 
execution of these events is not clear. Binding sites for transcription factors for which 
PCAF serves as a cofactor have been identified within the regulatory region of the 
TIGAR promoter such as HIF-1α (Xenaki et al., 2008), p53 (Bensaad et al., 2006), NF-
κB (Sheppard et al., 1999) and E2F1 (Frolov and Dyson, 2004).  
 
On the other hand, SCO2 protein levels were downregulated in etoposide and DSFX 
treated U2OS cells over-expressing PCAFwt whereas PCAFΔHAT overexpression 
resulted in a slight upregulation of SCO2 protein levels in hypoxia mimicking and DNA 
damage conditions (Figure 4.2.1 A and B). Taken together these results indicated that 
the HAT activity of PCAF negatively regulated SCO2 protein levels in hypoxia 
mimicking and DNA damage conditions. The downregulation of SCO2 protein levels in 
DSFX and etoposide treated U2OS cells is in disagreement with published reports 
indicating that p53 is recruited to the SCO2 promoter in DNA damage conditions 
(Matoba et al., 2006). Since the ChIP assays described in section 4.2.5 indicated that 
HIF-1α was not recruited in SCO2 promoter under hypoxia mimicking conditions this 
discrepancy could be explained by the fact that hypoacetylated HIF-1α might have 
higher affinity for binding with the HREs present within the SCO2 promoter or is more 
effective in recruiting p53 in the promoter of this gene in hypoxia mimicking 
conditions. Further experiments are required to verify this hypothesis. 
 
To study whether PCAF mediated regulation of TIGAR and SCO2 gene expression 
occurred at the transcriptional level, TIGAR and SCO2 mRNA levels were analysed in 
U2OS cells overexpressing either PCAFwt or PCAFΔHAT. In line with the protein 
expression patterns, TIGAR mRNA levels were down regulated in PCAFwt expressing 
cells in hypoxia mimicking conditions, whereas this inhibition was abolished in 
PCAFΔHAT transfected cells under the same conditions (Figure 4.3.3 A). In etoposide 
treated PCAFwt expressing cells a slight downregulation of TIGAR mRNA levels was 
evident that was again abolished in PCAFΔHAT transfected cells under the same 
conditions (Figure 4.3.3 A). The greater extent of TIGAR mRNA downregulation in 
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hypoxia mimicking conditions compared to that in etoposide treated cells might be an 
indication that PCAF recruited different transcription factors in hypoxia mimicking than 
in DNA damage conditions which comply with our previously published data 
demonstrating that PCAF under diverse stress conditions differentially acetylates p53 
and HIF-1α directing them to different subsets of their transcription target genes 
(Xenaki et al., 2008). 
 
In similar way to that observed for TIGAR, SCO2 mRNA levels were downregulated in 
PCAFwt over expressing U2OS cells in hypoxia mimicking conditions (Figure 4.3.3 B). 
However, increased SCO2 mRNA levels in PCAFΔHAT transfected cells in both DSFX 
and etoposide treated cells were evident (Figure 4.3.5 B) in accord with the pattern of 
SCO2 protein levels (Figure 4.3.2 A and B). To shed light in the role of the HAT 
activity of PCAF in the transcriptional regulation of TIGAR and SCO2 gene expression, 
luciferase reporter assays were performed using the TIGAR and SCO2 luciferase 
reporter constructs described in Materials and methods section. Gradually increasing 
amounts of PCAFwt transfected in DSFX treated U2OS cells decreased both TIGAR 
and SCO2 luciferase activity whereas the opposite trend was apparent in the cells 
transfected with gradually increasing amounts of PCAFΔHAT under the same 
conditions (Figure 4.3.4 A and Figure 4.3.5 A) supporting the view that the HAT 
activity of PCAF exerts negative effects on the transcriptional regulation of both 
TIGAR and SCO2 gene expression in U2OS cells under hypoxia mimicking conditions. 
In contrast to U2OS in the DSFX treated p53 null SaOS2 cells, the HAT activity of 
PCAF wielded a positive effect on both TIGAR and SCO2 gene expression (Figure 
4.3.4 B and Figure 4.3.5 B). This result could be an indication that PCAF mediated 
acetylation of p53 hindered the recruitment of this transcription factor to the TIGAR 
and SCO2 promoter in the DSFX treated U2OS cells. In addition PCAF mediated 
acetylation of HIF-1α or another hypoxia responsive transcription factor relieved this 
repression in DSFX treated SaOS2 cells. In other words, the absence of p53 enables 
PCAF to recruit hypoxia responsive transcription factor(s) to the regulatory region of 
the promoter of TIGAR and SCO2 genes inducing their expression.  
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In conclusion our results shown in Figure 4.3.6 A and B support the view that the HAT 
activity of PCAF exerts a suppressive effect on TIGAR and SCO2 gene expression in 
the presence of p53 and induces gene expression of these two enzymes in the absence of 
p53 in hypoxia mimicking conditions.   
5.2.6 The HAT activity of PCAF regulates energy production pathways and ROS 
generation 
TIGAR has been shown to inhibit glycolysis and hence reduce lactate production 
(Bensaad et al., 2006). Taking into account our results suggesting the involvement of 
HIF-1α and the HAT activity of PCAF in the regulation of TIGAR gene expression in 
hypoxia mimicking conditions we were interested to investigate whether the HAT 
activity of PCAF played any role in the TIGAR mediated repression of glycolysis in 
hypoxic conditions. To this direction, we initially confirmed the role of HIF-1α in the 
regulation of lactate production by silencing HIF-1α expression using RNAi in U2OS 
cells. In accord with published data (Semenza et al., 1994) HIF-1α over expressing cells 
exhibited elevated lactic acid levels compared to cells in which HIF-1α expression had 
been silenced in hypoxia mimicking conditions (Figure 4.4.1). Furthermore TIGAR 
overexpression in DSFX treated U2OS cells reduced the lactate levels (Figure 4.4.2) in 
agreement with previously published reports showing that TIGAR is an inhibitor of 
glycolysis (Bensaad et al., 2006). 
 
The role of the HAT activity of PCAF in the regulation of glycolysis was assessed by 
recording the lactate production in U2OS cells transfected with PCAFwt or 
PCAFΔHAT in normal and hypoxia mimicking conditions. In line with our results 
presented in Figure 4.3.1, Figure 4.3.3 A indicating reduced TIGAR protein and mRNA 
levels in U2OS cells overexpressing PCAFwt, elevated lactate levels were observed in 
U2OS cells overexpressing PCAFwt and reduced in those cells transfected with 
PCAFΔHAT in hypoxia mimicking conditions (Figure 4.4.3 A). Moreover the 
upregulation of TIGAR coincided with reduced protein levels of the bi-functional 
enzyme PFKFB3 (Obach et al., 2004) in PCAFΔHAT transfected U2OS cells in 
hypoxia mimicking conditions (Figure 4.4.3 B) suggesting that the lactic acid 
downregulation in these cells might be the outcome of both TIGAR upregulation and 
PFKFB3 downregulation, however, this concept requires further experimental support. 
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Given the inhibitory role of TIGAR in glycolysis we next were interested to investigate 
whether cells overexpressing TIGAR could cover their energy needs by producing ATP 
through increased OXPHOS. To address this question we assessed the ability of U2OS 
cells ectopically expressing TIGAR or SCO2 together with PCAFwt or PCAFΔHAT to 
uptake oxygen as a measure of their capability to produce ATP through OXPHOS. 
Oxygen consumption in DSFX treated PCAFΔHAT transfected U2OS cells was 
upregulated compared to PCDNA3 or PCAFwt transfected cells (Figure 4.4.4) 
indicating that the HAT activity of PCAF exhibited a repressive role in oxygen 
consumption in hypoxia mimicking conditions. Consistent with this conclusion was the 
observation that PCAFwt transfected cells co-expressing TIGAR exhibited low oxygen 
consumption in hypoxia mimicking conditions (Figure 4.4.4). On the other hand, 
overexpression of SCO2 increased OXPHOS in hypoxia mimicking conditions 
irrespectively of the presence of either PCAFwt or PCAFΔHAT, suggesting that 
overexpression of SCO2 abolishes the effects of the HAT activity of PCAF on the 
ability of the cells to uptake oxygen (Figure 4.4.4). 
 
To further investigate whether the HAT activity of PCAF played any role in the 
regulation of energy metabolism as well as in determining the cellular redox state we 
followed the NAD
+
/NADH ratio in U2OS and SaOS2 cells transfected with either 
PCAFwt or PCAFΔHAT. In PCAFΔHAT transfected and DSFX treated U2OS cells 
high NAD
+
 and low NADH levels were observed (Figure 4.4.5) indicating low 
glycolytic rate under these conditions. In contrast to U2OS cells in p53 null SaOS2 cells 
low NAD
+/NADH ratio was observed in those cells transfected with PCAFΔHAT and 
treated with DSFX (Figure 4.4.5) implying that the HAT activity of PCAF regulated the 
NAD
+
/NADH ratio in a p53 dependent mode. 
 
The effect of the HAT activity of PCAF in the regulation of intracellular ROS 
generation was assessed in U2OS cells transfected with PCAFwt or PCAFΔHAT.  
Slightly increased intracellular ROS levels were observed in DSFX treated and 
PCAFΔHAT transfected cells compared to PCDNA3 transfected and untreated cells 
(Figure 4.4.6) which returned to the basal levels after TIGAR was ectopically 
 168 
expressed. No significant changes in intracellular ROS levels were observed in the cells 
overexpressing PCAFwt although the variability between two experiments did not allow 
firm conclusions to be reached.  Taken together, these results indicated that the HAT 
activity of PCAF is involved in the determination of the pathway of cellular energy 
production and the intracellular ROS generation.  
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5.3 Conclusions 
5.3.1 HIF-1 is involved in the regulation of TIGAR and SCO2 gene expression in 
hypoxia mimicking conditions 
The tumour suppressor p53 modulates cellular energy metabolism by upregulating 
TIGAR and SCO2 gene expression. The HIF-1 transcription factor, on the other hand 
induces the expression of genes encoding for enzymes involved in cellular metabolism 
in hypoxic conditions thereby facilitating the production of sufficient energy to promote 
survival and confer proliferative advantage to cancer cells. Our study attempted to 
dissect the molecular mechanisms which fine tune TIGAR and SCO2 gene expression 
under hypoxia mimicking conditions.  
 
The results shown in chapter 1 suggest that HIF-1 is involved in the regulation of 
TIGAR gene expression in hypoxia mimicking conditions. Our observations (Section 
4.1.1, 4.1.2) indicated that TIGAR gene expression, was differentially regulated in 
hypoxia mimicking conditions as evidenced at both TIGAR protein and mRNA levels. 
This notion complies with published data suggesting that apart from p53, other factors 
are possibly involved in the regulation of TIGAR gene expression (Bensaad et al., 
2006). Bio-informatic analysis revealed the presence of putative HREs in the regulatory 
region of TIGAR promoter (Section 4.1.4). Further experiments using luciferase reporter 
and ChIP assays (Section 4.1.3 and Section 4.1.5) suggested that TIGAR gene 
expression is potentially under HIF-1 transcriptional control in hypoxia mimicking 
conditions.  
 
Similar to TIGAR, SCO2 gene expression was also differentially regulated in hypoxia 
mimicking conditions both at protein and mRNA levels (Section 4.2.1 and Section 
4.2.2). However, the lack of experimental evidence verifying the recruitment of HIF-1 
within the SCO2 promoter suggested that HIF-1 may not be directly involved in the 
regulation of SCO2 gene expression. Nevertheless, the upregulation of SCO2 gene 
expression recorded in luciferase reporter assays implied that HIF-1 might be involved 
in the regulation of SCO2 gene expression indirectly but this issue requires further 
investigation. 
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Taken together results presented in Chapters 4.1 and 4.2 indicated that HIF-1α might be 
involved in the regulation of TIGAR and SCO2 gene expression in hypoxia mimicking 
conditions either directly or indirectly. 
5.3.2 PCAF plays an important role in the regulation of TIGAR and SCO2 gene 
expression    
Previous work in our laboratory has reviled the important role of the transcriptional co-
factor PCAF as a common co-factor for both p53 and HIF-1α in determining their 
transcription target selectivity thereby regulating cell cycle arrest and apoptosis (Xenaki 
et al., 2008). Given that TIGAR and SCO2 are common p53 and HIF-1 targets (Chapters 
4.1 and 4.2), in this study we investigated whether PCAF exerted similar effects on 
cellular energy metabolism by selectively targeting p53 and/or HIF-1 to either TIGAR 
or SCO2. 
 
Results shown in Chapter 4.3 indicated that in hypoxia mimicking conditions, PCAF 
played crucial role in the regulation of TIGAR and SCO2 gene expression under hypoxia 
mimicking conditions. In particular, ectopic expression of PCAFwt downregulated both 
TIGAR and SCO2 protein and mRNA levels whereas PCAFΔHAT did not have any 
significant effect on the expression of these genes (Sections 4.3.1 and 4.3.2). Moreover, 
luciferase reporter assays confirmed the involvement of PCAF in the regulation of 
TIGAR and SCO2 gene expression under hypoxia mimicking conditions (Section 4.3.3). 
In conclusion, results shown in Chapter 4.3 indicated that PCAF played an important 
role in the regulation of TIGAR and SCO2 gene expression in hypoxia mimicking 
conditions. 
5.3.3 PCAF affects cellular energy metabolism and ROS generation by regulating 
TIGAR and SCO2 gene expression.  
The functional consequences of PCAF mediated regulation of TIGAR and SCO2 gene 
expression in hypoxia mimicking conditions, were investigated in cells overexpressing 
PCAFwt and PCAFΔHAT in the presence or absence of p53 (Chapter 4.4). Results 
shown in Chapter 4.4 suggested that PCAF HAT activity regulates cellular lactate 
production (Section 4.4.1), oxygen consumption (Section 4.4.2), and NAD
+
/NADH 
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levels (Section 4.4.3) under hypoxia mimicking conditions. The role of PCAF in the 
regulation of intracellular ROS levels needs further experimental evidence (Section 
4.4.4).  
5.4 Future work  
Further investigation is required to address the following issues which will take this 
project forward.  
 
Investigate the involvement of the other HREs identified within the TIGAR regulatory 
region of the promoter apart from the HRE5. Explore the possibility for the requirement 
of other transcription factors or cofactors required for HIF-1 to bind efficiently to these 
sites. In addition, confirm the functionality of the HREs within the TIGAR promoter by 
engineering mutated HIF-1 binding sites (5’-CGTG-3’) and perform luciferase reporter 
assays. 
 
Although SCO2 gene expression has been shown to be modulated differentially in 
hypoxic conditions (Section 4.2.1 and 4.2.2), the evidence for the direct involvement of 
HIF-1 in the regulation of SCO2 gene expression requires more experimental support. 
ChIP assays with different exposure times to hypoxia (2 hours, 4 hours, 10 hours and 16 
hours), or different levels of hypoxia (0.5%, 1% and 5% oxygen) or anoxia (0.01% 
oxygen) should be performed to study the involvement of HIF-1 in the regulation of 
SCO2 gene expression. 
 
The role of PCAF in the regulation of TIGAR and SCO2 gene expression in hypoxia 
mimicking conditions has been shown in Section 4.3. The role of PCAF should be 
further investigated in cells in which PCAF expression has been silenced using shRNA 
or RNAi targeting PCAF. Oxygen consumption, lactate production NAD
+
/NADH ratio 
and oxidative stress should be followed in these cells.   
 
The role of the NAD
+
 dependent histone deacetylases sirtuins need to be investigated 
under the light of the interaction between PCAF and SIRT1 (Yeung et al., 2004) and the 
fact that both p53 and HIF-1α are targeted by this HDAC.  
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The investigation of the role of other common transcriptional cofactors for p53 and 
HIF-1 such as p300/CBP and SRC-1 in the regulation of TIGAR and SCO2 gene 
expression might answer the question whether, TIGAR and SCO2 gene expression is 
regulated by different network of transcription factors and coactivators/corepressors 
under diverse stress conditions.  
 
Given that PFKFB3 is overexpressed in hypoxic conditions, and PCAF is shown to 
regulate the cellular lactate levels (in other words, glycolysis) it would be interesting to 
follow the role of PCAF in the modulation of kinase/phosphatase ratio of PFKFB3 
enzyme. This will shed light in the modulating process of two enzymes that exert 
opposing effects in glycolysis (PFKFB3 and TIGAR) and might provide some insight in 
possible ways to reverse the Warburg Effect in cancer cells. In addition, the possibility 
that the regulation of cellular ROS and autophagy by TIGAR (Bensaad et al., 2009), is 
mediated by PCAF could be further explored.   
 
In order to investigate the net effect of the HAT activity of PCAF on ROS generation 
transfected cells with either PCAFwt or PCAFΔHAT expression vectors need to be 
sorted using a surface marker (CD20) and ROS measurement cell cycle analysis be 
performed using FACs.  
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